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Background: Giant cell arteritis (GCA) is a relatively common form of primary systemic vasculitis, which,
if left untreated, can lead to permanent sight loss. We compared ultrasound as an alternative diagnostic
test with temporal artery biopsy, which may be negative in 9–61% of true cases.
Objective: To compare the clinical effectiveness and cost-effectiveness of ultrasound with biopsy in
diagnosing patients with suspected GCA.
Design: Prospective multicentre cohort study.
Setting: Secondary care.
Participants: A total of 381 patients referred with newly suspected GCA.
Main outcome measures: Sensitivity, specificity and cost-effectiveness of ultrasound compared with
biopsy or ultrasound combined with biopsy for diagnosing GCA and interobserver reliability in interpreting
scan or biopsy findings.
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Results: We developed and implemented an ultrasound training programme for diagnosing suspected
GCA. We recruited 430 patients with suspected GCA. We analysed 381 patients who underwent both
ultrasound and biopsy within 10 days of starting treatment for suspected GCA and who attended a
follow-up assessment (median age 71.1 years; 72% female). The sensitivity of biopsy was 39% [95%
confidence interval (CI) 33% to 46%], which was significantly lower than previously reported and inferior
to ultrasound (54%, 95% CI 48% to 60%); the specificity of biopsy (100%, 95% CI 97% to 100%) was
superior to ultrasound (81%, 95% CI 73% to 88%). If we scanned all suspected patients and performed
biopsies only on negative cases, sensitivity increased to 65% and specificity was maintained at 81%,
reducing the need for biopsies by 43%. Strategies combining clinical judgement (clinician’s assessment at
2 weeks) with the tests showed sensitivity and specificity of 91% and 81%, respectively, for biopsy and
93% and 77%, respectively, for ultrasound; cost-effectiveness (incremental net monetary benefit) was
£485 per patient in favour of ultrasound with both cost savings and a small health gain. Inter-rater analysis
revealed moderate agreement among sonographers (intraclass correlation coefficient 0.61, 95% CI 0.48 to
0.75), similar to pathologists (0.62, 95% CI 0.49 to 0.76).
Limitations: There is no independent gold standard diagnosis for GCA. The reference diagnosis used
to determine accuracy was based on classification criteria for GCA that include clinical features at
presentation and biopsy results.
Conclusion: We have demonstrated the feasibility of providing training in ultrasound for the diagnosis
of GCA. Our results indicate better sensitivity but poorer specificity of ultrasound compared with biopsy
and suggest some scope for reducing the role of biopsy. The moderate interobserver agreement for both
ultrasound and biopsy indicates scope for improving assessment and reporting of test results and
challenges the assumption that a positive biopsy always represents GCA.
Future work: Further research should address the issue of an independent reference diagnosis, standards
for interpreting and reporting test results and the evaluation of ultrasound training, and should also
explore the acceptability of these new diagnostic strategies in GCA.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Adventitia The outer layer of medium-sized and large arteries.
Amaurosis fugax A transient loss of vision, typically caused by a small embolic occlusion to the arterial
supply to the retina or other parts of the visual pathway.
Arteriosclerosis Chronic changes in the arterial wall with thickening, fatty change and calcification
typically associated with longstanding hypertension or cigarette smoking.
Axillary arteries Large arteries that are branches of the subclavian artery or innominate artery; they
provide arterial supply to the arms and are detectable in the axillae (armpits).
Calcification The presence of deposits of calcium, typically detected in the larger arteries of patients with
atherosclerosis or diabetes mellitus. They can be found in temporal arteries. On ultrasound they reflect
sound, giving a bright image that is very different from a halo.
Claudication (of the jaw or tongue) Pain in the tongue or the masseter muscles of the jaw which is
induced by exercise and is a result of a reduced blood supply. The pain should resolve with rest and is
similar to angina in its mechanism.
Fragmentation The break up and duplication of the internal elastic lamina of the temporal artery as a
result of giant cell arteritis or ageing. The histological appearance is best seen by staining the elastic, which
is a major component of the internal elastic lamina.
Giant cell A large multinucleate cell found in sites of chronic inflammation. The presence of giant cells
indicates that granulomatous inflammation is present but is not specific. The same cells are found in giant
cell arteritis, other forms of vasculitis, tuberculosis and other chronic infections. If they are found in a
biopsy from a patient with suspected giant cell arteritis, however, pathologists are very likely to diagnose
giant cell arteritis.
Giant cell arteritis (also known as temporal arteritis) A disease that is characterised by inflammation
of large and medium-sized blood vessels. An alternative name for this condition is ‘temporal arteritis’, as
the blood vessels in the temple area of the head (sides of the forehead) are commonly affected. The giant
cells referred to are specific collections of immune system cells seen in the areas of inflammation if a
biopsy is performed.
Glucocorticoids Potent immunosuppressive corticosteroid therapy, which is used to treat many forms of
inflammation. They are currently the main treatment for giant cell arteritis.
Halo An ultrasound finding of a dark shadow adjacent to a blood vessel, which may represent
inflammation in the vessel. It is the strongest single indicator of the presence of vessel wall inflammation
seen in patients with large vessel vasculitis such as giant cell arteritis or Takayasu’s arteritis.
Immunosuppressive agents Drugs that suppress the immune system, typically for treatment of patients
with inflammatory conditions such as giant cell arteritis. They include glucocorticoid, methotrexate,
azathioprine, cyclophosphamide, ciclosporin and leflunomide.
Internal elastic lamina The histological structural layer in medium-sized and large arteries that separates
the innermost layer (intima) from the middle layer (media).
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Intima The innermost layer of medium-sized and large arteries.
Intimal hyperplasia Increased numbers of cells (usually inflammatory) present in the intima. The intima is
often swollen (increased in thickness) because of accompanying oedema in this layer, as seen histologically.
This is a typical feature in patients with active giant cell arteritis but may also be seen in patients with
resolving disease, as well as in otherwise healthy older adults.
Occlusion (biopsy) Complete blockage of blood flow through a vessel, usually because of significant
intima hyperplasia and or thrombus. This is a typical histological finding of vessel wall inflammation.
Occlusion (ultrasound) A lack of colour Doppler flow through an artery, which is attributed to occlusion.
Reduplication The increased number of apparent layers of internal elastic lamina seen on histology in
temporal arteries. The finding is typical in giant cell arteritis, but can also occur in otherwise healthy
elderly people.
Stenosis Narrowed sections of an artery as demonstrated on ultrasound. It is characterised by visible
narrowing but also by an accelerated rate of colour Doppler flow through the area of stenosis. It is found
in patients with giant cell arteritis but is also seen in other conditions such as arteriosclerosis.
Systemic vasculitis A group of diverse and unusual conditions characterised by inflammation of the
vessel wall leading to organ or tissue infarction, affecting multiple organs or occurring throughout
the vasculature.
Temporal arteries Branches of the external carotid arteries, which supply the scalp with blood. Branches
of this artery also supply the retina, which means that narrowing of this artery can lead to critical
ischaemia of the central part of the retina, which may result in permanent visual loss.
Vasculitis Inflammation of blood vessels leading to organ or tissue damage as a result of ischaemia.
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List of abbreviations
ACR American College of Rheumatology
AE adverse event
ANCA antineutrophil cytoplasm antibody
BSR British Society for Rheumatology
BVAS Birmingham Vasculitis Activity
Score
CI confidence interval
CRF case record form
CRP C-reactive protein
CT computerised tomography
DCVAS Diagnostic and Classification
Criteria for Vasculitis Study
EGPA eosinophilic granulomatosis with
polyangiitis
EQ-5D EuroQol-5 Dimensions
ESR erythrocyte sedimentation rate
GCA giant cell arteritis
GP general practitioner
GPA granulomatosis with polyangiitis
ICC intraclass correlation coefficient
ICER incremental cost-effectiveness ratio
IL interleukin
IQR interquartile range
MRI magnetic resonance imaging
NICE National Institute for Health and
Care Excellence
NMB net monetary benefit
PMR polymyalgia rheumatica
QALY quality-adjusted life-year
R&D research and development
SD standard deviation
TAB temporal artery biopsy
TABUL The Role of Ultrasound Compared
to Biopsy of Temporal Arteries in
the Diagnosis and Treatment of
Giant Cell Arteritis
TTO time trade-off
VDI Vasculitis Damage Index
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Plain English summary
G iant cell arteritis (GCA) is a disease causing blood vessel inflammation which, if left untreated, cancause permanent blindness. Patients with suspected GCA usually have a minor surgical procedure that
involves taking a biopsy from one of the arteries on the side of the head. A positive biopsy confirms the
diagnosis, but many patients with negative biopsies are eventually diagnosed with GCA. We compared
the accuracy and cost of an alternative test for GCA, namely an ultrasound scan of arteries, with taking a
biopsy. We scanned and biopsied 381 patients with suspected GCA and followed them for up to 6 months
to see who actually had GCA; 257 (67%) patients were eventually diagnosed with GCA. Ultrasound was
better than biopsy at identifying patients who did have GCA: it identified 54% of these patients compared
with 39% identified from biopsy. Biopsy performed better than ultrasound in the patients who did not have
GCA: none of these patients had a positive biopsy, whereas 19% had a positive scan.
We also looked at different testing strategies combined with a doctor’s assessment of the patient. A strategy
that involves scanning all patients with suspected GCA identified 93% of those patients with GCA.
This strategy was also cheaper (by £485 per patient) than the current practice of relying on a doctor’s
assessment and biopsy alone.
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Scientific summary
Background
Giant cell arteritis (GCA) is a relatively common form of blood vessel inflammation, which usually affects
people over the age of 50 years. GCA typically causes headaches and systemic upset, but can be
associated with sudden and irreversible sight loss. For this reason, if a general practitioner (GP) sees a
patient with suspected disease, the patient will usually be commenced on high doses of glucocorticoids,
often before the diagnosis has been confirmed by further testing. Therefore, it is important to make the
diagnosis correctly in order to decide on the need to continue high-dose glucocorticoid therapy to improve
the condition and reduce the risk of visual loss. However, it is also important to avoid treating those
without the condition, because there is a very high incidence of side effects associated with long-term
glucocorticoid therapy. Temporal artery biopsy is the current gold standard test for establishing the
diagnosis, with a high specificity but low sensitivity. It can be misleading in a significant number of cases.
Up to 44% of patients with clinical features of GCA have a negative biopsy. There are many reasons for
this, including the adequacy of the specimen obtained, the duration of glucocorticoid treatment prior to
biopsy and the presence of skip lesions (intermittent, dispersed areas of abnormality in the artery that
might be missed because not all areas of the artery will be sectioned for examination). Ultrasound and
other imaging techniques are emerging as alternative tests to biopsy but have not been taken up widely.
Ultrasound imaging can be used to assess both temporal arteries as well as both axillary arteries, which has
been shown to increase the diagnostic yield.
Objectives
We aimed to test the clinical effectiveness and cost-effectiveness of ultrasound as an alternative to biopsy
in the diagnosis of patients with a new presentation of possible GCA. The primary objectives of the study
were (1) to evaluate the diagnostic performance (sensitivity and specificity) of ultrasound as an alternative
to biopsy for diagnosing GCA in patients who are referred with suspected GCA and in whom a biopsy
was going to be carried out; and (2) to perform a cost-effectiveness analysis to compare different potential
investigation strategies for diagnosing GCA, incorporating either or both ultrasound and biopsy.
The secondary objectives in the study were to evaluate:
l sequential diagnostic performance and cost-effectiveness of biopsy following ultrasound in patients
who have a negative ultrasound, compared with either ultrasound or biopsy alone
l the clinical effectiveness and cost-effectiveness of providing ultrasound results or biopsy results alone
on treatment decisions proposed by participating clinicians
l the diagnostic performance of ultrasound in specific subgroups such as individuals at high or low risk of
disease and the level of variation in ultrasound appearance in terms of halo size and degree of stenosis.
Methods
We conducted a multicentre, prospective study of new cases of suspected GCA. In order to ensure
standardisation of the new technique of ultrasound scanning of temporal arteries, we needed to develop a
training programme for sonographers to standardise the performance and interpretation of ultrasound
assessment of temporal and axillary arteries. The training consisted of a Microsoft PowerPoint® version
97–2003 (Microsoft Corporation, Redmond, WA, USA) presentation, an online assessment in which
sonographers were required to correctly identify video images of scans as showing or not showing features
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consistent with GCA (75% pass mark required), the provision of video and still images from 10 control
individuals and one patient with active GCA and evidence of ultrasound abnormalities consistent with
the diagnosis. All images were reviewed by an expert panel. If scan techniques were suspected to be
inadequate, the sonographers underwent retraining. We compared the standard of care in the investigation
of GCA [clinical evaluation, measurement of acute phase response and temporal artery biopsy (TAB) from
the most affected artery] with ultrasound. All patients underwent both tests in sequence (ultrasound first,
followed by biopsy) within 7 days of commencing high-dose steroids for the suspected diagnosis of
new-onset GCA. We did not provide any training in TAB or in the interpretation of the results by
pathologists, because these are established techniques in NHS care. All patients received normal care as
decided by their clinician. The clinician reviewed the patient at baseline, 2 weeks later (after the scan and
biopsy had been performed) and 6 months later. We used the clinician diagnosis made at 2 weeks as the
primary outcome measure for the study. We also established a reference standard diagnosis based on the
clinician’s submitted diagnosis, any revisions by 6 months, or any revisions by the expert panel who reviewed
all case records. The scan result was kept blinded from the clinician treating the patient to avoid the results
influencing the decision on diagnosis. The clinician was supplied with all other results including the biopsy
because this would reflect standard of care. After the clinician submitted their diagnosis at 2 weeks, they
were provided with the scan results on request if they were considering withdrawal of therapy if they
concluded that the patient did not have GCA. We excluded patients with a previous diagnosis of GCA or a
previous TAB; we also excluded patients who had been treated with high-dose steroids for any other reason
for more than 7 days prior to the ultrasound and biopsy. We created 30 case vignettes from the data
obtained from patients in the study who either did or did not have a reference standard diagnosis of GCA
and in whom the biopsy or scan could have been either positive or negative. We undertook two interobserver
rater exercises to assess variation in diagnosis based on interpretation of ultrasound and biopsy images.
Results
We recruited 35 centres for the study and provided ultrasound training for 49 sonographers. Only
26 sonographers from 22 sites completed the training. Two of these sites did not take any further part in
the study, leaving 24 sonographers at 20 recruiting sites. Seven sonographers passed all three components
of the training at first attempt; 13 required further attempts to pass; and four were exempted from some
parts of the training because they had already demonstrated expertise.
We enrolled 430 patients with suspected GCA into the study; 44 withdrew or did not have their scan
and biopsy within 10 days of starting glucocorticoid therapy and five withdrew before completing a
follow-up assessment. The remaining 381 patients were included in the primary analysis. The median age
[interquartile range (IQR)] was 71 years (64–78 years); 72% were female. The median time between first
symptom onset and baseline was 31 days (IQR 10–93 days, n = 377); the median time between symptom
onset and starting steroids was 33 days (IQR 13–99 days, n = 379). The reference diagnosis was based on
the 2-week and 6-month clinical diagnosis, as well as the opinion of an expert review panel, which
assessed all of the patient data apart from the ultrasound results. In total, 257 out of 381 patients were
considered to have GCA on the basis of the reference standard diagnosis. Twenty-one patients had a
change of diagnosis from the original clinician’s final available diagnosis following an expert review: in
eight patients, the diagnosis was changed from GCA to not GCA; in a further 13 patients, the diagnosis
was switched from not GCA to GCA. We compared the relative performance of ultrasound and biopsy in
257 patients with a reference standard diagnosis of GCA and 124 patients diagnosed as not having GCA.
The incidence of polymyalgia rheumatica was 28 cases at baseline, and ischaemic optic neuropathy was
reported in 9.7% of cases with GCA at baseline (compared with 4.8% in the non-GCA group), 6.2% of
cases at 2 weeks (compared with 0.8%) and 4% of cases at 6 months (compared with 2.8%). Baseline
comorbidity included hypertension in 52.5% of patients, diabetes mellitus in 14.2% of patients, ischaemic
heart disease in 7.3% of patients, heart failure in 5% of patients, malignancy in 2.4% of patients and
fracture in 0.3% of patients. At 6 months after diagnosis, the incidence of hypertension had increased to
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55.8% and the incidence of diabetes mellitus had increased to 18.2%. Four low-trauma fractures occurred
during the follow-up period.
In total, 101 cases had a biopsy consistent with the diagnosis and 162 cases had an ultrasound consistent
with the diagnosis. In 70% of patients, the results of biopsy and ultrasound were concordant (74 positive
and 192 negative), giving a kappa statistic of 0.35. In 27 patients the results were positive for biopsy but
negative for ultrasound and in 88 patients the results were negative for biopsy but positive for ultrasound.
The sensitivity of biopsy versus ultrasound was 39% [95% confidence interval (CI) 33% to 46%] compared
with 54% (95% CI 48% to 60%) and the specificity was 100% (95% CI 97% to 100%) compared with
81% (95% CI 73% to 88%). We analysed change in the degree of ultrasound abnormality (based on halo
size) during the 7-day assessment period. We found that the halo was likely to be much smaller after at
least 4 days of high-dose glucocorticoid therapy than after fewer than 4 days of steroid therapy. The
biopsy positivity rate also diminished significantly within 3 days of starting high doses of glucocorticoids.
We also evaluated alternative strategies for combining the two tests and incorporating clinical judgement
(the doctor’s assessment of GCA based on the patient’s characteristics and available test results). The most
cost-effective strategy was to perform an ultrasound examination of all patients with suspected GCA.
This strategy was more sensitive (93% vs. 91%), less specific (77% vs. 81%) and more cost-effective
(incremental net monetary benefit of £485 per patient) than current standard practice, that is, a strategy
involving biopsy and clinical judgement alone. The cost-effectiveness analysis accounted for the cost of the
testing and the consequences of correct or incorrect diagnosis resulting in drug toxicity (e.g. fracture),
as well as irreversible, potentially preventable, sight loss from anterior ischaemic optic neuropathy.
We measured inter-rater agreement for the two tests in a series of 30 cases selected from among the
cohort. Among sonographers the intraclass correlation coefficient for agreement was 0.61 (95% CI 0.48
to 0.75) and for biopsy the intraclass correlation coefficient was 0.62 (95% CI 0.49 to 0.76). Agreement
was strongest where the pathological findings included the presence of giant cells, but was much weaker
for cases in which only minimal change was found. This suggests that the current approach of classifying
test results as either positive or negative may be too simplistic because the tests are not always enough by
themselves to make the diagnosis, as there can be some degree of uncertainty in interpreting the results.
Conclusions
We conclude that ultrasound, in comparison with TAB, is a more sensitive and cost-effective investigation
in suspected cases of GCA. However, over one-third of the patients eventually diagnosed with GCA had
neither a positive scan nor a positive biopsy, highlighting the importance of assessing the patient for
clinical indicators to support the diagnosis rather than relying on test results alone. Temporal artery biopsy
has a much lower sensitivity in the current study (39%) than in previously published figures (> 70%). It is
tempting to speculate that this may reflect better awareness of the diagnosis of GCA and a willingness of
GPs to commence treatment early in the disease course. This is supported by the relatively short time from
symptom onset to diagnosis in this cohort (31 days) compared with other cohorts. The findings have
potential implications for improving the management of GCA through the more effective use of available
techniques to provide a clinically effective and cost-effective strategy for the diagnosis of GCA. Further
research should address the issue of an independent reference diagnosis, standards for interpreting and
reporting test results and the evaluation of ultrasound training and should explore the acceptability of
these new diagnostic strategies in GCA. Some clinicians and patients may be uncomfortable with a
strategy that does not involve a biopsy and may prefer to perform biopsies in all cases that are ultrasound
negative, or in all cases of patients at medium or high risk of GCA in terms of clinical features but who
have a negative ultrasound scan, to provide further evidence to rule in the disease as well as to support
withdrawing therapy if both tests are negative. Although these combined strategies would be more
expensive than our proposal (because a proportion of patients would require a biopsy), they remain
more cost-effective than current practice (performing a biopsy in all suspected cases) and may be more
acceptable to patients and clinicians.
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Future work
Further research should address the issue of an independent reference diagnosis, standards for interpreting
and reporting test results and the evaluation of ultrasound training and should explore the acceptability
of these new diagnostic strategies in GCA.
Funding
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Institute for Health Research.
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Chapter 1 Introduction
General introduction to giant cell arteritis
Giant cell arteritis (GCA), also known as temporal arteritis, is a common form of vasculitis that affects people
typically aged > 50 years.1 GCA often progresses rapidly and, if left untreated, leads to severe pain,
permanent visual loss, stroke and, in some cases, death. The incidence is approximately 220 per million per
year in the UK in people aged ≥ 40 years.2 Elsewhere, the incidence varies across the world, with published
figures ranging from 150 to 250 new patients per million per year. It is more common in northern European
countries, particularly in Scandinavia (313 per million per year in people aged > 70 years)3 and in Minnesota,
USA, which has a large Scandinavian-origin population (198 per million per year),4 and it is much less
common in other parts of the world such as Japan, China and Australia.
Rapid diagnosis and glucocorticoid treatment are recommended,5 but both are problematic. Glucocorticoid
treatment is usually started before a formal diagnosis is made, meaning that a proportion of patients are
treated unnecessarily and are thereby exposed to side effects including weight gain, altered body habitus,
hypertension, infection, osteoporosis, cataract, mood swings and thin skin. Glucocorticoid treatment also
affects the accuracy of the diagnosis. The heterogeneous nature of GCA means that its diagnosis is not
straightforward, but is usually based primarily on temporal artery biopsy (TAB) and supported by presenting
symptoms. Glucocorticoids, by their nature, impact on inflammation; if there is a large time difference
between commencement of glucocorticoids and biopsy, this reduces diagnostic accuracy. Although a
positive biopsy usually (although not always) confirms GCA, the sensitivity of TAB has been estimated to
vary from 39% to 91%,6,7 resulting in a large number of false negatives in the screened population. This
has led to high-dose glucocorticoid therapy being continued as a precaution (in case the patients actually
have GCA), even in the absence of a positive biopsy.
Ultrasound and other forms of imaging compared with the
traditional role of biopsy
An alternative to biopsy has been the development of ultrasound and other imaging techniques for the
diagnosis of GCA. Imaging first emerged in the 1990s as a potential means by which to provide evidence to
support a diagnosis of GCA.8–15 High-resolution magnetic resonance imaging (MRI) of temporal arteries
offers a non-invasive technique for investigating suspected GCA, but it is limited by availability and cost.
Ultrasound is the most practical and widely used modality. Three meta-analyses have supported the role of
ultrasound in the diagnosis of GCA.16–18 The presence of bilateral ultrasound abnormalities (both temporal
arteries involved) provides high specificity (100%) for the diagnosis of GCA, but its sensitivity was 43%.17
Two of the meta-analyses reported concerns with the quality of the included studies16,18 and the third did not
assess the methodological quality of the included studies.17 Currently, the use of ultrasound as a diagnostic
tool for GCA is relatively limited, perhaps as a result of practical reasons relating to training to use ultrasound
or equipment availability to facilitate rapid access and evaluation of patients with suspected GCA.
Ultrasound examination of temporal arteries is non-invasive and there is no ionising radiation involved.
Furthermore, it can provide information about the entire length of both temporal arteries. Additional
examination of the axillary arteries improves the sensitivity of ultrasound19 because some individuals with
GCA (especially those without headaches) will have isolated abnormalities in the axillary arteries but not in
the temporal arteries. This may be because of the longer persistence of scan abnormalities in larger vessels
than in temporal arteries, despite the use of steroids. The chief abnormality on ultrasound that suggests
the diagnosis of GCA is a halo, which is defined as a dark hypoechoic area around the vessel lumen and is
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thought to represent inflammatory change and oedema present in the wall and surrounding tissues of the
affected blood vessel.
The role of temporal artery biopsy in the diagnosis of giant
cell arteritis
A recent study of biopsy-proven GCA disease in South Australia suggested an incidence in people aged
> 50 years of only 32 per million per year,20 although the relatively low incidence may be a result of the
inclusion of biopsy-confirmed cases only. Biopsy for the diagnosis of GCA has a relatively low yield.16
The difficulty in diagnosis of GCA, which forms the main underlying question of this project, is the lack
of a high-quality gold standard test. Although biopsy is reported to be the current gold standard test for
diagnosis, the majority of patients in whom a diagnosis of GCA is suspected do not actually have a positive
result. This may reflect the fact that there is a lower index of suspicion for diagnosis, and, therefore, more
people with headaches are being evaluated for GCA; equally, it may reflect the relatively poor association
between the true multivessel disease of GCA and the TAB findings to support a diagnosis of GCA.
The spectrum of different forms of giant cell arteritis
In about 50% of patients with GCA, branches of the aorta, and even the aorta itself, may be involved,
suggesting that there is probably much more widespread inflammation of blood vessels (vasculitis)
than previously considered.21 In a study of 120 patients with large vessel vasculitis and 212 with more
conventional cranial symptoms of GCA, but without the evidence of large vessel disease, patients with
large vessel disease were significantly younger, by about 7 years, and had longer duration of symptoms
prior to diagnosis (3.5 months compared with 2.2 months). There was a strong association with
pre-existing polymyalgia rheumatica (PMR) in 26% of patients, compared with 15% of patients with
cranial GCA, and fewer cranial symptoms (41% of patients, compared with 83% of patients with cranial
GCA). Visual loss was also much less likely in large vessel GCA (4% compared with 11%). The risk of
relapse of GCA features was higher in patients with large vessel disease than in patients with cranial
manifestations only (4.9/10 person-years, compared with 3/10 person-years) and these patients were likely
to require higher doses of steroids for longer periods of time.
Clinical presentation of giant cell arteritis
Recognising new features of GCA can be very straightforward in a patient with no previous history of
headache who suddenly develops unaccustomed discomfort on the side of the head with swelling or
tenderness of the temporal arteries, general systemic onset and scalp tenderness. Although symptomatic
headache is very troublesome, the most feared complication of GCA is neuroischaemic damage, which can
result in inflammation and occlusion of small branches of the cranial arteries (including the posterior ciliary
artery and the ophthalmic artery) and ultimately in permanent visual loss. A warning symptom of ischaemia
is the presence of jaw or tongue claudication, typically reported by around 50% of patients with GCA at
presentation.22 Jaw and tongue claudication refers to discomfort in the patient’s masseter muscles or
tongue which stops them from eating or talking. When they stop to rest their jaw or tongue, the pain
resolves because it is a result of claudication of those muscles as a result of narrowing of the blood vessel
supply (e.g. the facial artery and its branches). Patients who have tongue or jaw claudication are at risk of
blindness because the disease can involve the posterior ciliary arteries, which supply the retina and cause
unilateral, and occasionally bilateral, permanent sight loss. Sometimes the visual loss starts on one side
and subsequently becomes bilateral. In an early series of 90 cases from neurology and ophthalmology
clinics, up to 60% of patients presented with permanent loss of vision attributable to either ischaemic
papillopathy or retinal artery occlusion;23 other cases presenting primarily to physicians demonstrated a
much lower risk of sight loss of 7.4% to 19.1%.24–27 The risk of sight loss associated with GCA has fallen
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
in recent decades, from 15% of cases with ischaemic optic neuropathy between 1950 and 1979 to
only 6% between 1980 and 2004.28 There is a small but significant risk of stroke, highlighted as possibly
being between 2.8% and 6% in two recent studies.29,30 Therefore, an early diagnosis and initiation
of immunosuppressive treatment with high doses of steroids is required, making the condition a
medical emergency.
It is likely that the mechanisms driving the neuroischaemic complications are different from those driving
the systemic inflammatory response. There is a suggestion that interleukin (IL)-12 and interferon-gamma are
the main cytokines responsible for myointimal proliferation leading to vessel occlusion; by contrast, the
mechanisms driving the systemic inflammatory response are likely to be IL-6 and IL-17.31 The underlying
pathological changes involve invading macrophages and lymphocytes which gain access to the blood vessels
via the vasa vasorum. They generate a local inflammatory response in the blood vessel wall, starting in the
adventitia, migrating through to the media and intima, with proliferation of the internal elastic lamina,
intimal proliferation and swelling, and eventually resulting in vessel narrowing and complete occlusion in
some cases.
Although intimal proliferation with intimal thickness and internal elastic lamina reduplication are typical
features, the hallmark histological finding is the presence of multinucleated giant cells, hence the term
GCA. These pathological mechanisms are the basis for the histological diagnosis of the condition, which
was first recognised by Horton et al.1 in 1932 who described two patients who were initially thought to
have a fungal infection (actinomycosis) of the temporal arteries.
Giant cell arteritis typically affects people aged over 50 years; it is two to three times more common in
women than in men. PMR is a related clinical syndrome characterised by generalised muscles aches and
pains. PMR is common in patients over the age of 50 years and presents with widespread aches and pains,
particularly involving proximal muscles. Criteria for classifying PMR are based on the presence of bilateral
limb girdle discomfort, early-morning stiffness and an elevated inflammatory response.32 Additional
ultrasound evidence of bursitis around the hips improves the specificity of the criteria from 78% to 81%
and maintains sensitivity of between 66% and 68%. PMR can be present in up to 50% of individuals
with GCA and it may occur either before, during or after the manifestations of GCA appear, suggesting
significant overlap between these two disease processes.33 Therefore, our interpretation of any individual
patient’s diagnosis of GCA would be influenced by either pre-existing or concomitant diagnosis of PMR or
might be validated by subsequent development of PMR.
Diagnosis and classification of giant cell arteritis
The 1990 American College of Rheumatology (ACR) classification criteria for GCA are based on
the following:
l aged at least 50 years
l new onset of headache
l temporal artery abnormality on physical examination
l elevated erythrocyte sedimentation rate (ESR) typically ≥ 50 mm/hour
l abnormal TAB showing features of vasculitis.
Classification of a patient as having GCA requires at least three of these criteria to be present.34 The
classification criteria are not diagnostic tests and are limited by the technology available at the time when
the criteria were being developed. As technology has improved, there are more sophisticated methods
available for evaluating the temporal artery with ultrasound, MRI and computerised tomography (CT).
Furthermore, it is possible to image the whole arterial tree more effectively for evidence of widespread
vascular abnormality using CT angiography, magnetic resonance angiography and 18F-fluorodeoxyglucose
positron emission tomography CT. These techniques have revealed that some cases of GCA have much
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more extensive vessel involvement than previously suspected.21 Imaging has demonstrated that GCA can
present without headaches but with other features such as constitutional symptoms and polymyalgia,
which is also termed polymyalgia arteritica.35
The awareness of GCA has probably increased and it is likely that the concern regarding the threat of
visual loss may affect a clinician’s decision to pre-emptively treat any patient who might have the condition
as soon as possible, in order to prevent these complications from occurring. As a result, it is likely that we
are starting to see a change in the level of suspicion of symptoms at which a clinician is confident in
starting treatment on the basis of a presumed diagnosis of GCA. Tests used for diagnosing GCA would
now be performed in different circumstances than existed previously. We may be dealing with milder cases
of the disease and/or more patients with a GCA-like symptom complex who do not actually have GCA.
If these patients are given steroids, the standard test result from a TAB may be significantly influenced by
the fact that the biopsy was performed on mild disease that had already been partly treated and/or was
performed in patients who do not actually have GCA. Kisza et al.36 assessed over 700 cases of GCA from
1994 to 2011, with 215 biopsy-positive cases, observing a peak incidence in 1996. Machado et al.37
observed a reduction in the frequency of patients presenting with classical features, but no change in the
likelihood of a positive biopsy from 1950 to 1985. In fact, Gonzalez-Gay et al.38 found that the incidence
of biopsy-proven GCA actually increased from 1981 to 2005. A more recent study3 of 840 biopsy-positive
cases of GCA in Sweden reported a reduction in incidence between 1997 and 2010, from 15.9/100,000
to 13.3/100,000, although this contrasts with an earlier Swedish study39 that reported an increased
incidence from 1976 to 1995, especially in women. In the UK, there was no evidence to suggest a change
in incidence between 1990 and 2001.2 This suggests that, although there may have been some changes
to the epidemiology of GCA over time, with possibly a rise in incidence in women, there has been no
significant change in the overall incidence of GCA. There is evidence of a diagnostic shift in other diseases
too; hypothyroidism is now recognised as significant and is associated with increased comorbidity at lower
levels of thyroid-stimulating hormone than before.40
The Diagnostic and Classification Criteria for Vasculitis Study
As a result of concerns about the classification and diagnosis of GCA and other forms of vasculitis, an
international effort to improve criteria for the diagnosis of vasculitis has been under way since 2009.41
The Diagnostic and Classification Criteria for Vasculitis Study (DCVAS) had, by 2015, recruited over 4000
patients with either a form of vasculitis or a comparator condition and included over 900 individuals with a
clinical diagnosis of GCA. Patients are recruited if they have any clinical features that might be consistent
with vasculitis. This includes patients who do not actually have vasculitis, because they are considered to
be part of the comparator population for the study. Patients are either newly diagnosed with vasculitis
or a comparator condition or have had a diagnosis made within 2 years of recruitment into the study.
A detailed pro forma is used to report standardised information regarding symptoms, signs and test results
(including blood tests, imaging and biopsy data) available at the time of diagnosis. A subsequent follow-up
visit 6 months later is required, so that any change in the original diagnosis can be reported and used as
the final submitting clinician’s diagnosis. The DCVAS study has not yet reported results, but limited access
to the DCVAS data was granted for The Role of Ultrasound Compared to Biopsy of Temporal Arteries in
the Diagnosis and Treatment of GCA (TABUL) study.
Difficulty with diagnosis of giant cell arteritis based on the
gold standard temporal artery biopsy
For clinicians managing patients who may have GCA, untreated disease can result in permanent visual
loss (as discussed in González-Gay et al.24) and the condition is therefore considered to be a medical
emergency. However, there are far more people with headache (it is an almost universal experience) than
there are patients with GCA.
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Toxicity of treatment versus need for urgent treatment
The other main consideration is that treatment for GCA, which involves high doses of glucocorticoids such
as prednisolone over a prolonged period and which will result in rapid control of the inflammatory process
and reduce the risk of ischaemic manifestations, is very toxic and results in side effects in over 80% of
patients.42 The most common side effects reported in the study by Proven et al.42 included cataracts in
41% of patients, fractures in 38% of patients, infection in 31% of patients, hypertension in 22% of
patients, diabetes mellitus in 9% of patients and gastrointestinal bleeding in 4% of patients.
With modern therapy, such as the prophylactic use of calcium, vitamin D and bisphosphonates to prevent
fractures, some of these complications can be avoided. Further measures to reduce risk of treatment-related
toxicity include better control of hypertension and diabetes mellitus, as well as prophylactic use of proton pump
inhibitors to prevent gastrointestinal bleeding (which could relate to previous use of high doses of non-steroidal
anti-inflammatory drugs combined with high doses of prednisolone). The risk of serious infections remains
significant and has been estimated to be 55% higher than in age- and sex-matched controls.43
Therefore, the balance of risk versus benefit in a patient with suspected GCA rests heavily on our ability
to be confident that the diagnosis is correct. A patient who is incorrectly diagnosed with GCA will be
subjected to significant risk of steroid toxicity without experiencing any advantage. However, if the patient
does have GCA but the diagnosis was not made and the patient was not established on high doses of
steroids, then there is a significant risk of ischaemic complications, including permanent visual loss or
stroke, which are the most important complications of the disease and which makes sight loss (and other
acute ischaemic complications) from GCA a preventable medical emergency.
Diagnosis of giant cell arteritis relying on a gold standard of
temporal artery biopsy
Since 1932 the conventional gold standard investigation for GCA has been a TAB.1 The characteristic
finding of histiocytes, epithelioid and giant cells (large multinucleated cells present in the arterial wall) at
the intimal–medial junction is useful in diagnosis,41 but not always present (e.g. giant cells were found in
75% of positive biopsies in a recent series). Other pathological features include transmural inflammation,
adventitial infiltrates or localised infiltrates of inflammatory cells, especially lymphocytes in the media or
intima. Reduplication of the internal elastic lamina and fragmentation of the internal elastic lamina are also
described. Intimal cellularity and increased thickness can occur and, in a number of cases, the vessel lumen
is narrowed to occlusion with associated thrombus formation.
Most patients have headache, which on closer questioning is localised around the temporal artery and is
usually worse on one side than the other. The most symptomatic artery is usually selected for biopsy and
is most likely to show evidence of pathological findings. In some centres, it has previously been a routine
procedure to sample both temporal arteries in suspected cases, but the value of bilateral testing is
relatively low,44 with only one of 91 bilateral biopsies showing discordance. In a recent study of 132 cases
undergoing bilateral biopsies, the diagnostic yield increased by 12.7%45 as a result of the second
simultaneous biopsy (38 patients had bilateral findings of GCA, compared with an additional 13 patients
whose biopsies showed abnormalities confined to one side only).
The purpose of high doses of glucocorticoid therapy is to resolve inflammation. Therefore, the characteristic
findings of cellular infiltration of the vessel wall with lymphocytes and giant cells may have disappeared by
the time the biopsy is performed if there is a significant delay between starting treatment and obtaining the
biopsy. Because of the ‘clock ticking’ as a result of glucocorticoids being administered as a precautionary
measure (in case the patient really does have GCA), it is not usually helpful to perform a second biopsy of
the opposite (and possibly asymptomatic) artery if the first biopsy is negative for patients in whom there is a
suspicion of GCA. A biopsy from the opposite artery is feasible but is less likely to have a positive result,
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unless the patient has active symptoms of GCA in the artery to be biopsied. Cellular infiltration is the most
important histological finding but can potentially resolve within 7–10 days of commencing high-dose
glucocorticoid therapy.46 Therefore, in some patients, biopsy evidence for GCA is inadequate. Many of the
changes seen in the intima and internal elastic lamina can also be found in older people who do not have
any features of GCA.47 A recent surgical series of 237 patients undergoing TABs reported positive findings
of GCA in only 36 (15.1%) cases48 and the result of the biopsy did not significantly contribute to the
diagnosis. Changes suggestive of GCA are not consistently present throughout the course of the vessel.
The biopsy may not actually contain any arterial tissue. Nerves or veins were sampled in error in 14 of
567 consecutive biopsies (2.5%).49 Biopsies of temporal arteries are typically sectioned transversely to
provide an overall assessment of the artery. If the pathological abnormalities are present in the areas of
artery that have not been cut, it is possible to miss the relevant findings. If the biopsy length is small, the
characteristic histological features, which may occur sporadically along the length of the tissue obtained
(skip lesions), may be missed. The biopsy is typically sectioned in cross-section and it is possible that, if the
material obtained is quite small, only a few cross-sections will be available to view. If the abnormalities to
be detected are not seen in these cross-sections, the interpretation would be that the biopsy was normal.
However, it is possible that if a longer specimen had been obtained and more cross-sections had been
viewed then the pathological changes might have been evident. Obtaining specimens that have been
subjected to more sections increases the diagnostic yield slightly but leads to significantly more work and
expense for the pathology laboratory.50
Biopsy length (after fixation) varies in different studies. Shrinkage is well recognised, with a recent study of
62 biopsies showing an average of 4.6 mm of shrinkage from the time of surgical excision to fixation.51
A study of 966 biopsies from six different hospitals suggested that a length of at least 0.7 cm increased the
diagnostic yield from 12.9% to 24.8% positive results.52 By contrast, another study of 151 biopsies from
149 patients yielded 20 positive biopsies (13.3%), and there was no difference in the length of positive
(mean 0.7 cm) compared with negative (mean 0.65 cm) biopsies.53 The British Society for Rheumatology
(BSR) guidelines recommend between a 1- and 2-cm length of artery to provide an adequate specimen,
usually from only the symptomatic or most symptomatic side.5
The presence of inflammatory infiltrates in the vasa vasorum was reported in 6.5% of 354 biopsies
considered positive in one large study of patients with clinical features of GCA.54 However, it remains
controversial whether or not these findings, as well as some of the other ‘characteristic findings’
suggesting GCA, may in fact occur in patients with other forms of vasculitis such as antineutrophil
cytoplasm antibody (ANCA)-associated vasculitis.55–58
It has been suggested that TAB may be a useful test to diagnose other forms of vasculitis, which could
mimic GCA.59
There is an inevitable tension between obtaining enough material to make a diagnosis and initiating
therapy before disease-related complications set in. In practice, it is common for patients to start on
treatment as soon as a physician suspects the diagnosis, typically based on symptoms suggesting the
diagnosis of GCA and possible laboratory investigations such as an elevated C-reactive protein (CRP) level or
ESR. Treatment is commonly initiated in primary care and the primary care physician would typically contact
secondary care services to request confirmation of the diagnosis with a biopsy. However, the acute phase
response markers are not reliable tests to diagnose GCA, although if they are elevated, the ESR and CRP
level are supportive of the diagnosis but cannot be used on their own because of their lack of specificity.
Standards for diagnosis of giant cell arteritis
The BSR guidelines on managing GCA recommend that biopsy should be considered if a diagnosis of GCA
is suspected and state that an early biopsy is desirable in patients with suspected cranial GCA, preferably
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within 7 days of initiating high-dose steroid therapy.5 The biopsy should be carried out by experienced
surgeons to give the highest yield of positive results. Similar recommendations were made by the
European League Against Rheumatism in their guidelines for the management of large vessel vasculitis.60
Unfortunately for the NHS in England and for other health-care systems, there may be difficulty in
accessing a surgical list promptly. This can result in significant delay in a biopsy being performed.
Furthermore, the procedure is often performed by a relatively junior and inexperienced member of the
team. The overall impact of these factors could be a reduction in the sensitivity of biopsy as a test for GCA.
Accuracy of temporal artery biopsy versus ultrasound or other
imaging modalities
A meta-analysis of the use of ultrasound in GCA16 examined 23 studies and involved 2036 patients. The
weighted sensitivity and specificity of the halo sign was 69% [95% confidence interval (CI) 57% to 79%]
and 82% (95% CI 75% to 87%), respectively, compared with biopsy, and 55% (95% CI 36% to 73%)
and 94% (95% CI 82% to 98%), respectively, compared with ACR criteria. A study of 55 patients who
underwent colour Doppler ultrasound for suspected GCA61 reported a sensitivity and specificity of 82%
and 91%, respectively, suggesting that an ultrasound scan could be a good alternative to biopsy in
many patients.
However, ultrasonography of the temporal and axillary arteries is highly operator dependent and it is
important to develop and maintain expertise in the technique before it can be applied. Therefore, any
ultrasound study requires quality assurance of the adequate training of sonographers prior to the
evaluation of patients with suspected GCA. By contrast, MRI is much less operator dependent. In a recent
multicentre study, the diagnostic accuracy of MRI was investigated in 185 patients referred for suspected
GCA, of whom 53% underwent TAB. The sensitivity and specificity of MRI for diagnosing GCA was
78.4% and 90.4%, respectively, and for TAB (in those patients who had biopsy), the sensitivity and
specificity were 88.7% and 75%, respectively.13 The accuracy of the imaging was high if the patients had
received either no glucocorticoids or glucocorticoids for no more than 5 days, but more than 5 days of
therapy resulted in a significant fall in diagnostic accuracy. A combined approach that used ultrasound to
try to identify the most appropriate site for biopsy had no effect on the sensitivity of detecting histological
evidence of GCA.62
Summary
In summary, the management of GCA requires a balance between ensuring that patients with GCA are
diagnosed and treated promptly (to avoid complications such as sight loss) and avoiding the burden of
unnecessary steroid treatment in people without GCA. TAB is useful in assisting with diagnosis but lacks
sensitivity. Research since the 1990s on the accuracy of ultrasound suggests that ultrasound has a role as
an alternative to, or in addition to, biopsy. However, within the UK, the routine use of ultrasound for GCA
is restricted to only a few centres; TAB remains the standard test for the majority of patients suspected of
having GCA.
Aims and objectives
The main aim of the TABUL study was to assess the relative merits of TAB and ultrasound in contributing
to the diagnosis of GCA. The objectives of the TABUL study are based on two assumptions about
diagnosing and treating GCA.
First, patients with suspected GCA are treated with steroids as soon as the diagnosis is suspected (in order
to reduce the risk of serious vascular complications) and before any biopsy results might be available.
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Therefore, the potential benefit of an ultrasound examination instead of, or in addition to, biopsy is the
ability to either continue or withdraw high-dose glucocorticoid treatment appropriately owing to greater
certainty of diagnosis.
Second, TAB is itself very problematic as a reference standard, because up to half or more patients with
true GCA may have a negative biopsy.6,7 This may be for a number of reasons including biopsy size, delay
between onset of symptoms followed by early use of high-dose glucocorticoid therapy before biopsy and
obtaining the biopsy specimen within 7–10 days of therapy commencing; furthermore, the processing and
interpretation of biopsy itself can influence the outcome. A positive biopsy does confirm the diagnosis in
most patients suspected of having GCA, with specificity approaching 100%. There are some exceptions
because other forms of vasculitis may produce exactly the same biopsy appearances as seen in GCA. The
difference for other forms of vasculitis is that patients experience clinical features in other organ systems
that support that diagnosis, such as the involvement of airways or kidneys in patient with granulomatosis
with polyangiitis (GPA) or eosinophilic GPA (EGPA). Ultrasound is not going to be able to achieve greater
specificity than biopsy but may achieve better sensitivity if used either instead of, or in addition to, biopsy.
The first primary objective of the study was to evaluate the diagnostic performance (sensitivity and
specificity) of ultrasound as an alternative to biopsy for diagnosing GCA in patients who are referred with
suspected GCA and in whom a biopsy was going to be carried out.
The second primary objective was to perform a cost-effectiveness analysis to compare ultrasound as an
alternative to biopsy for diagnosing GCA.
The secondary objectives in the study were to evaluate:
l interobserver agreement in the assessment of ultrasound and biopsy
l the performance (sensitivity and specificity) of alternative strategies involving ultrasound and biopsy for
diagnosing GCA
l the cost-effectiveness of alternative strategies involving ultrasound and biopsy for diagnosing GCA.
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Chapter 2 Methods
Summary of study design
The study used a prospective cohort design and recruited patients with suspected GCA who were
undergoing a TAB, the standard diagnostic test, as part of their routine care in order to assist with
establishing the diagnosis. Patients were recruited following referral from their primary care physician or a
secondary care physician and consented to have an additional diagnostic test, namely an ultrasound
investigation of their temporal and axillary arteries, before having their biopsy. The clinician treating the
patient, as well as the patient, was blinded to the results of the ultrasound. Patients were assessed at
presentation, at 2 weeks and after 6 months. The performances of TAB and ultrasound were evaluated
against a reference diagnosis derived from the clinician’s final diagnosis, which included any changes to
the diagnosis during the follow-up period, such as the emergence of any GCA-related complications.
The reference diagnosis confirmed the clinician’s final diagnosis using an algorithm based on the ACR
classification criteria; any unconfirmed cases (and all cases in which the ultrasound result was unblinded
and seen by the clinician) were independently reviewed by a panel of experts.
Agreement between sonographers and between pathologists in their interpretation of videos and images
was assessed in an inter-rater agreement exercise for a sample of recruited patients. Clinical vignettes for
these patients were constructed and assessed by clinicians to see what decisions about diagnosis and
treatment might have been made if ultrasound results were provided instead of biopsy results. The
cost-effectiveness of the different tests and combinations of tests was assessed in an economic evaluation.
Patient and public involvement
Advice on study design was sought and obtained from patients through the registered charity Polymyalgia
Rheumatica & Giant Cell Arteritis UK. Patient representatives on the Trial Steering Committee and the Data
Monitoring Committee provided valuable advice and input during the study (see Acknowledgements).
Recruitment of sites
Sites were eligible to take part in the study if they were responsible for seeing patients with suspected
GCA and used TAB as a routine test for its diagnosis. Sites were not eligible if they used ultrasound for
diagnosing GCA as part of their routine practice.
Prior to study commencement, 19 hospitals in England indicated their interest in becoming study sites for
potential recruitment. Sites were eligible to take part if a site principal investigator, typically a clinician
(e.g. a rheumatologist or ophthalmologist) involved in the management of patients with GCA, could be
identified who would have overall responsibility for the site’s involvement in the study. Sites also needed to
be able to identify the minimum of one pathologist who would have responsibility for assessing TABs and
one sonographer with responsibility for performing and assessing ultrasound. Study sonographers needed
to have some previous experience in the use of ultrasound but did not need to have specific experience in
ultrasound of the temporal or axillary arteries for GCA. Sonographers could come from a variety of clinical
disciplines and included rheumatologists, radiologists and radiographers. Sites also needed to provide
assurance that, for any individual patient, the roles of the sonographer and the clinician managing
the patient were separate. This was to prevent the managing clinician from knowing the results of the
ultrasound scan, except when specifically allowed in the study protocol. It did not preclude a clinician
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(e.g. a rheumatologist who carries out ultrasound) from performing either role in different patients
provided that the separation of responsibilities was maintained for each participant.
All sites needed to obtain the relevant local approvals before training could be commenced. Site
participation required sonographers to successfully complete a training package in ultrasound for GCA.
No training was provided to the site surgeons, who were asked to perform the biopsies as part of routine
care, or to pathologists, given that TAB specimen assessment is part of standard care. At some sites,
additional clinicians were involved in the management of study patients and this was a requirement if the
site’s principal investigator was designated as the study sonographer to ensure that the ultrasound result
was blinded for all patients. Research nurses at each site were responsible for co-ordinating recruitment
and arranging tests to ensure that both ultrasound and biopsy procedures could be performed within
7 days of commencing high-dose glucocorticoid therapy. All these site personnel comprised the local
TABUL team with responsibility for co-ordinating the study locally and completing the clinical, pathology
and ultrasound data collection. The process for ultrasound training is described in the next section.
Each site was provided with study training during an initiation visit from the central TABUL study team
which consisted of advice on data collection (including completion of study forms) and the process for
submitting data. Specific training was provided on the completion of two measures used to assess
patients: the Birmingham Vasculitis Activity Score (BVAS) and the Vasculitis Damage Index (VDI). Clinicians
and research nurses were required to achieve test scores of 85% for the BVAS and 75% for the VDI
(and at least 50% of all individual cases had to be correct) before they were approved for scoring the two
measures. Monitoring visits were conducted as per the study standard operating procedures to ensure that
the correct procedures were being followed.
Training in ultrasound for giant cell arteritis
Ultrasound assessment of temporal arteries is an established technique for the diagnosis of GCA but there
is no standardised protocol in widespread use. We therefore developed a training package for performing
and analysing ultrasound scans for the TABUL study. The purpose of the training package was to provide
assurance that the sonographers in the study had achieved competence in scanning the temporal and
axillary arteries and interpreting the results before recruiting patients to the study.
The training package included a standardised protocol for performing ultrasound in the TABUL study
and an accompanying presentation. Sonographers’ competence in ultrasound for GCA was assessed in
three ways: (1) undertaking ultrasound assessment of 10 patients or volunteers without GCA; (2) passing
an examination that tested each sonographer’s competence in interpreting ultrasound videos; and
(3) successfully completing a ‘hot case’ ultrasound assessment of a patient with active GCA. Sonographers
were encouraged to attend the TABUL training day for sonographers in Oxford and/or participate in site
visits from the TABUL study team. After successful completion of training, sonographers were required
to submit recorded scans of recruited patients for ongoing assessment of competency in scanning
and interpretation.
Sonographers were required to complete all components of the training before they were deemed eligible
to assess patients recruited to the main study. An exception was made for sonographers who were already
performing routine assessment for GCA; these sonographers were required to undergo part of the training
protocol by scanning 10 control cases and completing their online assessment. These sonographers were
exempt from completing the ‘hot case’ assessment on the merit of their curriculum vitae, which was
assessed by the ultrasound experts for the study.
Ultrasound protocol and training requirements
The standard protocol for ultrasound and training was set out in the standard operating procedure for
ultrasound and is available via the NIHR Journals Library website (www.journalslibrary.nihr.ac.uk).
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The study required the use of a linear probe with a grey-scale frequency of 10 MHz or greater and a
colour Doppler frequency of at least 6 MHz, using a vascular pre-set and applying colour Doppler mode
as opposed to power Doppler mode. It was important to ensure that the focus was positioned around
5 mm below the skin surface for temporal artery ultrasound, in order to detect the artery. Grey-scale
frequency was required to be > 10 MHz and the pulse repetition frequency was set at approximately
2–3 kHz. This was dependent on machine and vessel and would need to be altered according to the
velocity of flow because this differs from artery to artery. The colour box required angle correction of at
least 60º to avoid poor colour Doppler signals and inaccurate readings. The gain setting had to be adjusted
to be able to just fill the lumen with colour to avoid over- or under-filling, therefore creating a potential
halo or ‘bleeding’ over the vessel wall, which might give a false reading. We did not routinely employ a
compression test to occlude the artery completely to eliminate flow; however, this is a useful test and was
described to all sonographers to facilitate distinction between a true halo sign and a false one.63
Each site sonographer was required to register the model number and manufacturer of his or her
ultrasound machine with the TABUL office to ensure that it was of sufficiently high resolution for the
purposes of the study; this was also reported for the subsequent economic analysis. If the sonographer
changed the machine, he or she was required to inform the central TABUL office of the change, and the
TABUL office had to confirm that the machine that had been substituted was of sufficiently high quality
for the study.
The protocol required each patient to lie in a recumbent or semirecumbent position on their side and
pull back their hair behind their ears. Gel was applied to the area of the temporal artery and the probe
was placed over the middle of the common superficial temporal artery at the level of the tragus, and
the position of the probe was adjusted if necessary to locate the artery. The probe was applied in the
transverse and subsequently the longitudinal plane or vice versa. After completing a sweep of the artery
in one plane, the probe was rotated by 90° and a further sweep was performed in the opposite plane.
The level of the bifurcation between frontal and parietal branches of temporal arteries serves as the marker
point to define the start of the frontal and parietal branches, respectively. The patient was then asked to
turn over to the other side so that the opposite temporal artery could be scanned. The axillary artery was
examined by asking patient to remove outer clothing to expose the axilla. Gel was applied to the inner
aspect of the upper arm and the ultrasound probe was placed over the midaxillary line, and swept along
the expected course of the artery. The probe was applied in either the longitudinal or the transverse plane
and swept along until the brachial artery branch was identified. The sweep was then repeated with the
probe rotated at 90º, so that both longitudinal and transverse scans were performed. A longitudinal static
image was obtained for normal cases and a transverse and longitudinal static image was obtained for
abnormal cases.
The sonographers were required to sequentially scan the complete length of common superficial temporal
arteries with their frontal and parietal branches in transverse and longitudinal views. The axillary arteries
were also assessed in transverse and longitudinal views. The assessors were required to provide video and
static images in both transverse and longitudinal planes as evidence that they had adequately scanned
arteries. Each video or still image had to be labelled with the patient’s study identification number, and the
location of the image was defined using the standard formatting abbreviation listed in Table 1; for
example, a video sweep image of the transverse view of the left temporal artery was labelled LTSN.
The minimum recordings consisted of a 10-second transverse sweep along the length of each of the
temporal arteries up to and beyond the bifurcation of the frontal and parietal branches and a still image
of each axillary artery. All images had to be scanned using colour Doppler to assess for complete filling of
the vessel and accurate assessment of stenosis, and aliasing of colour within the vessel. Doppler pulse
wave was used to further characterise any areas of stenosis. The sonographers were asked to report the
presence or absence of any abnormalities for each of the temporal and axillary arteries on the ultrasound
case report form (see Appendix 1) while they were scanning and to indicate the relevant section(s) for
abnormalities in the temporal arteries.
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TABLE 1 Abbreviations used to define ultrasound arterial sites and abnormalities found in the TABUL protocol
Site Image Abnormality Left Right
Temporal artery Initial sweep with transverse video
(for normal scans)
None LTSN RTSN
Axillary artery Initial sweep with longitudinal video
(for normal scans)
None LALN RALN
Common superficial temporal artery Transverse video Halo LCTH RCTH
Longitudinal video Halo LCLH RCLH
Transverse video Occlusion LCTO RCTO
Longitudinal video Occlusion LCLO RCLO
Doppler pulse wave Stenosis LCDS RCDS
Longitudinal still image Stenosis LCLS RCLS
Parietal ramus of superficial
temporal artery
Transverse video Halo LPTH RPTH
Longitudinal video Halo LPLH RPLH
Transverse video Occlusion LPTO RPTO
Longitudinal video Occlusion LPLO RPLO
Doppler pulse wave Stenosis LPDS RPDS
Longitudinal still image Stenosis LPLS RPLS
Proximal frontal ramus of superficial
temporal artery
Transverse video Halo LPFTH RPFTH
Longitudinal video Halo LPFLH RPFLH
Transverse video Occlusion LPFTO RPFTO
Longitudinal video Occlusion LPFLO RPFLO
Doppler pulse wave Stenosis LPFDS RPFDS
Longitudinal still image Stenosis LPFLS RPFLS
Distal frontal ramus of superficial
temporal artery
Transverse video Halo LDFTH RDFTH
Longitudinal video Halo LDFLH RDFLH
Transverse video Occlusion LDFTO RDFTO
Longitudinal video Occlusion LDFLO RDFLO
Doppler pulse wave Stenosis LDFDS RDFDS
Longitudinal still image Stenosis LDFLS RDFLS
Axillary artery Transverse still image Halo LAFTH RAFTH
Longitudinal still image Halo LAFLH RAFLH
Transverse still image Occlusion LAFTO RAFTO
Longitudinal still image Occlusion LAFLO RAFLO
Doppler pulse wave Stenosis LAFDS RAFDS
Longitudinal still image Stenosis LAFLS RAFLS
METHODS
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If any abnormality was detected, then additional information by artery and section was collected in the
case report form and recordings of the abnormalities were required. For a halo, the sonographer reported
the maximum thickness and length and whether or not it ran along the entire length of the section.
A 3-second transverse and longitudinal video was recorded to support evidence of any reported halo,
stenosis or occlusion in sections of the temporal artery. A transverse and longitudinal still image was
recorded to demonstrate halo or occlusion in either axillary artery. If stenosis was reported then the
velocity in and out of the stenosis (and the minimum and maximum luminal diameter for axillary arteries)
was reported and a longitudinal still image and Doppler pulse wave were recorded. The presence of
arteriosclerosis was reported separately as an abnormality but no images of this were required. On
completion of the scanning, the sonographer was required to document whether or not the ultrasound
results were consistent with a diagnosis of GCA. The completed case report forms and recordings
(on compact disc) were submitted to the TABUL office.
We expected the scanning protocol to take between 20 and 45 minutes for each patient. The start time,
end time and total scanning time were collected for each training case or patient. The protocol also
required the sonographer to ensure that the results of the ultrasound, the case report form and the
recordings were not given to, or discussed with, the clinical staff involved in treating the patient. Each site
was supplied with guidance on how to perform the scans (see Appendix 2).
Ultrasound training programme
Although the biopsy of temporal arteries has been an established test in widespread use all over the world
for decades, the use of ultrasound as a diagnostic test is much more limited. Very few of the sites involved
in the study had sufficient expertise to undertake proficient vascular ultrasound scanning for GCA. We
therefore developed a pragmatic training programme consisting of attendance at a training day or a site
visit with hands-on training. Competence in ultrasound was assessed using a video examination to
correctly identify normal or abnormal scan appearances, evidence of successfully performed scans of
10 healthy control subjects, and evidence of a successfully performed scan of at least one patient with
scan findings of active GCA. Sonographers were allowed to take part in the study only once all elements
had been successfully completed. In addition, we required sonographers to submit recordings of scans
from all patients recruited into the study for ongoing quality control.
Ultrasound protocol training was provided during a training day in Oxford at the start of the study or at
site visits by the TABUL study team. The protocol and training emphasised the importance of keeping
the ultrasound result blinded from the clinician treating the patient. Sonographers were also provided
with a presentation on how to scan temporal and axillary arteries to look for evidence of GCA and
how to document the site and nature of the findings using standardised abbreviations (see Table 1).
The presentation was developed with the supervision of one of the authors (WAS) who had extensive
expertise in GCA ultrasound. The presentation provided information on recommended techniques and
described the minimum equipment required to perform optimal scanning.
Video examination
An online assessment was developed specifically for the study and consisted of groups of ultrasound
images of 20 cases representing patients with or without active GCA. The cases comprised still images and
videos of approximately 10 seconds’ duration from consenting patients (not part of the TABUL study),
supplied by two of the authors (WAS and BD). Sonographers could view the images by accessing a secure
password-protected online site designed for the study. For each case, the sonographer was required to
indicate the presence or absence of hypoechoic vessel wall oedema (the ‘halo’). Sonographers submitted
their responses to the online system for marking; they had to achieve a minimum of 75% correct answers
to pass the evaluation. Sonographers who failed to pass the test at their first attempt were required to
repeat the entire test or specific questions, depending on how many errors they had made.
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Scanning training cases
Sonographers’ competence in performing ultrasound was assessed by their provision of satisfactory scans
from 10 healthy or non-GCA training cases. All training case participants were screened and consented
prior to the ultrasound scan. Training cases had to be at least 50 years old and willing to attend for an
ultrasound scan of their temporal and axillary arteries. Anyone with suspected GCA or a history of
diagnosed or suspected GCA was ineligible, as were patients with any inflammatory condition or anyone
who had taken systemic steroids or immunosuppressants in the previous 3 months.
Scanning followed the process described in the protocol. Briefly, the sonographer was required to provide
correctly labelled (and anonymised) video images of both temporal and axillary arteries from 10 individual
training cases, with documentation of the findings in the case report form. The case report forms and
recordings were reviewed by four expert sonographers (WAS, BD, EM, APD), who assessed the sonographers’
competence and provided feedback. Sonographers were required to assess additional cases as specified by
the reviewer if there were concerns over their scanning. If any of the control patients showed any evidence of
an abnormality consistent with GCA then the general practitioner (GP) of the individual would be informed
of the result.
Assessment of a patient with active giant cell arteritis (‘hot case’)
All sonographers were required to scan at least one patient who had active GCA as part of their training
assessment in order to demonstrate competence in detecting and reporting the abnormal findings. The
‘hot case’ patient was consented to the study using NHS or local hospital consent but could not be a
patient recruited to the main TABUL study. The sonographer scanned the patient, completed the case
report form and submitted recordings following the ultrasound protocol. The expert reviewers assessed the
submitted recordings and case report form to ensure that (1) the ultrasound features were consistent with
GCA and (2) that the appropriate images had been recorded, were of suitable quality and were consistent
with the case report form. If the reviewers were not satisfied then the sonographer was required to
complete another ‘hot case’ and resubmit.
Monitoring ultrasound during the study: quality control by expert review
Once a sonographer had successfully completed and passed all three components of the training
assessment, they were approved to scan patients with suspected GCA who were recruited to the study.
In order to ensure that the quality of scanning was maintained, a process of ongoing quality control was
developed and implemented. The ultrasound case report forms and recordings for each patient were
submitted and reviewed by at least one of the four expert reviewers. Recordings were uploaded to a central
ultrasound database which allowed remote access for reviewers. Reviewers assessed the quality of images
collected and their agreement or otherwise with the sonographer’s interpretation of the recordings. If the
expert reviewers had concerns about the performance of a sonographer, then the sonographer was required
to undergo additional training before being approved for scanning patients in the study.
All recruited patients had their scans reviewed unless no uploaded images were submitted. At least one
expert sonographer reported their agreement, disagreement or uncertainty with the assessment made by
the sonographer and, if uncertain, an indication of whether or not this was attributable to concerns over
the quality of the scanned images that were submitted.
Study population, recruitment and sampling
The study aimed to recruit all eligible patients who were undergoing a TAB for suspected GCA. Patients
were eligible if there was a clinical suspicion of a new diagnosis of GCA and the treating clinician had
decided that the patient required an urgent TAB to help determine whether or not the diagnosis was
GCA. No particular symptoms were specified, although it was expected that patients would have typical
symptoms of GCA such as a new onset of headache, scalp tenderness, elevated CRP level or ESR, jaw or
METHODS
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tongue claudication or visual loss. Patients had to be at least 18 years of age and be willing to attend for
an ultrasound scan of their temporal and axillary arteries.
Patients were not eligible for the study if they had had a previous diagnosis of GCA or if it was not possible
to arrange for their ultrasound and biopsy to be performed within 7 days of starting higher doses of
glucocorticoids (defined as > 20 mg of oral prednisolone or equivalent daily). Patients were also ineligible if
they had prolonged use (> 1 month) of higher dose glucocorticoids (> 20 mg of prednisolone or equivalent
per day at any time) within the previous 3 months for any condition other than PMR. A current or previous
diagnosis of PMR or presenting symptoms of PMR were not exclusion criteria, because this group of
patients would be likely to require investigations for possible associated GCA, if they presented with new
features suggesting the diagnosis. No other selection criteria were used for the recruitment of patients.
All patients were required to give written informed consent. Additional consent was required to allow
serum, plasma and deoxyribonucleic acid samples to be taken at the first assessment and serum and
plasma to be taken at the second and third assessments for future, currently undefined studies. Patients
were also invited to consent to allow their remaining tissue biopsy samples (not required for diagnosis) to
be stored centrally in the Oxford Musculoskeletal Biobank for further, future currently undefined studies.
All slides that were originally required for diagnostic purposes were stored in the Oxford Musculoskeletal
Biobank or returned to the site pathologists, after they had been photographed. All screened patients
were allocated a unique screening number and a screening case record form (CRF) was completed
for each case (see Appendix 3). All eligible patients who consented were allocated a unique study
identification number.
It was expected that the majority of patients would be recruited from referrals from general practice to
secondary care (either to rheumatology and/or ophthalmology on-call teams). The clinician responsible for
the patient’s care obtained verbal consent from the potential patient and passed on their contact details to
the local TABUL team. Following an initial telephone call the TABUL team provided the potential patients
with the study invitation letter and participant/patient information sheet (see Appendix 4) and discussed
the study with them. Alternatively, if a patient was attending the hospital, the study documents were given
directly to them by the clinician or study team. The potential patient would then have sufficient time to
read and understand the information and to ask any questions before providing written informed consent
(see Appendix 5).
Study recruitment at sites was encouraged by providing study information flyers in non-patients areas
of sites as an aide-memoire for research teams and clinicians. Awareness of the study was raised with
rheumatologists at local, regional, national and international meetings such as the BSR, local meetings with
GPs, ophthalmologists, vascular surgeons, rheumatologists and clinicians treating other forms of vasculitis.
Guidance on recruitment was provided to all sites (see Appendix 6).
Sample size calculation
The sample size of 402 patients was calculated to provide 90% power at a 5% type I error rate to test the
joint hypotheses that:
1. ultrasound has greater sensitivity than TAB (based on an assumed sensitivity of 76% for TAB and 87%
for ultrasound)
2. the specificity of ultrasound is no less than 83% using the reference diagnosis.
The postulated sensitivity and specificity figures were based on a previous meta-analysis.16 The sample size
would allow estimation of a one-sided rectangular confidence region for ultrasound false- and true-positive
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fractions, assuming 80% prevalence of GCA in patients having a biopsy for suspected GCA, with the
sample size inflated (gamma 0.1) because of uncertainty in the ratio of cases to controls in a cohort design.64
In order to allow for losses to follow-up (failure to have either test done, lack of a follow-up assessment
or patient withdrawal) the plan was to recruit 430 participants to the study. After monitoring actual
recruitment and withdrawals during the course of the study, the target recruitment was increased to the
range 435–445.
Clinical data collection
Patients who were referred with suspected GCA were screened to check their eligibility for recruitment
into the study. Patients who were eligible and gave informed consent had a full clinical assessment at
presentation. Appointments for ultrasound scans and then biopsy were arranged and patients returned for
a follow-up clinical assessment after 2 weeks (Figure 1). After the 2-week assessment and after seeing the
biopsy report, the clinician (who remained blinded to the ultrasound results) decided whether or not the
patient had features consistent with a diagnosis of GCA.
The result of the ultrasound was unblinded only if the clinician concluded that the patient did not have
features consistent with GCA and was therefore planning to withdraw steroid therapy rapidly. The
procedure for doing so is described below (see Ultrasound test results: procedure for revealing test results).
Clinicians were allowed to alter their decision to withdraw steroids rapidly following unblinding of the
ultrasound result. Patients attended a final clinical assessment after 6 months.
Patient assessment at presentation
The first clinical assessment at presentation collected data on demographic information, relevant conditions
and past medical history, symptoms, physical examination findings, laboratory test results and medication.
Clinicians were also asked how certain they were of the diagnosis of GCA (definite, probable or possible).
Patient data included the patient’s age, sex, ethnicity, weight, blood pressure and smoking history.
Comorbidity was assessed by reporting relevant current and previous medical history, and the assessment
US of temporal and 
axillary arteries
Data to be kept ‘blinded’
from clinician
‘Unblinding’ of US 
only if rapidly 
withdrawing steroids
Suspected GCA
Review medication at
2 weeks (V2)
Baseline (V1)
Review at 6 months (V3)
TAB
7 
d
ay
s
FIGURE 1 Flow of patients in the study. US, ultrasound; V, visit.
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included specific questions on diabetes mellitus, hypertension, angina, myocardial infarction, heart failure,
low trauma fractures and neoplasia.
Information on symptoms was collected separately for symptoms that the patient had experienced prior
to commencing higher-dose glucocorticoid therapy, as well as symptoms present at the first assessment
(if the patient had already started on glucocorticoid treatment). This allowed us to separately report
whether or not the presenting symptoms had changed as a result of glucocorticoid therapy. The presence
of the following symptoms (typically seen in GCA) was reported: anorexia, fatigue, fever/night sweats,
localised pain in the head, scalp tenderness, swelling over the temporal artery, pain over the temporal
artery, jaw claudication, tongue claudication, reduced or lost vision, double vision and amaurosis fugax.
Symptoms of PMR (early-morning stiffness lasting longer than 1 hour, bilateral shoulder pain and bilateral
hip pain) were also collected. In addition, any other symptoms that the clinicians thought were relevant
could be reported manually.
Physical examination of the patient required an assessment of both temporal arteries for evidence of
thickening, tenderness and reduced or absent pulsation, and of both axillary arteries for tenderness.
Examination also included, if assessed, evidence of anterior or posterior ischaemic optic neuropathy,
relative afferent pupillary defect, III/IV/V nerve palsy or bruits on either side and evidence of stroke,
aneurysm or other features such as scalp or tongue necrosis.
The results of laboratory tests that were required for the study protocol before starting steroids and at
presentation comprised ESR, CRP level and/or plasma viscosity. Additional tests included measurement
of full blood count, haemoglobin, biochemistry, ANCA and urine dipstick testing if there was a
clinical indication. Data were also collected on whether or not, and when, treatment with high-dose
glucocorticoids for suspected GCA had been started, the route and dose and any treatment with an
immunosuppressant agent. The patient was asked to complete a EuroQol-5 Dimensions (EQ-5D) 3-levels
questionnaire at the assessment.65 EQ-5D is a generic measure of health-related quality of life, necessary
for the calculation of the cost-effectiveness of the two main diagnostic tests.
Patient assessment at 2 weeks and 6 months
The biopsy and ultrasound tests were completed prior to the patient assessment at 2 weeks. The results of
the biopsy were provided to the clinician before the 2-week assessment but the ultrasound results were
not shown. The 2-week assessment included the clinician’s assessment of the biopsy report and whether
or not the biopsy was consistent with GCA. It was therefore possible for the pathologist and clinician to
have different opinions on whether or not the biopsy result was consistent with GCA. The patient
assessments at 2 weeks and 6 months comprised changes in current conditions and symptoms, a repeat of
the physical examination performed at presentation and the results of laboratory tests.
Data for two measures of disease activity and damage were also collected at 2 weeks and 6 months.
The BVAS is a validated assessment questionnaire reported by the clinician in the evaluation of disease
activity in systemic vasculitis.66,67 It consists of a list of clinical features that commonly occur in patients
with vasculitis together with a weighted score to provide a measure of severity of disease activity; it is
widely used for clinical studies and is increasingly used in the clinical management of patients with small
vessel vasculitis. It can be used to define how active disease is, to measure response to therapy or to
define relapsing disease66,68 for the purpose of clinical trials. The most current validated version of the BVAS
was used.67 The VDI is a structured assessment to evaluate damage occurring in patients diagnosed with
systemic vasculitis.69 It is a record of irreversible consequences of having a diagnosis of vasculitis. Items are
reported in the VDI if they have been present for at least 3 months and have occurred since the onset of
vasculitis. There is no attribution to cause and it has been used in large cohorts of patients with primary
systemic small vessel vasculitis.70 Data from the BVAS and the VDI can also be used to examine the possible
presence of an alternative form of vasculitis. Data were also collected on weight, blood pressure, treatment
with steroids and immunosuppressive drugs, and quality of life using the EQ-5D.
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At the 2-week assessment, the clinician was required to state whether or not the patient had features
consistent with GCA and, if responding yes, to indicate which of the following influenced the response:
symptoms, signs, blood abnormalities, biopsy or other (to be specified). If the patient’s features were
not consistent with GCA then the clinician was required to give at least one alternative diagnosis.
After providing the clinical diagnosis at 2 weeks, in the event that the clinician did not plan to continue
high-dose glucocorticoid therapy because they did not think that the patient had GCA, they were
required to contact the TABUL office for the ultrasound result. At the 6-month assessment the clinician
was required to indicate if the diagnosis had changed and to indicate the influences for any patients in
whom the decision was made to alter the diagnosis to GCA. At least one alternative diagnosis was
required for any decision to alter the diagnosis away from GCA. The clinical CRF is shown in Appendix 7
and guidance on completion of the CRF is shown in Appendix 8.
Adverse events (AEs) and any attribution to either of the diagnostic test procedures were reported on AE
CRFs (see Appendix 9). Guidance on completion of the AE CRFs is shown in Appendix 10.
The standard test: temporal artery biopsy
The standard test for GCA is TAB. This normally involves a minor surgical procedure to remove a small
sample of temporal artery (the BSR recommends a minimum length of 1 cm5) which is examined for
abnormalities by a pathologist. Guidance on the collection, processing and storage of biopsy samples is
shown in Appendix 11. Sites followed their usual practice for obtaining and processing TABs. The only
changes to routine practice required by TABUL were that sites were instructed to send the actual
pathological slides used to make their diagnosis to the TABUL office and that, in addition to their standard
reporting of biopsy results, pathologists were required to complete a study-specific CRF (see Appendices 12
and 13) to report their pathological findings. We did not require any specific information from any of the
surgeons undertaking the biopsy but they were all informed that the patient had been recruited to the
TABUL study.
The pathologist was required to report which side or sides the biopsy had been taken from as well as the
length of the biopsy (after freezing or fixation), and a note was made of whether or not it was bifurcated.
They were able to add other comments on the macroscopic appearance of the sample. For each biopsy,
the staining protocol was reported. The macroscopic appearance was described and a note was made of
whether or not the biopsy was from the temporal artery and which sections were cut. The presence
of abnormalities in the intima (arteriosclerosis or intimal hyperplasia) and the internal elastic lamina
(fragmentation or reduplication) were reported. Pathologists were required to indicate if there was an
inflammatory infiltrate in the sample (and the predominant site of any inflammation) and indicate if any of
the following features were present: normal areas, giant cells, calcification or any other unusual features.
Data were also captured on presence and causes of complete occlusion of the vessel or presence of
thrombus or evidence of recanalisation in at least one section of the vessel.
The pathological diagnosis was reported as either normal or any the following: compatible with a
diagnosis of GCA, compatible with another vasculitis, compatible with arteriosclerosis and compatible with
any other diagnosis as specified by the pathologist. The actual pathological slides were sent to the TABUL
office for image acquisition. Digital image acquisition was achieved using an Aperio Scanscope Turbo
AT (Leica Biosystems, Buffalo Grove, IL, USA). Slides were loaded onto the machine’s autoloader and
pre-snapped to obtain a macroscopic image before proceeding with digital scanning. The macroscopic
image was used to set the tissue area, focal plane, focus points, white balance, scan/slide settings and
labelling description. Once the settings had been optimised the slides were scanned in fragments and
digitally stitched together to form one high-resolution virtual representation of the pathology slide. These
virtual slides were stored on an external physical server and a web-based database (Aperio eSlideManager
V1.0, Leica Biosystems) was used to archive and store the eSlides. Slides could be viewed remotely using
Aperio’s web-based viewing systems (Leica Biosystems).
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The biopsy result, which was the primary standard test, was defined as positive by the pathologist if the
pathological diagnosis was compatible with a diagnosis of GCA. This included patients whose biopsy
samples did not contain temporal artery (e.g. vein, fat, muscle or other tissue) or for whom no sample was
obtained from surgery. An alternative standard test result was defined as the clinician’s interpretation of
the biopsy result as reported on the clinical CRF at the 2-week assessment. This was reported because we
expected that the clinician might reach a different conclusion from the pathologist, based on the
biopsy report.
The main analyses included patients who had no sample from surgery or a biopsy sample that did not
include temporal artery; these were categorised as not compatible with a diagnosis of GCA. Additional
analyses excluded the indeterminate biopsy results.
The index test: ultrasound of the temporal and axillary arteries
The index test, an ultrasound of both temporal and both axillary arteries, was performed following the
protocol described earlier and is available on the NIHR Evaluation, Trials and Studies Coordinating Centre
website (www.nets.nihr.ac.uk) and was subject to ongoing monitoring for quality assurance. The presence
of ultrasound abnormalities (halo, occlusion, stenosis and arteriosclerosis) in different segments of the
temporal arteries and in the axillary arteries (as defined in Table 1) was captured in the ultrasound case
report form (see Appendix 1). The primary test result for ultrasound was defined as positive and was used
for the main analyses if the sonographer responded ‘yes’ to the question ‘In your opinion are the results
consistent with a diagnosis of GCA?’. Additional analyses used alternative definitions of a positive result
based on the presence or absence of a bilateral halo and on the interpretation of the ultrasound images
from the expert review.
Ultrasound test results: procedure for revealing test results
The clinician treating the patient was provided with the biopsy result but did not have access to the results
of ultrasound at the 2-week assessment. Study sonographers were required to keep the results of each
patient’s scans blinded from the managing clinician for the duration of the study. The only exception was
if the managing clinician had completed the 2-week assessment and was planning to withdraw steroid
treatment rapidly. In these circumstances the clinician was required to contact the TABUL office and was
provided with the scan results as reported by the sonographer. The clinician then had an opportunity to
reconsider their decision to withdraw steroids and alter their diagnosis. Thus, the 2-week assessment
included a report of the clinician’s original assessment of the diagnosis and any revision following the
revealing of the ultrasound result.
The reference diagnosis
The ideal reference diagnosis for evaluating diagnostic tests is one that is independent of the tests being
evaluated. No such reference diagnosis exists for GCA for evaluating the performance of biopsy and
ultrasound. Criteria for classifying GCA and usual clinical practice for reaching a GCA diagnosis incorporate
the results of the biopsy; therefore, they cannot be truly independent methods for defining a reference
diagnosis. Furthermore, the ACR classification criteria were not intended to be used as diagnostic criteria.34
For the purposes of the study, a partially independent approach was used, which combined elements of a
clinician’s final diagnosis, the ACR classification criteria (incorporating the biopsy result), the emergence of
complications consistent with GCA during follow-up, the emergence of alternative vasculitis diagnoses
during follow-up and expert review to determine the reference diagnosis. The process started with the
clinician’s final diagnosis for the patient as reported on the 6-month (or in its absence, 2-week)
assessment. An algorithm was devised to determine if evidence from the biopsy and the presence or
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absence of symptoms and emerging complications and diagnoses on follow-up supported the clinician’s
diagnosis or if expert review was required to determine the reference diagnosis.
If the clinician’s final diagnosis was GCA, then a reference diagnosis of GCA was given if any of the
following criteria were met:
1. a stricter version of the ACR classification criteria using either the standard or tree method was met
based on the patient’s symptoms and physical examination from their baseline assessment (Table 2)
2. the emergence of PMR during follow-up in patients with no previous history of PMR and no symptoms
of PMR at presentation
3. the emergence of new or worsening jaw claudication, tongue claudication, abnormal anterior optic
neuropathy, abnormal posterior optic neuropathy, or relative afferent pupillary defect during follow-up.
If the clinician’s final diagnosis was not GCA, then a reference diagnosis of ‘not GCA’ was given.
If an alternative vasculitis diagnosis was made, these included Takayasu’s arteritis, large vessel vasculitis,
polyarteritis nodosa, GPA, microscopic polyangiitis, EGPA, cryoglobulinemic vasculitis, IgA vasculitis
TABLE 2 Definitions and sources of items in the ACR classification criteria
Criterion Definition Source
(1) Age at disease onset
of at least 50 years
Development of symptoms or findings
beginning at ≥ 50 years of age
Baseline patient assessment: symptoms
started at ≥ 50 years of age pre-steroids or
at presentation
(2) New headache New onset of or new type of localised pain
in the head
Baseline patient assessment: symptoms of
new onset or type of localised pain in head
pre-steroids or at presentation
(3) Temporal artery
abnormality
Temporal artery tenderness to palpation
or decreased pulsation unrelated to
arteriosclerosis of carotid arteries
Baseline patient assessment: abnormal
tender temporal artery on physical
examination
(4) Elevated ESR (at least
50 mm/hour)
ESR at least 50 mm/hour as assessed by the
Westergren method
Baseline patient assessment: laboratory test
results ESR at least 50 mm/hour pre-steroids
or at presentation
(5) Abnormal artery
biopsy
Biopsy specimen with artery showing
vasculitis characterised by a predominance
of mononuclear cell infiltration of
granulomatous inflammation, usually with
multinucleated giant cells
Pathology CRF: pathologist reports biopsy
result as consistent with a diagnosis of GCA
(6) Claudication of jaw,
tongue, or on deglutition
Development or worsening of fatigue or
discomfort in muscles of mastication,
tongue, or swallowing muscles while eating
Baseline patient assessment: symptoms of
jaw or tongue claudication pre-steroids or
at presentation
(7) Scalp tenderness or
nodules
Development of tender areas or nodules
over the scalp, away from the temporal
artery or other cranial arteries
Baseline patient assessment: symptoms of
new-onset generalised scalp tenderness
pre-steroids or at presentation
Classification as GCA
Traditional method (standard): at least three of (1) to (5) are met
Traditional method (strict): at least four of (1) to (5) are met
Tree method (standard): classified as GCA if (1) is met and any of (3), (5) or (6) are met. Criterion (2) replaces (5) in the
absence of a TAB result; criterion (7) replaces (3) if (3) is not met
Tree method (strict): classified as GCA if (1) is met and at least two of (3), (5) or (6) are met. Criterion (2) replaces (5) in the
absence of a TAB result; criterion (7) replaces (3) if (3) is not met
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(Henoch–Schönlein purpura), or any other vasculitis to be specified. A reference diagnosis of ‘not GCA’
was also given if all of the following criteria were met.
1. The patient failed to meet the ACR classification criteria using either the standard or tree methods
(see Table 2).
2. No new-onset PMR occurred during follow-up.
3. No new or worsening jaw claudication, tongue claudication, abnormal anterior optic neuropathy,
abnormal posterior optic neuropathy or relative afferent pupillary defect occurred during follow-up.
4. No symptom of reduced or lost vision in either eye occurred or worsened during follow-up.
5. No evidence of abnormal III/IV/VI nerve palsy or stroke on clinical examination was observed at 2 weeks
or 6 months.
6. No sudden visual loss, cerebrovascular accident or cranial nerve palsy reported on the BVAS occurred
during follow-up.
7. No retinal change, optic atrophy, visual impairment/diplopia, blindness in one eye, blindness in the
second eyes or cerebrovascular accident reported on the VDI occurred during follow-up.
Any patient who was not given a confirmed reference diagnosis based on the above was referred for
expert review. Furthermore, any patient who had their diagnosis altered during follow-up (typically for a
diagnosis altered to GCA from not GCA following unblinding of the ultrasound report) was automatically
referred for expert review regardless of any confirmed reference diagnosis given above.
The expert review group comprised five rheumatologists involved in the study. Each case requiring
expert review was independently assessed by three of the five rheumatologists, and no rheumatologist
could review cases from their own site. A summary report for each patient was extracted from the clinical
data and included information on symptoms, GCA-related complications, items from the ACR classification
criteria and the clinician’s diagnosis. Access to the clinical database was also given so that expert reviewers
could examine all data collected as part of the study with the exception of the ultrasound results. Each
expert reviewer independently reported their agreement or disagreement with the clinician’s final diagnosis.
The clinician’s final diagnosis was supported if at least two of the experts agreed with the diagnosis. The
clinician’s diagnosis was altered if all three experts disagreed with the diagnosis. If two experts disagreed
with the clinician’s diagnosis then the patient was discussed by the relevant experts during a moderated
teleconference until the three experts reached a consensus.
Inter-rater agreement data collection and analysis
The aim of the inter-rater agreement component of the study was to assess the extent of agreement
between trained sonographers in their interpretation of ultrasound videos, and between experienced
pathologists in their interpretation of biopsy images, for a sample of cases using data, videos and
images from patients recruited to TABUL. Sonographers and pathologists assessed the same cases using
a web-based exercise. Intrarater agreement was also assessed by repeating cases in the exercise. The
impact of providing additional information about the patient was examined by including a brief vignette.
All pathologists and sonographers who assessed patients in the main TABUL study were asked to complete
a web-based exercise. The exceptions were pathologists and sonographers who were involved in the
management of TABUL or in the expert review of ultrasound for quality control (two pathologists and four
sonographers.) Pathologists and sonographers who agreed were sent instructions for completing the
exercise and a password to access the exercise.
The overall design involved a web exercise with 44 cases. Each case represented a patient recruited to
TABUL and comprised ultrasound videos of both temporal arteries, scanned images of the biopsy slide and
a brief clinical vignette describing the patient. The first five cases were defined as training/practice cases
that allowed raters to familiarise themselves with the exercise. The remaining cases, the rating cases,
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consisted of 30 unique cases, six repeats of unique cases (for intrarater assessment) and three reserve
cases. The reserve cases were available to replace any of the 30 cases that were subsequently found to
be ineligible once the exercise had started. The overall number of cases was chosen to keep the task
manageable, and the aim was to have at least 10 pathologists and 10 sonographers complete the exercise.
This was to allow results to be generalised to the wider populations of pathologists and sonographers.
The criteria for including a patient’s videos and biopsy images as rating cases in the exercise were
ultrasound videos of adequate quality of the right and left temporal arteries, biopsy slides received and
scanned, inclusion of the patient in the main TABUL analyses and patient consent for the use of the
images. Cases were ineligible if the biopsy specimen did not consist of artery or if the ultrasound was
abnormal owing to axillary artery involvement without temporal artery abnormalities. Cases were also
ineligible if the biopsy images or ultrasound videos included information that identified the patient or
clinician involved or included markings indicating abnormality and this information could not be removed
or hidden. Finally, cases were excluded if the quality of the ultrasound images was judged to be poor by
expert review during quality control. Disagreement with the original sonographer’s interpretation by expert
review or difficulty in interpreting the ultrasound by expert review despite adequate quality videos were
not criteria for exclusion.
Identification of cases was performed in three stages before the start of the exercise because the main
TABUL database and the ultrasound and biopsy databases had not been locked at the time of initial
selection and because of the work involved in ensuring that videos and images were eligible. The first
stage involved identifying potentially eligible cases from the list of patients recruited to the main study who
had had their ultrasound videos uploaded. This list of potentially eligible cases was ordered using random
numbers generated using Stata version 13 (StataCorp LP, College Station, TX, USA). The second stage
involved populating the 33 rating cases from the top of the list. Any case found to be ineligible was
replaced with the next available case from the list. This process was repeated until all 33 rating cases were
deemed eligible. The third stage involved pilot testing of the exercise and review of all videos and images
by two pathologists (BM, KW) and two sonographers (WAS, JP) to ensure that the criteria relating to the
videos and images were met. The five training cases were selected purposively starting at the bottom of
the ordered list. These were selected to ensure that there were at least two abnormal and two normal
cases for the biopsy images and for the ultrasound videos. A final post-exercise stage involved a further
eligibility check of the rating cases against the locked database. Any of the 30 rating cases subsequently
found to be ineligible were replaced with one of the three reserve rating cases for inclusion in
the analyses.
A web-based exercise was designed to allow remote access to the videos and images and to capture data
from the assessments made by the sonographers and pathologists. Each case in the exercise began by
giving access to two video images showing left and right temporal arteries (for sonographers) or one
biopsy slide image for each stain available (for pathologists). Videos could be replayed as often as required
and biopsy images allowed zooming for magnification at the equivalent of up to 40 times in high
resolution. Raters were asked to answer yes or no to the question ‘In your opinion, do the ultrasound (or
pathology) images show features of GCA?’ and to answer certain or uncertain in response to the question
‘How certain are you?’. They then gave their answers and confirmed that they were confident to submit
their answers.
All cases were rated before and after seeing a brief clinical vignette describing the patient. The vignette
was added to reflect a more realistic scenario for interpreting the videos or images. For example,
the sonographer would see the patient in front of them when conducting temporal and axillary artery
ultrasound. The pathologist might receive a brief description of the patient on the biopsy request form.
The vignettes provided basic information on age, sex, glucocorticoid treatment, comorbidity, presenting
symptoms and laboratory test results, for example ‘79 year old male started glucocorticoid therapy
2 days ago for suspected GCA. Patient has hypertension. Presented with new localised pain in head, jaw
claudication and reduced vision. Elevated ESR and CRP’. The vignette was identical for the ultrasound and
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biopsy versions of each case except for the duration of glucocorticoid therapy (which varied depending on
when the test was done). For repeat cases, the core information was identical to the original case but the
order of wording was altered.
Cases had to be completed in order and rating cases could not be started until all five training cases
had been completed. Once a rating case had been completed it was not possible to return to that case
to view the videos or images or to look at the answers given. This was because six of the cases were
repeated. It was possible to return to the training cases for reference. The locations of repeated cases in
the 36 rating cases were assigned before the random ordering of eligible cases. Repeated cases all made
their first appearance in the first 18 cases and all made their second appearance in the final 18 cases.
For each of the six repeated cases there was a minimum gap of 16 cases between its first and second
appearances.
Clinical vignettes data collection and analysis
The aim of the assessment of the clinical vignettes was to determine what decision about a patient’s
diagnosis and treatment would have been made if there was no biopsy performed, leaving the clinician
to rely on the results of the ultrasound. Two overlapping samples of cases were selected from patients
recruited to the study. The first sample was the same random sample used for the assessment of
inter-rater agreement. The second sample comprised all patients in the main study who had a positive
biopsy and a negative ultrasound.
Clinical vignettes were structured to provide data on the patients at the times when two key decisions are
made. The first is on initial presentation, when the possibility of a diagnosis of GCA is considered and a
decision is taken to recommend a TAB. The second is after 2 weeks, when a decision to continue or
withdraw high-dose steroids for GCA is made. Vignettes were populated with data collected during the
study. Information provided at presentation comprised the patient’s age, sex, relevant current conditions
and medical history, symptoms, symptom onset and any laboratory test results (ESR, CRP level or ANCA)
prior to starting steroids, duration and dose of steroids, new symptoms and symptoms still present at
presentation, results of the physical examination at presentation and any laboratory test results (ESR, CRP
level or ANCA) at presentation. Clinicians were then asked to give their indication of the likelihood of the
patient having GCA (definite, probable, possible or not GCA) and indicate whether or not, in the absence
of alternative tests such as ultrasound, they would recommend this patient for a TAB.
The information at 2 weeks was presented once responses to the questions had been confirmed.
Information on the vignettes comprised the results of the ultrasound test and information about the
patient’s health after 2 weeks. The ultrasound test was reported as either consistent or not consistent
with a diagnosis of GCA and included additional information on any abnormalities identified on
ultrasound, for example ‘consistent with GCA; halo on right temporal artery; normal left temporal artery;
normal axillary arteries; no occlusion or stenosis’. Other information comprised symptoms present at
2 weeks (categorised by new, worse, no change, better and resolved), results of the physical examination
at 2 weeks, results from laboratory tests and any changes in current conditions. Clinicians were then asked
to give their indication of the likelihood of the patient having GCA (definite, probable, possible or not
GCA) and to indicate the appropriateness of continuing to treat the patient with high-dose steroids for
GCA on a nine-point scale (1, extremely inappropriate; 5, uncertain; 9, extremely appropriate).
Data on the appropriateness of continuing treatment with high-dose steroids were categorised as
appropriate, inappropriate or uncertain using the method outlined in The Rand/UCLA Appropriateness
Method User’s Manual.71 A panel median of 7–9 without disagreement is considered appropriate, a panel
median of 4–6 or any median with disagreement is categorised as uncertain, and a panel median of 1–3 is
categorised as inappropriate. Disagreement was determined using the interpercentile range adjusted for
symmetry and the common approach of rounding up medians of 3.5 and 6.5 was applied.71
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Statistical analysis
The statistical analyses of the diagnostic accuracy of TAB and ultrasound were specified in the statistical
analysis plan (see Appendix 14). Sensitivities and specificities were calculated for TAB and ultrasound in
comparison with the gold standard reference diagnosis. The kappa statistic was used to assess agreement
between TAB and ultrasound, and McNemar’s test was used to detect systematic discordance.
The inter-rater agreement between sonographers and between pathologists was evaluated using a
two-way random-effects analysis of variance to estimate the intraclass correlation coefficients for
agreement with 95% CIs. Both cases and raters were treated as random effects in order to generalise
findings to all cases (from the sample selected) and to the potential population of trained sonographers
(from the sample of sonographers doing the exercise). Intrarater agreement was evaluated by estimating
kappa statistics for agreement and by examining agreement for the individual repeated cases and raters.
Statistical analysis was performed in Stata versions 12 and 13.
Pre-test probability of giant cell arteritis: definition of
risk categories
The availability of data from the DCVAS study provided an opportunity to define categories of pre-test risk
of a GCA diagnosis from an independent sample of patients and was used in preference to obtaining
expert opinion elicited from clinical vignettes.41 Data on 585 patients recruited to centres not participating
in TABUL, and who had had a TAB, were used to derive definitions for high-, medium- and low-risk groups.
The high-risk group was defined as patients with (1) claudication of the jaw or tongue and (2) elevated
ESR or CRP level (ESR of at least 60 mm/hour or CRP level of at least 40 mg/l) either at pre-steroids or at
presentation assessments. The low-risk group was defined as patients (1) without jaw or tongue claudication
and (2) without elevated ESR or CRP level at both the pre-steroids and presentation assessments of symptoms
and laboratory tests. The remaining patients were categorised as medium risk.
Changes to the study protocol
There were two substantial amendments to the study protocol. The first amendment was made in
February 2011 and comprised the following key changes.
1. To alter the decision always to offer each potential participant 24 hours to consider their participation in
the study. This amendment was made because there were some circumstances in which treatment may
be delayed while waiting for consent, for example in an emergency (to minimise delay in normal care
such as performing the biopsy) or when sites are able to provide a fast turnaround time for performing
the biopsy. In these circumstances we offered the opportunity for participants to provide full written
informed consent in < 24 hours from receiving information about the study.
2. To provide further clarification on the collection of additional blood and biopsy samples during the
course of the study.
The second amendment was made in February 2013 and comprised the following key changes.
1. To increase the target sample size for recruitment from 430 to 435–445 (with 402 completing the
primary end point).
2. To extend the recruitment period by 12 months.
3. To clarify the recruitment strategy (including the production of a poster summarising the study for use
in non-patient areas).
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4. To clarify the process for the managing clinician to contact the TABUL office in order to be given the
results of the ultrasound result (unblind the ultrasound result).
5. To allow inclusion of patients in whom the biopsies were performed more than 7 days after starting
high-dose glucocorticoids because of safety concerns about when the biopsy could be performed,
for example to allow discontinuation of warfarin so that it was safe to perform the biopsy. This would
be part of standard care for any patient who required a biopsy but was receiving warfarin.
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Chapter 3 Site recruitment and ultrasound
training
Site recruitment
The study aimed to recruit sites that routinely performed biopsy of the temporal artery as part of the
care pathway in the diagnosis of GCA. Forty-four sites expressed an interest in recruiting patients to the
study. Two sites already made some use of temporal artery ultrasound to assist in diagnosing GCA on a
non-routine basis but were in equipoise and accepted the study requirement to keep the ultrasound result
hidden from the clinician managing the patient. One site made occasional use of ultrasound to mark
the area of disease for surgeons to biopsy. For the purposes of the study the site agreed to suspend
this practice.
Before the study began there were 19 sites in England that had indicated an interest in taking part.
Recruitment of sites in the UK began in November 2009 and the first training case, as part of the
ultrasound training, was recruited in March 2010. The first approval of a site to recruit patients to the main
study was in June 2010. The process of gaining the relevant research approvals [e.g. NHS research and
development (R&D) approval] for sites, the availability of suitable sonography staff and staff time at each
site, and the process of training sonographers delayed recruitment of sites to the study. By December
2011, six sites were approved to recruit patients (four of these had begun recruiting patients) and eight
sites had started ultrasound training. The study was opened up to sites in Europe following international
interest in the study to increase site recruitment, with four sites (in Germany, Ireland, Portugal and Norway)
beginning the process to gain approval to recruit patients.
A total of 44 sites expressed an interest in taking part in the study, although eight sites were unable to
obtain R&D approval and therefore did not progress to the ultrasound training stage. One site (the
ophthalmology department at the John Radcliffe Hospital, Oxford) obtained the relevant R&D approvals
but acted as a referral site for the Nuffield Orthopaedic Centre, Oxford, so did not require ultrasound
training. Thus, 35 sites began the process of ultrasound training to become eligible to recruit patients to
the study. Two of the sites (Stoke Mandeville Hospital, Aylesbury, and Royal Berkshire Hospital, Reading)
did not have their own sonographer and instead relied on the trained sonographers from the Nuffield
Orthopaedic Centre for ultrasound scanning at their sites. The two sites did not require ultrasound training
but did need to complete other study requirements for site approval. Twenty of the 35 sites achieved
approval to recruit patients to the study and the progress of 18 of these sites in obtaining approval is
shown in Figure 2.
Ultrasound training
The key factor that limited progress to full-site approval to recruit patients to the study was the ultrasound
training for site sonographers. There were 49 sonographers representing 35 sites who started ultrasound
training and 26 sonographers representing 22 sites who passed their training. Two sites had a sonographer
who passed training but the sites did not go on to recruit patients to the study. In the first site the sonographer
moved to a different hospital so the site lost its approval to recruit to the study because it had no trained
sonographer. The second site did not complete another component of site training (completion of BVAS and
VDI training) and could not provide appropriate research nurse support to achieve approval to start the study
before recruitment to the study had actually completed. Thus, there were 24 sonographers who passed
training who were all located at sites that were approved and that were able to recruit patients to the study.
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The main reason for not successfully passing the ultrasound training was the requirement to perform a
‘hot case’ assessment. Twenty-one sonographers did not provide or pass a ‘hot case’ assessment and
28 (58%) either passed or were exempt (Table 3). For the video examination component, 39 (80%)
sonographers passed [although 21 (42%) needed more than one attempt at the examination] or were
exempt and two experienced sonographers were exempt because they were study investigators involved in
setting and marking the examination. For the training case component a total of 450 healthy volunteers or
patients without any suspicion of GCA were scanned. Forty (82%) sonographers passed the component,
although five were required to scan additional training cases before passing.
The 24 sonographers who scanned patients in the study were made up of 10 clinicians, six radiologists and
eight professional sonographers. Four had previous experience in ultrasound for GCA and were exempt
from the ‘hot case’ assessment and two sonographers were exempt from the video examination component
as well. All 24 sonographers satisfactorily completed the training case component, as assessed by one of
the study expert sonographers (WAS) not involved in scanning patients, although two sonographers needed
to scan additional cases before passing. Half of the sonographers taking the video examination achieved the
75% pass mark at their first attempt with the remaining sonographers achieving this at their second or
third attempt.
Seven of the 24 sonographers passed all components without requiring further attempts at any
component: three professional sonographers, two radiologists and two clinicians. The 13 sonographers
who did need a further attempt at one or more components comprised five professional sonographers,
two radiologists and six clinicians. The four experienced sonographers (two radiologists and two clinicians)
all passed those components that they took at the first attempt.
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FIGURE 2 Time from starting ultrasound training to approval for patient recruitment for 18 sites (two sites not
requiring ultrasound training are not shown; they received approval to recruit patients in 2011).
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Ultrasound monitoring during the study
Once a sonographer had completed training and started scanning patients recruited to the study, all their
recorded scans and completed case report forms for these patients were monitored. The team of expert
reviewers assessed all submitted scans and forms to monitor the quality of video and still images being
recorded, as well as the sonographers’ record of the scan findings, in order to identify any concerns with
either the performance of the scans or the interpretation of the results. Details of the results of the expert
review are reported in Chapter 5. The results of the expert review are reported in Chapter 4.
One site was suspended from scanning any further training cases because of the poor quality of scanning;
the original sonographer at the site subsequently took no further part in the study. A new sonographer
was identified who successfully passed the training requirements. Another site was suspended from
recruiting patients to the study after the findings from the expert review disagreed with the ultrasound of
TABLE 3 Characteristics and training assessment of sonographers
Characteristic Detail
Sonographers starting
training (N= 49), n (%)
Sonographers approved
at 20 recruiting sites
(N= 24), n (%)
Occupation Sonographer 15 (31) 8 (33)
Radiologist 8 (16) 6 (25)
Clinician 26 (53) 10 (42)
Previous experience Yes 6 (12) 4 (17)
No 43 (88) 20 (83)
Video examination Pass (first attempt) 18 (37) 11 (46)
Pass (second attempt) 11 (22) 6 (25)
Pass (third attempt) 10 (20) 5 (21)
Exempt (experienced) 2 (4) 2 (8)
Not done 8 (16) –
Ten training cases Passed (10 cases) 35 (71) 22 (92)
Passed (with additional cases) 5 (10) 2 (8)
Not completed 6 (12) –
Not started 3 (6) –
‘Hot case’ assessment Pass (first attempt) 17 (35) 15 (63)
Pass (second attempt) 4 (8) 4 (17)
Pass (third attempt) 1 (2) 1 (4)
Exempt (experienced) 6 (12) 4 (17)
Failed 12 (24) –
Not done 9 (18) –
Overall Passed at first attempt 8 (16) 7 (29)
Passed with further attempt(s) 13 (27) 13 (54)
Passed with exemptions 5 (10) 4 (17)
Not passed 23 (47) –
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their second enrolled patient; the site was required to submit and pass an additional ‘hot case’ assessment
before being allowed to resume recruitment. In another site, patient recruitment was suspended after
expert reviewers disagreed with scans reported as ultrasound positive and recommended retraining for the
sonographer. Recruitment was resumed following successful retraining.
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Chapter 4 Description of the study population,
recruitment and eligibility
A total of 430 patients were recruited from 20 participating centres over 42 months, as shown inFigure 3. The first patient was recruited in June 2010 and the last patient was recruited in
December 2013. Forty-nine of these patients were excluded from the primary analyses because they did
not have both an ultrasound scan and a biopsy, their biopsy was done > 10 days after starting steroid
treatment or they did not have a follow-up assessment. The main study results are based on the remaining
381 patients.
Figure 3 shows that there were 730 patients originally screened for eligibility into the study, 300 of whom
did not meet the inclusion criteria and were therefore not evaluated further, leaving 430 patients recruited
for the baseline assessment. A further 30 patients were excluded at this stage, chiefly because it was not
Screening for eligibility
(n = 730)
Recruited and week 0 assessment
(n = 430)
Ultrasound and TAB
(n = 400)
Primary analysis, n = 381a
Secondary analysis, n = 391a
Week 2 assessment
• Did not meet inclusion criteria, n = 185
• Declined to participate, n = 115
Excluded
(n = 300)
• Withdrew consent, n = 8
• Investigator decision, n = 2
• Biopsy not done or not scheduled in 
   time, n = 16
• US not done, n = 4
Excluded
(n = 30)
• Biopsy outside time frame, n = 4
• Investigator decision, n = 2
• Withdrew consent, n = 1
• Lost to follow-up, n = 1
• Other, n = 1
Excluded
(n = 9)
• Lost to follow-up, n = 14
• Withdrew consent, n = 11
• Patient died, n = 16
• Biopsy outside 7 days, n = 4b
• Investigator decision, n = 1
• Other, n = 3
Excluded
(n = 49)
Week 26 assessment
(n = 342)
FIGURE 3 Flow of participants through the TABUL study. US, ultrasound. a, Patients included in the primary analysis
underwent their biopsy within 10 days of starting steroids. Patients included in the secondary analysis underwent
their biopsy at any time after starting steroids. One participant missed the 2-week visit (leaving 380 patients with a
2-week assessment) but continued in the study and completed the 26-week assessment. b, Based on original protocol
exclusion criteria.
DOI: 10.3310/hta20900 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 90
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Luqmani et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
31
feasible to arrange a biopsy in the time frame required. Of the 400 patients who completed both
assessments (the ultrasound and biopsy), a further nine were excluded, leaving 391 patients for the
secondary analysis. Ten of these patients could not be included in the primary analysis because their biopsy
had been performed at least 10 days after starting steroid treatment. Before the final assessment (after
6 months) another 49 patients were excluded from the analysis. The main reasons were death (n = 16),
lost to follow-up (n = 14) or had withdrawn consent for the study (n = 11). The recruitment numbers for
each centre are shown in Figure 4, and Figure 5 demonstrates the cumulative recruitment over the course
of the whole study. Two sites recruited the majority of patients, but eight other sites recruited > 10 cases
each. Initial recruitment was slower than predicted. An extension to the recruitment period was agreed
and revised planned recruitment is shown in Figure 5.
Summary of test results and the reference diagnosis
All 381 patients underwent ultrasound examination in accordance with the study protocol, and all patients
had a TAB performed as part of the normal standard of care for investigations of patients with suspected
GCA. In total, 101 patients (27%) had an abnormal biopsy that was consistent with a diagnosis of GCA.
In a total of 28 patients biopsies failed; in four cases no samples were obtained and in 24 cases the biopsy
sample did not contain arterial tissue. These patients are defined in the main analyses as having a diagnosis
that is not consistent with GCA (i.e. they are analysed on the assumption that they do not have the
disease). In total, 162 patients (43%) had an abnormal ultrasound that was compatible with a diagnosis of
GCA. After expert review, the reference diagnosis of GCA was given to 257 patients, a prevalence of 66%
in the study cohort. The diagnosis of GCA conventionally rests on the clinical pattern at presentation,
combined with the results of laboratory tests, including ESR or CRP level, the response to steroid therapy
and the TAB result. For many patients, not all of these aspects (clinical findings and symptoms, serological
abnormalities or biopsy results) are entirely consistent with the diagnosis, which leads to a degree of
variability in interpreting the findings. For example, patients who have symptoms suggestive of GCA,
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such as new-onset headache and jaw claudication, may actually have a normal or low ESR and or CRP level;
furthermore, the biopsy result may be negative, especially if the test was performed after the patient had
been treated with high doses of glucocorticoid therapy for > 7 days and/or the biopsy was small (less than
1 cm of artery). Under these circumstances it might be difficult to be absolutely certain of the diagnosis and
by the time the biopsy result is provided to the clinician, it is usually too late to go back to recheck any of
the tests again because, in the meantime, the patient has continued to receive high-dose glucocorticoid
treatment, which is likely to significantly suppress any evidence of inflammation.
The clinical diagnosis of GCA requires the clinician to use their expertise in interpreting these different
pieces of information. We therefore included an expert review in our study, so that all cases in which there
was any doubt about the diagnosis of GCA were subject to expert review of the clinical and serological
findings. The end result was to produce a ‘reference diagnosis’ of GCA based on the clinician’s
interpretation of all of this information. Figure 6 summarises the different combinations of biopsy and
ultrasound test results (GCA, not GCA or, in the case of biopsy, unsuccessful) and the final reference
diagnosis for the 381 patients in the primary analysis group.
In 187 patients the clinician’s interpretation was submitted for expert review, and in 23 patients the
interpretation was altered (from an interpretation of GCA to a reference diagnosis of not GCA in
14 patients and from an interpretation of not GCA to a reference diagnosis of GCA in nine patients).
Figure 7 illustrates these interpretations and reference diagnoses with respect to the clinicians’ initial
assessment of GCA at presentation.
Participant characteristics
Demographics
Demographic characteristics of the cohort are shown in Table 4; 377 patients (99%) were aged > 50 years
(one of the ACR criteria). The median age of participants was 71 years [interquartile range (IQR) 64–78 years]
and 72% were female. Two recruiting centres provided the majority of patients (Nuffield Orthopaedic
Centre and Southend University Hospital); 11 centres recruited fewer than 10 patients each. The majority of
patients were white British (80%); most of the remainder were either white Irish or from another white
background. Only 3% of patients were from a non-white background. The low numbers of non-white
patients is in keeping with other data suggesting that GCA is much less common in these populations.72
Presenting characteristics
Current and previous medical histories at baseline are shown in Tables 5 and 6. The most common
symptoms at baseline were localised pain in the head (88%), fatigue (65%), generalised scalp tenderness
(59%) and pain over the temporal artery (51%). Although 145 and 99 patients were reported as still
experiencing headache after 2 weeks and 6 months, respectively, only two patients developed new
headache after the baseline visit (two new cases at 6 months). Systemic features such as fever, night sweats
and anorexia affected around one-third of patients. Features suggesting accompanying PMR were reported
in one-third of patients. The median time between first symptom onset and baseline was 31 days (IQR
10–93 days, n = 377); the median time between symptom onset and starting steroids was 33 days (IQR
13–99 days, n = 379). Symptoms suggesting ischaemic complications such as jaw or tongue complications
were common, affecting up to 43% of patients. Baseline features of visual involvement were very common
(43%), in keeping with other studies.26 However, when we separated patients with GCA from the non-GCA
patients, the frequency of visual features was only marginally higher at baseline (45% vs. 37%), 2 weeks
(30% vs. 23%) and 6 months (27% vs. 22%) in the patients with GCA, as shown in Table 7. The frequency
of ischaemic optic neuropathy on physical examination (when performed) was higher in the GCA group
than in the non-GCA group at baseline (10% vs. 5%), 2 weeks (6% vs. 1%) and 6 months (4% vs. 3%).
Ten new cases of reduced or lost vision in either eye were reported during follow-up: three cases (1%) were
reported at 2 weeks and seven cases (2%) were reported at 6 months. Six (2%) new cases of double vision
were reported at 6 months. The clinician overseeing the patient’s care was responsible for reporting these
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TABLE 4 Characteristics of study participants
Characteristic Summary (N= 381)
Age (years)
Number (%) of responses 381 (100.0)
Mean (SD) 71.1 (9.8)
Median (IQR) 71.7 (64.3–77.8)
Sex, n (%)
Male 108 (28.3)
Female 273 (71.7)
Site, n (%)
Chapel Allerton Hospital, Leeds, UK 16 (4.2)
City Hospital, Birmingham, UK 4 (1.0)
Dudley Hospital, Dudley, UK 4 (1.0)
Gateshead Hospital, Gateshead, UK 14 (3.7)
Great Yarmouth Hospital, Great Yarmouth, UK 2 (0.5)
Hospital de Santa Maria, Lisbon, Portugal 2 (0.5)
Hospital of Southern Norway Trust, Kristiansand, Norway 25 (6.6)
Jena University Hospital, Jena, Germany 12 (3.1)
Musgrave Park, Belfast, UK 6 (1.6)
Nuffield Orthopaedic Centre, Oxford, UK 111 (29.1)
Princess Alexandra Hospital, Harlow, UK 7 (1.8)
Queen Alexandra Hospital, Portsmouth, UK 7 (1.8)
Queen’s Hospital Romford, Essex, UK 8 (2.1)
Queen’s Medical Centre, Nottingham, UK 22 (5.8)
Royal Berkshire Hospital, Reading, UK 4 (1.0)
Royal Derby Hospital, Derby, UK 3 (0.8)
Southend University Hospital, Southend, UK 90 (23.6)
St Vincent Hospital, Dublin, Ireland 18 (4.7)
Stoke Mandeville Hospital, Stoke, UK 20 (5.2)
Sunderland Royal Hospital, Sunderland, UK 6 (1.6)
Ethnic group, n (%)
White British 303 (79.5)
Irish 22 (5.8)
Other white background 45 (11.8)
Other mixed background 1 (0.3)
Indian 5 (1.3)
Pakistani 2 (0.5)
Other Asian 1 (0.3)
Caribbean 1 (0.3)
Chinese 1 (0.3)
IQR, interquartile range; SD, standard deviation.
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TABLE 5 Symptoms by visit
Symptoms
Baselinea
(N= 381), n (%)
2 weeks (N= 381), n (%) 6 months (N= 335), n (%)
All New All New
Localised pain in the head 337 (88.5) 145 (38.1) 0 (0.0) 99 (29.6) 2 (0.6)
Generalised scalp tenderness 223 (58.5) 83 (21.8) 6 (1.6) 49 (14.6) 4 (1.2)
Pain over temporal artery 194 (50.9) 67 (17.6) 1 (0.3) 45 (13.4) 7 (2.1)
Swelling over temporal artery 92 (24.1) 25 (6.6) 2 (0.5) 12 (3.6) 4 (1.2)
Bilateral shoulder pain 123 (32.3) 40 (10.5) 1 (0.3) 42 (12.5) 11 (3.3)
Bilateral hip stiffness or pain 68 (17.8) 17 (4.5) 3 (0.8) 20 (6.0) 7 (2.1)
Early-morning stiffness > 1 hour 75 (19.7) 22 (5.8) 3 (0.8) 26 (7.8) 11 (3.3)
Fatigue 246 (64.6) 141 (37.0) 10 (2.6) 120 (35.8) 11 (3.3)
Anorexia 140 (36.7) 45 (11.8) 3 (0.8) 27 (8.1) 6 (1.8)
Symptoms of fever or night sweats 143 (37.5) 60 (15.7) 4 (1.0) 53 (15.8) 10 (3.0)
Jaw claudication 163 (42.8) 62 (16.3) 2 (0.5) 26 (7.8) 3 (0.9)
Tongue claudication 20 (5.2) 7 (1.8) 1 (0.3) 3 (0.9) 1 (0.3)
Reduced or lost vision in either eye 133 (34.9) 95 (24.9) 3 (0.8) 80 (23.9) 7 (2.1)
Amaurosis fugax 14 (3.7) 5 (1.3) 5 (1.3) 3 (0.9) 2 (0.6)
Double vision 31 (8.1) 11 (2.9) 0 (0.0) 9 (2.7) 6 (1.8)
a Present at either pre-steroids or baseline.
TABLE 6 Medical history and conditions at baseline
Clinical feature (N= 381) Current, n (%) Past, n (%)
Medical history
PMR 28 (7.3) 9 (2.4)
Stroke/TIA 5 (1.3) 27 (7.1)
Migraine 13 (3.4) 4 (1.0)
Headache 7 (1.8) 3 (0.8)
Shingles 1 (0.3) 6 (1.6)
Sinusitis 6 (1.6) 1 (0.3)
Conditions
Diabetes mellitus 54 (14.2) 0 (0.0)
Hypertension 200 (52.5) 9 (2.4)
Angina 28 (7.3) 24 (6.3)
Myocardial infarction 0 (0.0) 23 (6.0)
Heart failure 19 (5.0) 8 (2.1)
Malignancy 9 (2.4) 53 (13.9)
Low trauma fracture (hip, spine, forearm, other) 1 (0.3) 56 (14.7)
TIA, transient ischaemic attack.
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data, which may or may not have been independently verified by an ophthalmologist. Ascertaining whether
or not the visual features are definitely related to GCA is very difficult. We expected that there would be a
tendency to report any visual features as possibly related to GCA, however unlikely this is, because the
consequences of missing early ischaemic ophthalmological complications would be disastrous for the
patient. If we look for more robust evidence of visual loss directly as a result of GCA, we may have to accept
that reporting the number of patients with ischaemic optic neuropathy will underestimate the real risk,
while accepting all reported visual loss will overestimate the real risk. The presence of ischaemic optic
neuropathy or an afferent pupillary defect could be explained by a complication of a presumed diagnosis
of GCA. However, non-arteritic anterior ischaemic optic neuropathy73 can present in a similar way to GCA
with visual loss but is not typically associated with headache or an elevation of the acute phase response.
Non-arteritic anterior ischaemic optic neuropathy was reported in 5% of the non-GCA cases in this study
at baseline.
Twenty-eight patients had a diagnosis of PMR at baseline and a further nine patients had a previous
history of PMR. Levels of hypertension were high (52% of the cohort), 14% of the cohort had pre-existing
diabetes mellitus at baseline, 7% were suffering from angina and 5% had heart failure. A total of 2% of
the cohort had a current history of cancer but 14% had a previous history of any form of malignancy.
Around 15% had previously suffered a low-trauma fracture; one of the patients had a fracture at the time
of presentation. Not all patients had ESR or CRP level measured prior to starting steroids. Only 73% of
patients had a CRP level tested before starting treatment and 73% had an ESR performed before steroids
TABLE 7 Visual features by visit
Visual feature
Baseline 2 weeks 6 months
GCA
(N= 257),
n (%)
Not GCA
(N= 124),
n (%)
GCA
(N= 257),
n (%)
Not GCA
(N= 124),
n (%)
GCA
(N= 227),
n (%)
Not GCA
(N= 108),
n (%)
Symptoms and physical examination
Any visual featurea 115 (44.7) 46 (37.1) 77 (30.0) 29 (23.4) 61 (26.9) 24 (22.2)
Visual loss 94 (36.6) 39 (31.5) 69 (26.8) 26 (21.0) 58 (25.6) 22 (20.4)
Anterior or posterior ischaemic
optic neuropathy
25 (9.7) 6 (4.8) 16 (6.2) 1 (0.8) 9 (4.0) 3 (2.8)
BVAS
Blurred vision 32 (12.5) 21 (16.9) 10 (4.4) 4 (3.7)
Sudden visual loss 25 (9.7) 2 (1.6) 3 (1.3) 1 (0.9)
VDI
Blindness (no cataracts) 8 (3.1) 1 (0.8) 15 (6.6) 0 (0.0)
Blindness and cataracts 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Optic atrophy 2 (0.8) 0 (0.0) 3 (1.3) 1 (0.9)
Visual impairment/diplopia 8 (3.1) 3 (2.4) 26 (11.5) 7 (6.5)
Combined
Any visual featuresb 115 (44.7) 46 (37.1) 84 (32.7) 34 (27.4) 71 (31.3) 28 (25.9)
Any visual lossc 94 (36.6) 39 (31.5) 69 (26.8) 26 (21.0) 58 (25.6) 22 (20.4)
Optic neuropathy or atrophy 25 (9.7) 6 (4.8) 18 (7.0) 1 (0.8) 11 (4.8) 3 (2.8)
a Defined as presence of reduced or lost vision in either eye, double vision or amaurosis fugax.
b Defined as presence of reduced or lost vision in either eye, double vision or amaurosis fugax, blurred vision or sudden
visual loss on the BVAS, blindness or visual impairment/diplopia on the VDI.
c Defined as presence of visual loss, sudden visual loss on the BVAS or blindness on the VDI.
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were commenced. There were 75 (19.7%) patients in whom neither ESR nor CRP levels were measured
before starting steroids, and in only one of these was plasma viscosity measured.
We would expect a dramatic and rapid reduction in the acute phase response as a result of glucocorticoid
therapy. Laboratory results for ESR were higher prior to the use of high doses of glucocorticoid therapy
[mean 46.5 mm/hour, standard deviation (SD) 33.4 mm/hour] when compared with the results at baseline
(mean 37.1 mm/hour, SD 31.4 mm/hour). Similar results were found for CRP values, which were higher
before glucocorticoid therapy than at baseline (mean 63.8 mg/l, SD 58.9 mg/l, compared with mean
39.0 mg/l, SD 40.4 mg/l).
Visual features over time are displayed in Table 7. Visual features at baseline were reported in a total of
162 (42%) participants, with a slightly higher proportion in the reference GCA group than in the group of
patients whose diagnosis was not GCA. Thirty-seven per cent of patients with GCA and 31% of patients
without GCA experienced visual loss at baseline; these values fell to 26% and 20%, respectively, at
6 months. If we look at reporting of visual features based on data in the BVAS and VDI assessments at
2 weeks and 6 months, respectively, blurred vision was reported as frequently in patients with GCA as in
those who did not have GCA. Sudden visual loss was more often reported in patients with GCA than
in patients without GCA (10% vs. 2%) at 2 weeks. The VDI reported blindness (not related to cataract) in
eight patients (3%) with GCA at the 2-week assessment, and in one patient in the non-GCA group; by
6 months, 7% of patients with GCA were reported as blind. In one case this was recorded as blindness
in both eyes; in all other cases blindness was recorded as occurring in one eye. The number of patients
reported as having visual impairment or diplopia increased from 2 weeks to 6 months in both groups,
possibly suggesting a side effect of the glucocorticoid treatment. Combining the data from the main
CRF with the BVAS and VDI reporting of visual features, there were slightly more visual features (and
specifically visual loss) at each visit in the GCA patients than in the non-GCA patients. More objective
findings of ischaemic optic atrophy were less common in both groups but not dissimilar at baseline
(10% vs. 5%), 2 weeks (7% vs. 1%) and 6 months (5% vs. 3%).
Table 8 shows findings from the physical examination at baseline; the most common symptom was
tenderness of the temporal arteries (50% abnormal) that was most commonly unilateral, but in 11% was
bilateral. Thickening of one or both temporal arteries was reported in 27% of patients and reduced or
absent pulsation in the temporal artery was detected in 91 patients. Tenderness of either axillary artery
was much less common and reported in only 34 patients. Bruits were detected in 15 individuals and could
in some patients represent extracranial large vessel vasculitis, but in other patients could have been
pre-existing bruits due to atherosclerosis. In fact, only 5 out of 15 patients with detectable bruits had
abnormal findings on ultrasound of the axillary arteries. Of the 296 who did not have detectable bruits,
42 had abnormal axillary findings on ultrasound. In seven patients, stroke was part of the initial
presentation of their GCA. Cranial nerve palsy was reported in three patients. Three patients presented
with aneurysms of an artery at diagnosis. Four participants had no abnormal features reported.
Table 9 shows the physical examination findings by the length of time on steroids. Reduced or absent
pulsation and thickened temporal artery appear to have been less common in those patients who
had been on steroids for ≥ 3 days than in those on glucocorticoid therapy for a shorter duration. The
documentation of physical examination findings was structured to elicit specific features that would be
expected to occur in patients with GCA. Some of these physical examination findings would require input
from other clinical staff such as ophthalmologists to confirm the presence or absence of anterior ischaemic
optic neuropathy/posterior ischaemic optic neuropathy; this would explain the large number of missing
values attributed to these two items. Reporting of relative afferent pupillary defect was often omitted.
This feature could have been evaluated by a generalist with no specific expertise in ophthalmology, but it
would require the use of a torch or an ophthalmoscope to shine in the patient’s eyes. It is possible that in
some centres such equipment was not available in the department while patients were being seen.
Table 9 summarises the relationships between glucocorticoid use and the presence of physical findings.
It demonstrates that 92 of the patients had either not started high doses of glucocorticoids at all or had
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started them only on the same day as the initial assessment. Overall, 149 patients had received high doses
of glucocorticoids for 1–2 days prior the assessment and 138 patients had been treated with glucocorticoids
for at least 3 days before assessment. Table 9 shows that clinically detectable abnormalities in the temporal
arteries were less evident the longer patients had been treated with high doses of steroids, but, nevertheless,
26 patients still had detectable, thickened temporal arteries and 66 had tender temporal arteries despite
3 days of high-dose glucocorticoid therapy.
TABLE 9 Findings from physical examination at baseline by length of time on steroids
Feature
Abnormal, n (%)
Unilateral Bilateral Normal Missing
Not started steroids or started same day (N = 92)
Tender temporal artery 32 (34.8) 11 (12.0) 49 (53.3) 0 (0.0)
Thickened temporal artery 18 (19.6) 12 (13.0) 62 (67.4) 0 (0.0)
Reduced or absent pulsation in temporal artery 24 (26.1) 6 (6.5) 62 (67.4) 0 (0.0)
Tender axillary artery 6 (6.5) 0 (0.0) 85 (92.4) 1 (1.1)
Bruits 4 (4.3) 3 (3.3) 66 (71.7) 19 (20.7)
Anterior ischaemic optic neuropathy 6 (6.5) 0 (0.0) 27 (29.3) 55 (59.8)
Posterior ischaemic optic neuropathy 2 (2.2) 0 (0.0) 26 (28.3) 62 (67.4)
Relative afferent pupillary defect 4 (4.3) 0 (0.0) 51 (55.4) 35 (38.0)
III/IV/VI cranial nerve palsy 2 (2.2) 0 (0.0) 20 (21.7) 70 (76.1)
1–2 days after starting steroids (N = 149)
Anterior ischaemic optic neuropathy 12 (8.1) 1 (0.7) 41 (27.5) 94 (63.1)
Bruits 2 (1.3) 2 (1.3) 116 (77.9) 28 (18.8)
III/IV/VI nerve palsy 1 (0.7) 0 (0.0) 25 (16.8) 122 (81.9)
Posterior ischaemic optic neuropathy 3 (2.0) 0 (0.0) 38 (25.5) 106 (71.1)
Reduced or absent pulsation in temporal artery 28 (18.8) 10 (6.7) 111 (74.5) 0 (0.0)
Relative afferent pupillary defect 5 (3.4) 0 (0.0) 106 (71.1) 36 (24.2)
Tender axillary artery 7 (4.7) 6 (4.0) 135 (90.6) 1 (0.7)
Tender temporal artery 58 (38.9) 23 (15.4) 68 (45.6) 0 (0.0)
Thickened temporal artery 30 (20.1) 15 (10.1) 104 (69.8) 0 (0.0)
≥ 3 days after steroids (N = 138)
Anterior ischaemic optic neuropathy 6 (4.3) 2 (1.4) 33 (23.9) 93 (67.4)
Bruits 3 (2.2) 1 (0.7) 112 (81.2) 20 (14.5)
III/IV/VI nerve palsy 0 (0.0) 0 (0.0) 18 (13.0) 116 (84.1)
Posterior ischaemic optic neuropathy 1 (0.7) 1 (0.7) 32 (23.2) 102 (73.9)
Reduced or absent pulsation in temporal artery 14 (10.1) 8 (5.8) 115 (83.3) 1 (0.7)
Relative afferent pupillary defect 5 (3.6) 1 (0.7) 99 (71.7) 29 (21.0)
Tender axillary artery 12 (8.7) 3 (2.2) 121 (87.7) 2 (1.4)
Tender temporal artery 58 (42.0) 8 (5.8) 71 (51.4) 1 (0.7)
Thickened temporal artery 17 (12.3) 9 (6.5) 111 (80.4) 1 (0.7)
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Anterior ischaemic optic neuropathy was reported in 27 patients (7% of the cohort) at baseline, which
included 23 patients with a subsequent diagnosis of GCA and four patients with a subsequent diagnosis
of not GCA; it was reported in six patients who had received either no steroid therapy or < 1 day of
steroids; in 13 patients who had received between 1 and 2 days of steroids; and in eight patients with
≥ 3 days of treatment with high doses of steroids. The length of time on steroids may have been a
reflection of the severity of the condition (i.e. with patients with visual symptoms being treated more
aggressively by their primary care physician before referral to the study).
Table 10 shows that the ESR and CRP level were higher before steroids (mean 46mm/hour, SD 33.4 mm/hour)
than at baseline (mean 37.1 mm/hour, SD 31.4 mm/hour). Similar results were reported for CRP values, which
were higher pre-steroids than at baseline (mean 62.6 mg/l, SD 58.5 mg/l, compared with mean 39.3 mg/l,
SD 43.8 mg/l). Not all patients had their ESR or CRP level measured prior to starting steroids. CRP level was
measured before starting treatment in 74% of patients and ESR was measured in 73% before steroids were
commenced. The CRP level and ESR values reported in patients who were diagnosed as having GCA were
higher than in those patients diagnosed as not having GCA. This is likely to be explained by the inherent bias
in the diagnosis, which would have been influenced by these results.
Ultrasound results
Ultrasound examination was performed on all 381 patients. Abnormalities consistent with GCA were
found in 162 (43%) of the ultrasound scans (Table 11). Table 11 shows that the majority of patients with
abnormal scans had changes in the temporal arteries (35%) and that 11.5% had abnormalities in the
axillary and temporal arteries. Abnormalities were more likely to be bilateral than unilateral (29% vs. 20%).
Halo was the most commonly cited reason for reaching a diagnosis of GCA (42.5%). Stenosis (12%) or
occlusions (11%) were seen less commonly, but there was an overlap with patients also showing halo. The
maximum length of halo in those patients in whom a halo was present was 20 mm (median) in the axillary
arteries and 9 mm in the temporal arteries. It was, however, sometimes extremely difficult (especially in
temporal arteries) to measure the length as a result of vessel tortuosity. In some patients the halo extended
the entire length of the scanned artery. The maximum reported median thickness of halo was 1.1 mm
(IQR 0.6–1.4 mm) in the axillary arteries and 0.6 mm (IQR 0.4–0.9 mm) in the temporal arteries.
TABLE 10 Laboratory test results at baseline
Test
Pre-steroids Baseline
GCA (N= 257) Not GCA (N= 124) GCA (N= 257) Not GCA (N= 124)
ESR value (mm/hour)
Number (%) of responses 187 (72.8) 92 (74.2) 231 (89.9) 110 (88.7)
Mean (SD) 55.0 (33.5) 29.4 (26.0) 44.5 (33.0) 21.7 (20.7)
Median (IQR) 53.0 (28.0–83.0) 18.0 (8.5–49.5) 38.0 (19.0–63.0) 14.0 (6.0–33.0)
CRP value (mg/l)
Number (%) of tests 191 (74.3) 87 (70.1) 238 (92.6) 113 (91.1)
CRP level in the normal range
(no value reported), n (%)
35 (13.6) 38 (30.6) 63 (24.5) 75 (60.5)
Number (%) of CRP values
reported
156 (60.7) 49 (39.5) 175 (68.1) 38 (30.6)
Mean (SD) 70.4 (56.6) 38.1 (58.1) 42.2 (42.3) 26.4 (49.1)
Median (IQR) 54.0 (27.0–101.5) 16.0 (7.8–36.1) 31.0 (14.0–54.0) 10.4 (3.0–24.6)
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TABLE 11 Ultrasound findings in 381 patients with suspected GCA
US finding Summary (N= 381)
Presence of abnormality, n (%)
No 195 (51.2)
Yes 186 (48.8)
Site of abnormality, n (%)
Temporal 133 (34.9)
Axillary 9 (2.4)
Both temporal and axillary 44 (11.5)
Spread of abnormality, n (%)
Unilateral 75 (19.7)
Bilateral 111 (29.1)
Sonographers’ opinion, n (%)
Not GCA 219 (57.5)
GCA 162 (42.5)
Any halo 162 (42.5)
Any stenosis 45 (11.8)
Any occlusion 41 (10.8)
Axillary halo maximum length (mm)
Number of measurements 15
Mean (SD) 26.1 (22.9)
Median (IQR) 20.0 (12.0–34.0)
Axillary halo maximum thickness (mm)
Number of measurements 62
Mean (SD) 1.1 (1.0)
Median (IQR) 1.1 (0.6–1.4)
Minimum, maximum 0.1, 6.7
Temporal halo maximum length (mm)
Number of measurements 181
Mean (SD) 12.0 (11.3)
Median (IQR) 9.0 (6.0–14.0)
Temporal halo maximum thickness (mm)
Number of measurements 461
Mean (SD) 0.7 (0.7)
Median (IQR) 0.6 (0.4–0.9)
Minimum, maximum 0.1, 8.8
If scan abnormal, number of abnormal segments
Number of measurements 186
Mean (SD) 3.6 (2.8)
Median (IQR) 2.5 (1.0–6.0)
US, ultrasound.
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Table 12 details the artery on which the halo was identified. In total, at least one halo on ultrasound was
reported in 162 patients, in the majority of whom (n = 118) haloes were seen only on the temporal artery
(bilateral, n = 60; unilateral, n = 58). By contrast, just nine patients had a halo on the axillary artery only,
with no halos seen in the temporal arteries. In the remaining 35 patients halos were observed on both
temporal and axillary arteries.
In 24 patients, ultrasound showed abnormalities but the sonographer’s diagnosis was not GCA. Table 13
describes the characteristics of these patients. The majority of the abnormalities were found in the
temporal arteries (18 patients) but eight patients had axillary artery abnormalities. The abnormal findings
were unilateral in 14 patients and bilateral in 10 patients and halo was detected in 10 patients, stenosis in
nine and occlusion in four. Of these 24 assessments, 10 were in agreemeent with the ultrasound expert
reviewers, seven were in disagreement and seven were unclear. In 23 of these 24 patients, the scan
findings were attributed to atherosclerosis; one abnormal case was attributed to the use of radiotherapy
for breast cancer.
Having completed training (which included 10 ultrasound test cases and at least one hot case), 23
sonographers performed ultrasound scans in the TABUL study. Around half of the scans in the study were
undertaken by two sonographers, who performed more than 80 scans each. Figure 8 shows the number
of ultrasound assessments undertaken by the 23 sonographers.
It is possible that the reliability of sonographers who completed fewer than 10 scans was lower than the
reliability of sonographers recruiting more than 10 patients. We examined the evidence for this, which
demonstrated an effect on sensitivity but not specificity (see Chapter 5). Table 14 compares the
TABLE 12 Halo findings in the temporal arteries compared with the axillary arteries
Halo findings Temporal
Axillary N Bilateral (N= 81), n (%) Left (N= 34), n (%) Right (N= 38), n (%) None (N= 228), n (%)
Bilateral 20 13 (16.0) 3 (8.8) 1 (2.6) 3 (1.3)
Left 13 6 (7.4) 0 (0.0) 4 (10.5) 3 (1.3)
Right 11 2 (2.5) 4 (11.8) 2 (5.3) 3 (1.3)
None 337 60 (74.1) 27 (79.4) 31 (81.6) 219 (96.1)
TABLE 13 Characteristics of the ultrasound assessments with abnormalities but where the sonographer’s diagnosis
is not GCA
US finding Summary (N= 24)
Site of abnormality, n (%)
Temporal 18 (75.0)
Axillary 8 (33.3)
Spread of abnormality, n (%)
Unilateral 14 (58.3)
Bilateral 10 (41.7)
Any halo 10 (17.5)
Any stenosis 9 (15.8)
Any occlusion 4 (7.0)
US, ultrasound.
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sonographers’ diagnoses with the ultrasound expert review. The expert reviewers agreed with the
sonographers’ findings in 260 out of 381 patients for whom the images were clear. In 61 patients (16%),
there was a disagreement about interpretation of the scan findings, but in a further 60 patients the main
reason for disagreement was on the basis of an unclear or unreviewed scan result, suggesting that
technical ability to perform the scan rather than interpretation of the scan result was the main problem.
The limitation of technical proficiency at scanning is an important problem to address and highlights the
need to consider more training if this is the main issue for the sonographer. It is also possible that the
problem is a result of patient factors; for example, the presence of very tortuous temporal arteries can
make it more difficult for less experienced sonographers to adequately visualise the whole of the artery.
Figure 9 shows the time interval from starting steroids to undertaking the ultrasound scan or the biopsy as
well as the number of days between performing each test. Scans were performed more quickly than
biopsies (as part of the protocol, the scan had to be performed before the biopsy because if the biopsy
was carried out first, then that section of the artery would no longer be available for scanning). In general,
the scan was easier to obtain at very short notice, typically within a few days of starting the steroid
treatment, whereas the biopsy was sometimes not possible to schedule until later in the week after
commencing steroids (or even later for 10 patients). However, despite these potential difficulties, for 215
out of 391 patients (55%), the tests were performed within 2 days of each other, including 52 patients
(13%) for whom the scan and biopsy were performed on the same day.
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FIGURE 8 Number of ultrasound study assessments performed by the sonographers (n= 23). US, ultrasound.
TABLE 14 Comparison of sonographer diagnosis and ultrasound expert review
Diagnosis
US expert review diagnosis, n (%)
GCA (n= 109) Not GCA (n= 212) Unclear (n= 58) Not reviewed (n= 2)
Sonographer diagnosis
GCA 95 (87.2) 47 (22.2) 22 (37.9) 0 (0.0)
Not GCA 14 (12.8) 165 (77.8) 36 (62.1) 2 (100.0)
US, ultrasound.
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We attempted to measure the time taken to perform each scan by asking each sonographer to report the
time of starting and finishing each scan. Complete data were available for 371 patients. The median time
to complete a scan was 30 minutes (IQR 20–35 minutes). Looking across the centres, however, there was
considerable variation. Some centres had much longer scanning times (median of 45 minutes); by contrast,
the shortest scanning time was only 8.5 minutes, as shown in Table 15.
We could not see any relationship between the duration of the scan and when during the course of the study
the scan was performed (Figure 10). It is likely that the scan times recorded were an estimate of the actual
time taken. Ultrasound positive scans appeared to take longer than negative scans; the median time taken for
positive scans was 33.5 minutes (IQR 30–40 minutes), compared with 25 minutes (IQR 20–30 minutes) for
negative scans, as shown in Figure 11. This indicates that it takes longer to scan and document and record
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FIGURE 9 Days between starting steroids and performing ultrasound or TAB, and number of days between performing
ultrasound and TAB for the 391 patients included in the secondary analysis. US, ultrasound. (a) Days from starting
steroids to ultrasound scan; (b) days from starting steroids to biopsy; and (c) days between ultrasound and biopsy.
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TABLE 15 Reported time (minutes) taken to perform an ultrasound scan of both temporal and both axillary arteries
by site
Site N Mean SD Median IQR
1 18 9.3 4.0 8.5 6–12
2 6 22.5 16.0 15.0 15–20
3 2 20.0 0.0 20.0 20–20
4 7 35.4 21.2 25.0 20–40
5 109 26.0 8.0 25.0 20–30
6 21 25.8 8.7 25.0 20–29
7 4 27.5 10.4 27.5 20–35
8 4 32.5 11.9 27.5 25–40
9 19 32.1 16.7 28.0 25–35
10 8 33.8 13.1 29.0 27–40.5
11 24 26.7 8.6 30.0 20–30
12 13 33.8 10.8 30.0 25–40
13 88 33.5 6.8 30.0 30–40
14 16 32.9 14.3 33.5 25–40
15 4 36.3 12.5 37.5 27.5–45
16 7 50.7 19.9 40.0 35–60
17 12 44.6 12.1 40.0 37.5–52.5
18 3 44.3 5.1 43.0 40–50
19 6 45.0 14.1 45.0 35–60
All 371 29.9 12.3 30.0 20–35
Ranked from the fastest to the slowest median time. No data were available for scan times at one site.
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FIGURE 10 Range of times taken to complete scans during the course of the study (n= 371). US, ultrasound.
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areas if there are abnormalities than if normal areas only are found. There was a wider range of times taken
to complete scans towards the end of the study, which might be explained by the inclusion of a larger
number of sites.
Biopsy results
As part of the study protocol, all patients were scheduled to undergo a TAB within 7 days of starting
high-dose glucocorticoid therapy. Table 16 shows that a significant minority (n = 28, 7%) of biopsy
procedures resulted in no useful tissue. The most common reason for a failed biopsy was that the surgeon
took a sample that contained vein instead of artery (n = 13, 3.4%). Although this could reflect the difficulty
in obtaining material from tortuous vessels, it could also reflect the relative inexperience of the surgeon
given the task of obtaining the biopsy. The BSR guidelines recommend that a surgical biopsy with a
minimum of 1 cm of temporal artery is obtained for each patient with suspected GCA; the procedure
should be performed by a trained surgeon with experience in the technique. We did not mandate this,
given that the study was comparing current standard practice in the NHS with the new technique of
ultrasound. It seems likely that some of the biopsies were performed by less experienced surgeons, resulting
in relatively poor diagnostic yield with no artery at all in 13% of patients. In addition, the length of temporal
artery obtained in 43% of patients was below the BSR-recommended length of 1 cm (Table 17). These
factors could have contributed to the relatively poor performance of biopsy as a diagnostic test in GCA.
Table 15 shows that giant cells were seen in 19% of biopsies overall, representing 71% of patients with
GCA (72/101). Occlusion was reported in 25 biopsies. Of the 161 biopsies with abnormal pathology, four
(1%) were compatible with another vasculitis and 35 (9%) were compatible with arteriosclerosis. Table 16
highlights some potential issues in interpreting the biopsy results. Of the biopsy-negative patients who were
ultimately diagnosed as not having GCA according to the reference diagnosis, 19% had intimal hyperplasia
and 35% showed fragmentation or reduplication of the internal elastic lamina. The frequency of these
changes was lower than those seen in patients with a positive biopsy, but almost identical to those seen in
patients who were diagnosed as having GCA but who had a ‘negative’ biopsy. These findings raise further
concerns about the validity of interpreting the TAB in the absence of cellular changes.
The rheumatologists interpreted the biopsy findings at 2 weeks, as well as evaluating the patient’s clinical
condition. In 11 patients the rheumatologist over-ruled or ignored the pathologist’s conclusions, switching
the diagnosis from not being consistent with GCA to being consistent with GCA (Table 18). There were no
patients in whom the pathologists’ diagnosis of GCA was over-ruled by rheumatologists, and it seems
most likely that the rheumatologists would also have agreed with the pathologists’ diagnosis in the case of
two patients in whom information was missing.
Table 19 shows that there is no clear association between biopsy findings in those patients with a positive
biopsy and presenting symptoms. Different histological features were present in patients with all three
types of symptoms at baseline. We have not included a comparison between histological features and the
presence of headache because this was a very common symptom at presentation.
Clinical and reference diagnoses
Any treatment decisions were independent of the study itself. The only eligibility criterion was that the
clinician suspected a diagnosis of GCA and was intending to arrange a TAB to establish the likely diagnosis.
High-dose steroid treatment was not an exclusion criterion, as long as the patient had not been given
high-dose steroid treatment for > 7 days prior to obtaining the scan and biopsy. The physician was allowed
to use any treatment, which could include methotrexate or another immunosuppressive therapy. The
duration of use of therapies (apart from high-dose steroids) did not influence eligibility for the study.
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TABLE 16 Characteristics of the TABs by reference diagnosis and biopsy result
Biopsy characteristics All (N= 381)
Biopsy positive
(N= 101)
Biopsy negative
Reference GCA
(N= 156)
Reference not GCA
(N= 124)
Biopsy sample, n (%)
Temporal artery definitely obtained 353 (92.7) 101 (100.0) 138 (88.5) 114 (91.9)
Vein 13 (3.4) 9 (5.8) 4 (3.2)
Fat or muscle 5 (1.3) 3 (1.9) 2 (1.6)
Nerve 2 (0.5) 2 (1.3) 0 (0.0)
Fat or muscle, vein and nerve 2 (0.5) 2 (1.3) 0 (0.0)
Other 2 (0.5) 0 (0.0) 2 (1.6)
No sample obtained 4 (1.0) 2 (1.3) 2 (1.6)
Occlusion, n (%)
No 336 (88.2) 77 (76.2) 143 (91.7) 116 (93.5)
Yes 25 (6.6) 24 (23.8) 1 (0.6) 0 (0.0)
Features normal areas 234 (61.4) 18 (17.8) 118 (75.6) 98 (79.0)
Features giant cells 72 (18.9) 72 (71.3) 0 (0.0) 0 (0.0)
Features calcification 44 (11.5) 18 (17.8) 19 (12.2) 7 (5.6)
Other unusual features 22 (5.8) 11 (10.9) 6 (3.8) 5 (4.0)
Normal pathology 205 (53.8) 0 (0.0) 108 (69.2) 97 (78.2)
Abnormal pathology 161 (42.3) 101 (100.0) 38 (24.4) 22 (17.7)
Compatible with a diagnosis of GCA 101 (26.5) 101 (100.0) 0 (0.0) 0 (0.0)
Compatible with a diagnosis of other
vasculitis
4 (1.0) 2 (2.0) 1 (0.6) 1 (0.8)
Compatible with a diagnosis of
arteriosclerosis
35 (9.2) 0 (0.0) 22 (14.1) 13 (10.5)
Compatible with another diagnosis 27 (7.1) 1 (1.0) 16 (10.3) 10 (8.1)
Intima normal 196 (51.4) 10 (9.9) 99 (63.5) 87 (70.2)
Intima abnormal, n (%)
Arteriosclerosis present 39 (10.2) 14 (13.9) 16 (10.3) 9 (7.3)
Intimal hyperplasia present 149 (39.1) 88 (87.1) 37 (23.7) 24 (19.4)
Lamina normal 186 (48.8) 15 (14.9) 90 (57.7) 81 (65.3)
Lamina abnormal, n (%)
Fragmentation 156 (40.9) 84 (83.2) 44 (28.2) 28 (22.6)
Reduplication 82 (21.5) 26 (25.7) 31 (19.9) 25 (20.2)
Length of sample (mm)
Number of measurements 371 100 150 121
Mean (SD) 11.4 (7.4) 12.0 (8.9) 10.9 (7.1) 11.5 (6.5)
Median (IQR) 10.0 (7.0–15.0) 10.0 (7.0–15.0) 9.0 (6.0–15.0) 10.0 (7.0–14.0)
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The clinicians recorded the baseline and pre-steroid clinical features for all patients with suspected GCA.
They were also given access to any available blood tests results and could request any investigation apart
from a temporal artery and axillary ultrasound scan. In 10% of cases no baseline ESR result was available,
and in 27% of cases no pre-steroid ESR result was available; in 8% of cases there was no baseline CRP
level was available and in 27% of cases no pre-steroid CRP value was available.
Table 20 shows the initial diagnosis and treatment recommended for the patients in the study. In 21%
of patients the clinicians reported definite GCA, in 54% they reported probable GCA and in 25% they
reported possible GCA. The level of certainty of diagnosis of GCA is potentially biased in the data set
because all patients were required to have at least the possibility of GCA in order to be eligible for inclusion
in the study. It is conceivable that although the GP who referred the patient might have thought it possible
that the patient had GCA, the study clinician reviewing the patient may have thought otherwise. However,
TABLE 17 Biopsy diagnosis by length of biopsy sample
Length
Biopsy diagnosis
Normal
(N= 206), n (%)
Consistent with GCA
(N= 101), n (%)
Other pathological diagnosisa
(N= 60), n (%)
Biopsy lengthb
TAB length < 1 cm 106 (51.5) 43 (42.6) 15 (25.0)
TAB length ≥ 1 cm 98 (47.6) 57 (56.4) 44 (73.3)
Missing 2 (1.0) 1 (1.0) 1 (1.7)
a 33 patients were diagnosed with arteriosclerosis, three had multiple possible diagnoses, including other forms of
vasculitis, and 24 had miscellaneous other conditions.
b BSR guidelines suggest that the biopsy sample is at least 1 cm long.
TABLE 18 Comparison of pathologists and rheumatologists interpretation of biopsy
Pathologist’s
interpretation N
Rheumatologist’s interpretation
GCA (N= 110), n (%) Not GCA (N= 256), n (%) Missing (N= 15), n (%)
GCA 101 99 (90.0) 0 (0.0) 2 (13.3)
Not GCA 280 11 (10.0) 256 (100.0) 13 (86.7)
TABLE 19 Comparison of biopsy findings with symptoms present at baseline for those 101 patients whose biopsy
was defined by the pathologists as consistent with GCA
Feature N
Symptoms at baseline
Visual, n (%) PMR, n (%)
Jaw/tongue
claudication, n (%)
Intima 7 5 (9.8) 3 (7.1) 5 (6.8)
Internal elastic lamina 14 5 (9.8) 7 (16.7) 8 (10.8)
Media 21 8 (15.7) 6 (14.3) 14 (18.9)
Adventitia 32 9 (17.6) 14 (33.3) 18 (24.3)
Vasa vasorum 5 3 (5.9) 1 (2.4) 3 (4.1)
Transmural 38 21 (41.2) 11 (26.2) 26 (35.1)
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given the constraints of options available to the study clinician, they could define the patient only as
having definite, probable or possible GCA. Therefore, the category of ‘possible’ GCA might actually
contain a mixture of patients whom the study clinician might have considered did not have GCA and
patients with a low likelihood of GCA. The majority of the patients were already in receipt of high doses
of oral glucocorticoids (89%) at the time of the baseline visit. Very few patients (5%) were taking an
immunosuppressive agent (only 18 out of the 381 patients) and, in all cases, these drugs were being given
for other comorbid medical conditions rather than for suspected GCA (100% of the 18 patients).
Table 21 describes the clinical diagnosis made at 2 weeks and 6 months and shows that the majority of
patients had a clinical diagnosis of GCA at both 2 weeks (67%) and 6 months (70%). In other words,
most patients who were initially diagnosed as having GCA did not have any change made to their clinical
diagnosis. However, in 19 patients the diagnosis was changed from not GCA to GCA following unblinding
of the ultrasound results (after the 2-week visit the diagnosis has been reported). In a further 25 patients
the diagnosis was changed at 6 months (this constitutes 6% of patients with available data); in 17 of these
patients the diagnosis was switched from GCA to another diagnosis and in three cases the patients were
reported as having a reference diagnosis of GCA. Twenty-one patients had their diagnosis changed
following expert review of all the clinical data. In 13 of these patients the diagnosis was changed from
GCA to another diagnosis, and in eight patients the diagnosis was changed from not GCA to GCA.
There were fewer data available at 6 months than at 2 weeks (46 fewer patients available at 6 months).
Three patients were diagnosed with other forms of vasculitis at the 2-week visit and five patients had a
diagnosis of another form of vasculitis at 6 months. These data highlight the potential overlapping
presentation between different forms of vasculitis. In patients who did not have GCA or any form of
vasculitis, non-specific headache was the most common diagnosis made (14% at 2 weeks and 12% at
6 months).
Table 22 shows the features present at 2 weeks and 6 months that were reported as influencing the
clinician in making a diagnosis of GCA. There was consistent influence from the clinical symptoms (98%),
signs (70%) and blood abnormalities (65%) at the 2-week visit: biopsy results influenced findings in 40%
of cases. For the three cases diagnosed as GCA at 6 months but not 2 weeks, it is difficult to comment on
the pattern of influence, but it looks similar to the findings at baseline.
TABLE 20 Initial diagnosis and treatment
Features at diagnosis Baseline (N= 381), n (%)
Certainty of GCA diagnosis
Definite 80 (21.0)
Probable 204 (53.5)
Possible 96 (25.2)
Missing 1 (0.3)
Taken high-dose glucocorticoid therapy
No 54 (14.2)
Yes 327 (85.8)
Taking immunosuppressant agents
No 362 (95.0)
Yes 18 (4.7)
Missing 1 (0.3)
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Characteristics and outcomes over time
The prevalence of diabetes mellitus increased from 14% at baseline to 18% at 6 months. By contrast,
other conditions appeared to be unchanged in frequency across the visits (Table 23). Twenty-four
participants had new-onset hypertension during the follow-up period and five participants who had
documented hypertension at baseline no longer had it reported as an active condition during the
follow-up period. Four fractures occurred during the 6-month follow-up. The fracture that occurred at
2 weeks was of the spine/vertebrae.
TABLE 21 Clinical diagnosis at 2 weeks and 6 months
Clinical diagnosis
Visit, n (%)
2 weeks (N= 381) 6 months (N= 335)
GCA 257 (67.5) 234 (69.9)
Other vasculitis
Takayasu’s arteritis 1 (0.3) 1 (0.3)
EGPA 0 (0.0) 1 (0.3)
GPA 1 (0.3) 1 (0.3)
Retinal vasculitis 0 (0) 1 (0.3)
Othera 1 (0.3) 1 (0.3)
Other disease
Non-specific headache 55 (14.4) 39 (11.6)
Multiple alternative diagnoses 12 (3.1) 10 (3.0)
Cervical spondylosis 7 (1.8) 6 (1.8)
Migraine 7 (1.8) 6 (1.8)
Myofascial pain 8 (2.1) 6 (1.8)
Temporomandibular dysfunction 7 (1.8) 6 (1.8)
Sinusitis 7 (1.8) 5 (1.5)
Shingles 1 (0.3) 0 (0.0)
Other 16 (4.2) 17 (5.1)
a ANCA-related vasculitis (2 weeks) or primary cerebral vasculitis (6 months).
TABLE 22 Influences on GCA diagnosis at 2 weeks and 6 months
GCA diagnosis influence
Visit, n (%)
2 weeks (N= 257) 6 months (N= 3)
Influenced by symptoms 251 (97.7) 3 (100.0)
Influenced by signs 181 (70.4) 1 (33.3)
Influenced by blood abnormalities 167 (65.0) 3 (100.0)
Influenced by biopsy report 104 (40.5) 1 (33.3)
Influenced by other factor(s) 16 (6.2) 1 (33.3)
Response to steroids 11 (4.3) 0 (0.0)
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Physical examination findings at each study visit are shown in Table 24. The number of abnormalities
decreased at each study visit. The prevalence of thickened temporal artery fell from 50% at baseline to
13% at 2 weeks which would be in keeping with the expected clinical resolution of the physical findings
of the disease as a result of treatment.
TABLE 23 Change in the prevalence of comorbid conditions over time
Condition
Visit, n (%)
Baseline (N= 381) 2 weeks (N= 381) 6 months (N= 335)
Diabetes mellitus 54 (14.2) 54 (14.2) 61 (18.2)
Hypertension 200 (52.5) 204 (53.5) 187 (55.8)
Angina 28 (7.3) 28 (7.3) 24 (7.2)
Heart failure 19 (5.0) 19 (5.0) 19 (5.7)
Neoplasiaa 9 (2.4) 0 (0.0) 0 (0.0)
Low-trauma fracture
(hip, spine, forearm, other)a
1 (0.3) 1 (0.3) 3 (0.9)
a Occurred since last visit.
TABLE 24 Physical examination findings over time
Feature
Baseline (N= 381),
n (%)
2 weeks (N= 381),
n (%)
6 months (N= 335),
n (%)
Abnormal Normal Abnormal Normal Abnormal Normal
Tender temporal artery 192 (50.4) 188 (49.3) 51 (13.4) 329 (86.4) 21 (6.3) 314 (93.7)
Thickened temporal artery 102 (26.8) 278 (73.0) 27 (7.1) 353 (92.7) 6 (1.8) 329 (98.2)
Reduced or absent pulsation in
temporal artery
91 (23.9) 289 75.9) 51 (13.4) 328 (86.1) 26 (7.8) 309 (92.2)
Tender axillary artery 34 (8.9) 343 (90.0) 22 (5.8) 356 (93.4) 10 (3.0) 324 (96.7)
Bruits 15 (3.9) 296 (77.7) 7 (1.8) 298 (78.2) 7 (2.1) 271 (80.9)
Anterior ischaemic optic neuropathy 27 (7.1) 102 (26.8) 16 (4.2) 101(26.5) 12 (3.6) 82 (24.5)
Posterior ischaemic optic neuropathy 7 (1.8) 97 (25.5) 2 (0.5) 87 (22.8) 4 (1.2) 75 (22.4)
Relative afferent pupillary defect 15 (3.9) 257 (67.5) 9 (2.4) 249 (65.4) 11 (3.3) 221 (66.0)
III/IV/VI nerve palsy 3 (0.8) 310 (81.4) 3 (0.8) 304 (79.8) 1 (0.3) 274 (81.8)
Present,
n (%)
Absent,
n (%)
Present,
n (%)
Absent,
n (%)
Present,
n (%)
Absent,
n (%)
Stroke 7 (1.8) 362 (95.0) 5 (1.3) 367 (96.3) 6 (1.8) 323 (96.4)
Aneurysm 3 (0.8) 320 (84.0) 2 (0.5) 326 (85.6) 2 (0.6) 294 (87.8)
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Chapter 5 Agreement between ultrasound, biopsy
and the reference diagnosis
Primary analysis
The primary outcome was the performance of ultrasound and biopsy in relation to the reference diagnosis
of GCA. The reference diagnosis (defined in Chapter 2) for each patient was based on the 2-week and
6-month clinical diagnosis, as well as on the opinion of an expert review panel that assessed patient data
(without the ultrasound result).
Ultrasound versus biopsy
The results of ultrasound and biopsy diagnosis were discordant in 115 patients (30%; Table 25). The two
tests had fair agreement (κ = 0.35); overall, ultrasound was more likely than biopsy to find evidence
consistent with a diagnosis of GCA (162 ultrasound-positive cases vs. 101 biopsy-positive cases,
p ≤ 0.0001).
Biopsy versus reference diagnosis
Temporal artery biopsy had a sensitivity of 39% (95% CI 33% to 46%) and a specificity 100% (95% CI
97% to 100%) for the reference diagnosis. All of the 101 participants whose biopsy was positive for
evidence of GCA had a reference diagnosis of GCA. By contrast, 156 participants who had a reference
diagnosis of GCA had a TAB that was not consistent with that diagnosis (Table 26).
Ultrasound versus reference diagnosis
Ultrasound examination had a sensitivity of 54% (95% CI 48% to 60%) for GCA, which is higher than
that of biopsy, but had a lower specificity of 81% (95% CI 73% to 88%). Ultrasound examination showed
evidence of findings consistent with GCA in 23 patients in whom GCA was not the ultimate diagnosis.
By contrast, in 118 patients with a reference diagnosis of GCA, the ultrasound examination did not show
features consistent with GCA (Table 27). When comparing the sensitivity and specificity of ultrasound and
TABLE 25 Giant cell arteritis diagnoses tabulated by biopsy and ultrasound method
US
Biopsy
Kappa statistic McNemar’s testGCA Not GCA Total
GCA 74 88 162
Not GCA 27 192 219
Total 101 280 381 0.35 p ≤ 0.0001
US, ultrasound.
TABLE 26 Giant cell arteritis diagnosis tabulated by biopsy and reference standard
Biopsy
Reference diagnosis
Sensitivity (%) (95% CI) Specificity (%) (95% CI)GCA Not GCA Total
CA 101 0 101
Not GCA 156 124 280
Total 257 124 381 39 (33 to 46) 100 (97 to 100)
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biopsy, we have to bear in mind that negative and positive biopsy results would have influenced the final
diagnosis (the reference standard); by contrast, the ultrasound result had no influence on either a final
positive diagnosis or a final negative diagnosis. Thus, true ultrasound-positive and biopsy-negative patients
may have been misclassified as non-GCA and false-positive biopsy patients whose ultrasound scan results
were negative may have been misclassified as GCA. Therefore, the sensitivity and specificity of ultrasound
could be a significant underestimate, whereas the sensitivity and specificity for biopsy might be falsely high.
Main results: robustness to variations in sample, biopsy
diagnosis and reference diagnosis
Per protocol population: biopsy within 7 days of starting steroids
The primary analysis was based on 381 patients who had a TAB within 10 days of starting steroid
treatment. We repeated this analysis, excluding 23 participants whose biopsy had been performed more
than 7 days after starting steroids. The agreement between biopsy and ultrasound was marginally higher
when both ultrasound and biopsy were performed within 7 days of starting steroids. Ultrasound and
biopsy findings disagreed in 103 cases (28.8%, as shown in Table 28) and the kappa statistic was slightly
larger than for the primary analysis (κ = 0.37).
The sensitivity of biopsy was very similar for the patients whose biopsies were performed within 7 days of
commencing steroids, compared with the primary analysis group (sensitivity 40%, specificity 100%; Table 29).
Successful biopsy
Twenty-eight participants had an unsuccessful biopsy; in four participants no material was obtained at
all (usually because the surgeon was unable to identify any structure resembling an artery during the
procedure) and in 24 patients the sample consisted of material other than temporal artery. Repeating
the primary analysis for the participants who had a successful biopsy (see Table 29) results in a similar
sensitivity estimate for the value of biopsy compared with the population used for the primary analysis
(42%, 95% CI 36% to 49%).
Table 16 summarises the biopsy findings and shows that the most common surgical error was to obtain
vein instead of artery, which occurred in 13 patients. In five patients, fat or muscle was obtained,
TABLE 27 Giant cell arteritis diagnosis tabulated by ultrasound and reference diagnosis
US
Reference diagnosis
Sensitivity (%) (95% CI) Specificity (%) (95% CI)GCA Not GCA Total
GCA 139 23 162
Not GCA 118 101 219
Total 257 124 381 54 (0.48 to 0.60) 81 (73 to 88)
US, ultrasound.
TABLE 28 Giant cell arteritis diagnosis by ultrasound and biopsy for all patients in whom biopsy was performed
within 7 days of commencing steroids
US
Biopsy
Kappa statistic McNemar’s testGCA Not GCA Total
GCA 71 77 148
Not GCA 26 184 210
Total 97 261 358 0.37 p= 0.0000
US, ultrasound.
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in two patients nerve tissue was obtained and in four other patients the material consisted of fat or
muscle, vein or nerve or other tissue.
Biopsy diagnosis from the rheumatologist
We analysed the data according to the rheumatologist’s interpretation of the biopsy findings at 2 weeks.
In 11 patients the rheumatologist over-ruled the pathologist’s findings by switching the diagnosis from
not being consistent with GCA to being consistent with GCA. The results are shown in Table 18; one
participant was incorrectly diagnosed as having GCA. The sensitivity was slightly higher (43%, 95% CI
37% to 49%) than for the pathologist’s interpretation (39%, 95% CI 33% to 46%). The disparity
between pathologists’ findings and the clinicians’ interpretation of the biopsy result would primarily reflect
confidence in the clinical diagnosis and interpretation of any comments in the biopsy that might be
consistent with the diagnosis of GCA, probably influenced by how long the patient had been on high-dose
glucocorticoids prior to the biopsy being obtained. For example, if the patient had a very compelling
history and examination to suggest GCA, supported by a high acute-phase response, and had experienced
considerable improvement with high-dose glucocorticoid therapy, the clinician might interpret minor
changes in the biopsy, such as internal elastic lamina reduplication or fragmentation, as being consistent
with resolving GCA.
Participants with 6-month data
Of the primary analysis set, 335 participants completed their 6-month follow-up. There is little difference
in the sensitivity and specificity of ultrasound and biopsy after excluding patients without 6-month data
(see Table 29).
Using final clinician diagnosis in place of the reference diagnosis
The reference diagnosis was based on the 2-week and 6-month clinical diagnoses, as well as the opinion
of an expert review panel that assessed all of the patient data apart from the ultrasound results (see the
detailed algorithm in Chapter 2). A sensitivity analysis was conducted by substituting the clinician’s final
diagnosis (which consisted of the clinician’s decision on diagnosis at 6 months or at 2 weeks in the
absence of 6-month data) instead of the reference diagnosis.
Twenty-one patients had a change of diagnosis following an expert review, using the original clinician’s
diagnosis (from 6 months or 2 weeks if no 6-month data were available) in place of the reference
diagnosis. The effect was to change eight patients’ results from GCA to not GCA; a further 13 patients
switched from not GCA to GCA. The sensitivity and specificity of biopsy and ultrasound showed similar
results to the primary analysis; the specificity of ultrasound was slightly higher (85% vs. 81%) when the
clinician’s final diagnosis was used in place of the reference diagnosis (Table 30).
TABLE 29 Diagnostic accuracy for the variations in sample and biopsy diagnosis
Source of diagnostic test result N
Reference diagnosis
GCA Not GCA
Test+/true+
Sensitivity (%)
(95% CI) Test–/true–
Specificity (%)
(95% CI)
Per protocol: biopsy 358 97/241 40 (34 to 47) 117/117 100 (97 to 100)
Successful biopsies only 353 101/239 42 (36 to 49) 114/114 100 (97 to 100)
Biopsy diagnosis from the rheumatologist 381 111/257 43 (37 to 49) 123/124 099 (96 to 100)
Population with 6-month data
Biopsy 335 90/227 40 (33 to 46) 108/108 100 (97 to 100)
US 335 124/227 55 (48 to 61) 87/108 81 (72 to 88)
US, ultrasound.
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Variations in ultrasound
We reviewed the variations in the interpretation of the ultrasound findings in the context of a diagnosis of
GCA in order to investigate whether or not the sensitivity and specificity of ultrasound for diagnosis of
GCA could be improved.
Halo with positive opinion of giant cell arteritis
The presence or absence of a halo on its own is the most important finding in considering the diagnosis of
GCA. There was tight concordance between a positive halo and a positive overall ultrasound finding
consistent with the diagnosis of GCA. Of 381 participants, 10 were reported to have a negative ultrasound
result, even though a halo was detected. A further 10 cases had ultrasound reported as positive despite the
absence of a halo. The distribution of reference diagnosis is similar in these participants, which would mean
that the detection of a halo alone on the ultrasound scan was similar to that of the overall interpretation of
the ultrasound scan, including other features such as stenosis or occlusion. Combining the two (i.e. presence
of a halo and overall positive ultrasound diagnosis) also gives similar results to those obtained previously,
as shown in Table 31.
Of the 10 patients reported as having features consistent with GCA on ultrasound scan and in whom no
halo was seen, nine had abnormalities in the temporal arteries and one patient had abnormalities in both
axillary and temporal arteries. Five patients had abnormalities at one site, two at two sites, two at three
sites and one at four sites. Six patients had occlusion and six had stenosis.
Of the 10 patients in whom the ultrasound features were thought not to be consistent with GCA despite the
presence of a halo, seven had a halo in one site, two had a halo at two sites and one had a halo at seven sites.
TABLE 30 Diagnostic accuracy of biopsy and ultrasound with respect to clinician’s final diagnosis
Diagnostic test (N= 381)
Clinician’s final diagnosis
GCA (N= 262) Not GCA (N= 119)
Test+ Sensitivity (%) (95% CI) Test– Specificity (%) (95% CI)
Biopsy 101 39 (33 to 45) 119 100 (97 to 100)
US 144 55 (49 to 61) 101 85 (77 to 91)
US, ultrasound.
TABLE 31 Variations in interpretation of ultrasound findings in relation to supporting or not supporting a
diagnosis of GCA, including the influence of expert review of the ultrasound results
Change in US result (N= 381)
Reference diagnosis
GCA (N= 257) Not GCA (N= 124)
Test+
Sensitivity (%)
(95% CI) Test–
Specificity (%)
(95% CI)
Original ultrasound diagnosis as reported in Table 27 139 54 (48 to 60) 101 81 (73 to 88)
Variations in US diagnosis
Halo plus positive opinion 132 51 (45 to 58) 104 84 (76 to 90)
Bilateral halo plus positive opinion 84 33 (27 to 39) 115 93 (87 to 97)
US expert review opinion
Change where disagreement is the most common 113 44 (38 to 50) 108 87 (80 to 92)
Change for reviews that are certain (i.e. no reviewer says disagree) 128 50 (44 to 56) 105 85 (77 to 91)
US, ultrasound.
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Bilateral halo and positive opinion of giant cell arteritis
We investigated if the presence of halo on both sides (left and right temporal arteries or axillary arteries)
affected the likelihood of interpreting the ultrasound findings as being consistent with GCA or not. This
could be used as a stricter definition of positive ultrasound results by reducing false positives (increasing
specificity) but potentially increasing false negatives (reducing sensitivity).
The results are shown in Table 31. The modified criteria resulted in 59 patients reclassified as ‘not GCA’
and a higher specificity (93%; 95% CI 87% to 97%). The presence of bilateral halo coupled with positive
overall interpretation identified patients with GCA at a sensitivity of only 33%, because only a small
proportion of patients demonstrated this feature (93 patients). This suggests that ultrasound could be used
as a ‘rule in’ test, whereby the presence of bilateral halo indicates a positive diagnosis and thereby avoids
TAB in around one-quarter of participants with few false positives, albeit with lower sensitivity and
specificity than TAB alone.
Axillary involvement
A potential benefit of ultrasound is that it scans both temporal and axillary arteries. Of the abnormal
ultrasound scans, 53 showed axillary involvement, which in 27 cases was bilateral. Of the 53 ultrasound
assessments with axillary involvement, nine showed no temporal involvement. In three of these cases, the
patient was biopsy positive and in six cases the patient was biopsy negative; seven patients were given the
reference standard diagnosis of GCA and two were reported as not having GCA. Based on these data, in
only a few patients would the diagnosis be changed to GCA on the basis of an ultrasound scan showing
axillary involvement. Therefore, the role of ultrasound in the detection of axillary artery involvement may
be important but limited because only a small number of patients are likely to have isolated axillary
involvement in the absence of temporal involvement as demonstrated by ultrasound. In other words,
the presence of abnormalities in the axillary arteries provides further support for the diagnosis of GCA.
The low numbers may reflect the inclusion of patients predominantly presenting with cranial GCA.
Ultrasound expert review
As part of the study protocol, all ultrasound scans obtained by individual sonographers were reviewed
centrally by an expert panel. This was made possible because the protocol required recording of still and
video images from the scan procedure for all participants. The images were uploaded onto a secure
password-protected central web-based system designed for this purpose, so that the images could be
reviewed online or downloaded for review by the expert panel. The reviewers were asked to provide an
assessment of the quality of the available images as either clear or unclear (the latter because of the
absence of sufficient images, poor-quality images or because the reviewer was unsure for other technical
reasons). If the images were clear, the expert was asked either to agree with the sonographer’s
interpretation or to disagree with it.
If we used data obtained from the ultrasound findings according to the expert panel, this would result in
14 out of 219 patients having their ultrasound diagnosis changed from not consistent with GCA to
consistent with GCA, and 47 out of 162 patients would have their ultrasound findings changed from
consistent with GCA to not consistent with GCA.
The expert reviewers provided stricter definitions of scans being consistent with GCA or not (see Table 31),
which resulted in a lower sensitivity (44%) and higher specificity (87%) than for the original interpretation
of ultrasound findings by the sonographers (sensitivity 54% and specificity 81%; see Table 31). One
ultrasound reviewer assessed all patients (but every case was reviewed by at least two reviewers). Using
this reviewer’s decisions alone would result in four changes with respect to the method above: two to
disagree and two to agree. All four of these patients were ultrasound positive and reference diagnosis
GCA negative. Hence, the results from this reviewer are identical to the overall results.
Following the analysis of expert reviewers’ opinions, we examined the effect of changing only the ultrasound
interpretation findings in patients when there was consensus among the reviewers. The results of this
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interpretation (see Table 31) were that six patients had their results changed from not being consistent with
GCA to being consistent with GCA; a further 21 patients were changed from being consistent with GCA
based on ultrasound to being not consistent with GCA based on ultrasound. The sensitivity and specificity
are closer to the original ultrasound diagnosis because fewer patients have been changed.
Two-week diagnosis and test findings
Two-week diagnosis with biopsy finding
At the review visit, 2 weeks after baseline, the clinician was asked for their diagnosis based on observed
signs, symptoms, laboratory test results and the biopsy result. Table 32 shows that the sensitivity (91%)
and specificity (81%) are high for the 2-week diagnosis compared with the reference diagnosis. There was
disagreement between the 2-week diagnosis and the reference diagnosis for 46 participants (12%). The
2-week opinion of the clinician was based on the clinical presentation and subsequent findings; the biopsy
result is likely to have been one of the major contributions to this opinion. This introduces some circularity
to the interpretation of data because we are independently evaluating the role of biopsy in contributing to
the diagnosis when, in fact, the biopsy has already contributed to the diagnosis by forming part of the
clinical opinion of the clinician interpreting all the data available at the time (but not including information
from the ultrasound scan that was kept confidential from the clinician managing the case, at least until
they had formally reported their diagnosis).
Two-week diagnosis with biopsy and unblinded ultrasound findings
If at 2 weeks the clinician’s diagnosis was not GCA and he or she was considering rapidly withdrawing
steroids, the ultrasound findings were unblinded. Following this, the diagnosis changed for 19 participants
(all to GCA). We analysed the sensitivity and specificity of the 2-week diagnosis compared with reference
diagnosis when accounting for the unblinding of these 19 patients. The sensitivity was higher when
including the results of the unblinding for the 2-week diagnosis than when we included only the results of
the 2-week diagnosis without the unblinding (96% vs. 91%), but at the same time the specificity of the
2-week diagnosis for the reference diagnosis was lowered (77% vs. 81%), as shown in Table 33.
TABLE 32 Giant cell arteritis diagnosis tabulated by reference and 2-week diagnosis
Two-week diagnosis
Reference diagnosis
Sensitivity (%) (95% CI) Specificity (%) (95% CI)GCA Not GCA Total
GCA 234 23 257
Not GCA 23 101 124
Total 257 124 381 91 (87 to 94) 81 (73 to 88)
TABLE 33 Giant cell arteritis diagnosis tabulated by reference and 2-week diagnosis (updated post ultrasound
unblinding)
Two-week diagnosis
Reference diagnosis
Sensitivity (%) (95% CI) Specificity (%) (95% CI)GCA Not GCA Total
GCA 247 29 276
Not GCA 10 95 105
Total 257 124 381 96 (93 to 98) 77 (68 to 84)
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Ultrasound: learning effect
Ultrasonography of the temporal arteries is operator dependent; therefore, as part of the study protocol,
training was given to sonographers at the beginning of the study to ensure proficiency with the technique
before applying it to study participants. Some sonographers with sufficient experience were deemed
exempt from the full training. The results of the training attempts are shown in Chapter 3. In addition to
providing the training, as part of the protocol, all scans performed by each site’s sonographer were
recorded and the images were sent to the TABUL office in Oxford, so that they could be uploaded onto a
server for assessment by the expert reviewers. Scans were reviewed during the course of the study as part
of the quality control and some sonographers were retrained if necessary.
The ultrasound scans are split into two groups:
1. First 10 – this included the first 10 scans (post training) within the TABUL cohort for each sonographer
who received full training, or all scans before retraining for those sonographers who subsequently
received further training.
2. After 10 – included all patients after the first 10 scans for the sonographers who received full training.
It also includes all scans from sonographers exempt from full training. If a sonographer was retrained
during the study, it included all scans after the date of retraining.
The specificity of ultrasound was almost the same for the first 10 scans (82%) and the later scans (81%),
but the sensitivity was higher for the later scans (increasing from 45% to 62%), as shown in Table 34.
This strongly suggests that there is a learning effect, as the sonographers become more experienced at
performing the scan, and that this will predominantly influence sensitivity of the test result.
We repeated the analysis, excluding the sonographers deemed to be experts and exempt from full training
(leaving n = 110 patients), splitting the data based on the first five scans versus the rest of the scans. There
appears to be an improvement in sensitivity in the scans assessed between the first five patients scanned
and subsequent patients scanned (rising from 42% to 59%, respectively), with similar levels of specificity
(80% vs. 82%).
Timing effect
Accuracy of tests in relation to time since starting steroids
All patients had an ultrasound test performed more rapidly than or on the same day as a biopsy. Overall,
107 patients had an ultrasound performed within 1 day of starting steroid treatment, whereas only 26 patients
TABLE 34 Diagnostic accuracy of ultrasound by sonographer training-level subgroups
Learning curve subgroups N
Reference diagnosis
GCA Not GCA
Test+/true+
Sensitivity (%)
(95% CI) Test–/true–
Specificity (%)
(95% CI)
All sonographers
Including first 10 scans 181 54/120 45 (36 to 54) 50/61 82 (70 to 91)
Excluding first 10 scans 200 85/137 62 (53 to 70) 51/63 81 (69 to 90)
Non-experts only
Including first five scans 70 23/55 42 (29 to 56) 12/15 80 (52 to 96)
Excluding first five scans 40 17/29 59 (39 to 76) 9/11 82 (48 to 98)
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had a biopsy performed within 1 day of starting steroid treatment. By comparison, 246 patients had their
biopsy performed after having started steroids at least 5 days previously, compared with only 57 patients who
had an ultrasound scan performed after 5 days of steroid therapy. Within the time frame of the study, the
sensitivity was higher (64%) for participants whose test was up to 1 day after starting steroids than for those
whose test was ≥ 2 days after starting steroids (47%); the specificity remained unchanged (Table 35).
Table 36 shows the potential effect of duration on high doses of glucocorticoid therapy on the
interpretation of the biopsy and ultrasound test results. For those patients with a reference diagnosis of
GCA, the proportion who were correctly detected by biopsy decreased with time since starting steroids.
Sensitivity was highest for the biopsies that were performed within 3 days of starting steroids (48%; 95% CI
37% to 60%). Sensitivity was lowest (33%; 95% CI 22% to 46%) for biopsies that were performed
≥ 7 days after starting steroids.
The effect of delay in performing biopsy in relation to ultrasound on the
agreement between two tests
We investigated whether or not the modest agreement between biopsy and ultrasound tests results was
affected by the time interval between performing each test. Table 37 shows that, contrary to expectation,
the agreement between tests was similar when the biopsy was performed within 1 day of ultrasound
(κ = 0.33) or when the biopsies were performed either 2 or 3 days after ultrasound (κ = 0.4), or ≥ 4 days
after ultrasound (κ = 0.32).
TABLE 35 Diagnosis of biopsy and ultrasound by time since starting steroids
Number of days since
starting steroids
Reference GCA Reference not GCA Total
Test GCA,
n (%)
Test not GCA,
n (%)
Test GCA,
n (%)
Test not GCA,
n (%)
Test GCA,
n (%)
Test not GCA,
n (%)
Days between starting steroids and TAB
TAB performed before
steroids
2 (50.0) 2 (50.0) 0 (0.0) 1 (100.0) 2 (40.0) 3 (60.0)
Same day or 1 day 6 (42.9) 8 (57.1) 0 (0.0) 7 (100.0) 6 (28.6) 15 (71.4)
2 days 11 (42.3) 15 (57.7) 0 (0.0) 12 (100.0) 11 (28.9) 27 (71.1)
3 days 20 (54.1) 17 (45.9) 0 (0.0) 7 (100.0) 20 (45.5) 24 (54.5)
4 days 13 (52.0) 12 (48.0) 0 (0.0) 12 (100.0) 13 (35.1) 24 (64.9)
5 days 13 (35.1) 24 (64.9) 0 (0.0) 21 (100.0) 13 (22.4) 45 (77.6)
6 days 18 (31.0) 40 (69.0) 0 (0.0) 25 (100.0) 18 (21.7) 65 (78.3)
7 days 14 (35.0) 26 (65.0) 0 (0.0) 33 (100.0) 14 (19.2) 59 (80.8)
≥ 8 days 7 (30.4) 16 (69.6) 0 (0.0) 9 (100.0) 7 (21.9) 25 (78.1)
Days between starting steroids and US
US performed before
steroids
6 (60.0) 4 (40.0) 0 (0.0) 3 (100.0) 6 (46.2) 7 (53.8)
Same day 27 (73.0) 10 (27.0) 4 (33.3) 8 (66.7) 31 (63.3) 18 (36.7)
1 day 34 (59.6) 23 (40.4) 4 (14.3) 24 (85.7) 38 (44.7) 47 (55.3)
2 days 27 (54.0) 23 (46.0) 2 (12.5) 14 (87.5) 29 (43.9) 37 (56.1)
3 days 13 (41.9) 18 (58.1) 5 (20.0) 20 (80.0) 18 (32.1) 38 (67.9)
4 days 14 (36.8) 24 (63.2) 3 (17.6) 14 (82.4) 17 (30.9) 38 (69.1)
5 days 14 (51.9) 13 (48.1) 1 (7.1) 13 (92.9) 15 (36.6) 26 (63.4)
6 or 7 days 8 (57.1) 6 (42.9) 4 (33.3) 8 (66.7) 12 (46.2) 14 (53.8)
US, ultrasound.
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Sequential and combined test analyses
Performing both ultrasound and biopsy may not be necessary in all patients. We would speculate that
ultrasound could be useful as a ‘rule-in’ test to support the diagnosis of GCA. If the ultrasound result was
consistent with GCA and the clinical features supported that diagnosis, the diagnosis of GCA could be
made without any further testing required. If, however, ultrasound was not consistent with GCA, patients
would be recommended to have a biopsy in order to help to decide whether or not they had GCA.
This test strategy can be explored in the TABUL data set and lends itself to a full economic evaluation,
which is provided in Chapter 7.
The following steps describe a potential algorithm for investigating patients with suspected GCA:
l Patients present with the clinical or laboratory features suggesting a diagnosis of GCA.
l An ultrasound scan is performed and, if the results show evidence supporting a diagnosis of GCA,
a diagnosis of GCA is made.
l If the ultrasound scan does not show features consistent with GCA, the patient is scheduled to have a TAB.
l If the TAB is supportive of a diagnosis of GCA, the patient is diagnosed with GCA.
l If both TAB and ultrasound are negative, the conclusion is that the patient does not have ultrasound or
histological evidence to support the diagnosis of GCA.
TABLE 36 Diagnostic accuracy of biopsy by time since starting steroids
Time between test
and starting steroids N
Reference diagnosis
GCA Not GCA
Test+/true+ Sensitivity (%) (95% CI) Test–/true– Specificity (%) (95% CI)
Biopsy
≤ 3 days 108 39/81 48 (37 to 60) 27/27 100 (87 to 100)
Between 4 and 6 days 178 44/120 37 (28 to 46) 58/58 100 (94 to 100)
≥ 7 days 105 21/63 33 (22 to 46) 42/42 100 (92 to 100)
US
≤ 1 day 147 67/104 64 (54 to 74) 35/43 81 (67 to 92)
≥ 2 days 244 76/160 47 (40 to 56) 69/84 82 (72 to 90)
US, ultrasound.
TABLE 37 Agreement between ultrasound and biopsy by time between the two tests
Time between biopsy and US N
Biopsy positive Biopsy negative
Kappa
statistic
McNemar’s
test
US
positive
US
negative
US
positive
US
negative
Biopsy same day or 1 day after 155 27 13 33 82 0.33 p= 0.0045
2–3 days after 113 21 8 22 62 0.4 p= 0.0161
≥ 4 days after 123 28 7 35 53 0.32 p= 0.0000
US, ultrasound.
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Table 38 illustrates the effects of applying this sequential strategy on the 381 patients in the TABUL study.
Overall, 162 patients would have been diagnosed with GCA based on the ultrasound scan alone, the
majority (139, 86%) correctly. The remaining 219 ultrasound-negative patients would then have a biopsy.
Twenty-seven of these ultrasound-negative patients had a positive biopsy and would also have been
diagnosed with GCA. The 192 patients who were both scan and biopsy negative would not have received
a diagnosis of GCA despite the fact that in almost half of these patients the reference diagnosis was GCA.
Table 38 shows the number of patients who would have a positive or negative result on the test compared
with the eventual reference diagnosis via not GCA or GCA.
Table 39 shows the accuracy of applying a sequential strategy to the TABUL cohort. The effect of applying a
second test, the biopsy, to patients who are ultrasound negative is to improve on the sensitivity of the
ultrasound-only strategy (from 54% to 65%) while maintaining its specificity at 81% (although specificity is
lower than the 100% obtained for a biopsy-only strategy). If this strategy was used for the cohort, 162 (43%)
patients would have avoided having a TAB. However, on the basis of this strategy, without a clinician
over-riding (ignoring) the test results, 91 true cases of GCA as defined by the reference diagnosis would have
been missed and 23 patients would be wrongly diagnosed as having GCA according to the reference
diagnosis. It is a difficult dilemma because no single test or evaluation can be used to rule out the diagnosis,
whereas any single test or evaluation could be used to rule it in, over-riding a negative result.
Pre-test probability of having giant cell arteritis or not
We investigated which (if any) subgroups of the cohort could have been diagnosed without the need for
biopsy and/or ultrasound, entirely based on a pre-test clinical assessment of patients being at high,
medium or low likelihood of having GCA.
There is likely to be significant bias because the clinician’s opinion on the diagnosis would be strongly
influenced by the factors defining the risk groups; therefore, the items to define risk groups were extracted
TABLE 38 Effect of implementing the sequential strategy of ultrasound followed by biopsy if required
Test results
Reference diagnosis
GCA, n (%) Not GCA, n (%) Total, n (%)
US positive 139 (85.8) 23 (14.2) 162 (100)
US negative, biopsy positive 27 (100.0) 0 (0.0) 27 (100)
US negative, biopsy negative 91 (47.4) 101 (52.6) 192 (100)
US, ultrasound.
TABLE 39 Accuracy of sequential diagnostic strategy (ultrasound first)
Test diagnosis
Reference diagnosis
Sensitivity (%) (95% CI) Specificity (%) (95% CI)GCA Not GCA Total
GCA 166 23 189
Not GCA 91 101 192
Total 257 124 381 65 (58 to 70) 81 (73 to 88)
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from DCVAS data, representing an independent cohort, giving the process external validity. We applied
the same rules for DCVAS to the TABUL data to define participants as follows:
l Participants were defined as being at high risk of having GCA if they had an elevated ESR or CRP level
(ESR of > 60 mm/hour or CRP level of > 40 mg/l) and jaw or tongue claudication at presentation or
prior to use of steroids.
l Participants were defined as being at medium risk of having GCA if they had either elevated ESR/CRP
level or jaw/tongue claudication at presentation/before steroids.
l Participants were defined as being at low risk if they had neither elevated ESR/CRP level nor jaw/tongue
claudication at presentation/before steroids.
Table 40 shows the relationship between pre-test risk groups and the clinician’s certainty of a diagnosis of
GCA reported at baseline. The proportion of participants with ‘definite’ GCA is higher in the high-risk
group (42%) than in the medium- and low-risk groups (20% and 9%, respectively). There was good
agreement between the clinicians’ certainty of diagnosis and the pre-test risk of diagnosing GCA. Among
the TABUL cohort, 93% of the high-risk group had a reference diagnosis of GCA. The prevalence of GCA
was lower (78%) in the medium-risk group and lower still in the low-risk group (39%).
Accuracy of test within pre-test subgroup
Table 41 shows the accuracy of biopsy and ultrasound within the pre-test probability subgroups. The
sensitivity of biopsy increases as the pre-test risk increases. The sensitivity of ultrasound is slightly higher in
the medium- and high-probability subgroups than in the low-probability group (57%, 57% and 44%,
respectively). The specificity of ultrasound is similar across the subgroups; however, it is difficult to make a
comparison owing to the small numbers of participants without GCA, in the medium- and high-probability
subgroups (n = 34 and n = 6, respectively).
Diagnostic strategies
We considered the implications of introducing a test strategy dependent on the pre-test probability of a
patient having or not having a diagnosis of GCA. As the prevalence of GCA is very high in the high-risk
group (93%), one strategy could be not to perform either ultrasound or biopsy in this group and simply
diagnose the patients as having GCA without any further testing (we have defined these patients as H0).
Although this would be most economic, by avoiding either test, in clinical practice both clinicians and
TABLE 40 Relationship between pre-test risk and diagnosis
Diagnostic certainty Total (N= 381)
Pre-test risk, n (%)
High (N= 89) Medium (N= 154) Low (N= 138)
Certainty of GCA diagnosis at baseline Definite 37 (41.6) 31 (20.1) 12 (8.7)
Probable 43 (48.3) 94 (61.0) 67 (48.6)
Possible 8 (9.0) 29 (18.8) 59 (42.8)
Reference diagnosis GCA 83 (93.3) 120 (77.9) 54 (39.1)
Not GCA 6 (6.7) 34 (22.1) 84 (60.9)
Biopsy diagnosis GCA 52 (58.4) 40 (26.0) 9 (6.5)
Not GCA 37 (41.6) 114 (74.0) 129 (93.5)
US diagnosis GCA 48 (53.9) 71 (46.1) 43 (31.2)
Not GCA 41 (46.1) 83 (53.9) 95 (68.8)
US, ultrasound.
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patients would find it difficult to accept the diagnosis without at least some attempt to support the
diagnosis with further investigation (biopsy or scan). We would therefore also consider a strategy of
performing an initial ultrasound in the high-risk group and then performing a biopsy if the scan is negative
(i.e. the scan is not consistent with a diagnosis of GCA). We would define a positive result on ultrasound
as consistent with a diagnosis of GCA using four possible criteria as follows.
1. The sonographer’s opinion is that the ultrasound scan is consistent with a diagnosis of GCA (defined
as H1).
2. Bilateral halo is present (in either the temporal or axillary arteries) (H2).
3. Either the sonographer’s opinion is that the ultrasound is consistent with a diagnosis of GCA or there
are abnormalities in the axillary arteries (regardless of the overall sonographer opinion) (H3).
4. Bilateral halo or any axillary involvement is present (H4).
In the medium-risk groups we considered the above four strategies in which ultrasound is performed first,
followed by biopsy (M1 to M4 would be equivalent to H1 to H4).
In the low-risk groups, we considered the same four strategies as well as two further strategies.
1. Using a negative ultrasound result as a ‘rule-out’ test for GCA. If ultrasound is positive, then perform a
biopsy and take the diagnosis from the biopsy result (L5).
2. Use the absence of any abnormal finding on the ultrasound as a ‘rule-out’ test for GCA. If there are any
abnormalities, perform a biopsy and take the diagnosis from the biopsy result (L6).
The accuracy of the diagnostic test strategies for each subgroup is shown in Table 42. These strategies
are combined and the accuracy of all possible combinations displayed in Figure 12 (for full results, see
Appendix 15) alongside point estimates for biopsy and ultrasound alone. It is apparent from the graph
that TAB alone provides relatively poor performance in helping to diagnose GCA; by contrast, many of
the combined strategies have better sensitivity and specificity than ultrasound alone. The two combined
strategies that give the highest sensitivity are H0-M1-L1 and H0-M1-L3.These combine no test in the
high-risk group, testing with ultrasound first and following with biopsy if the ultrasound result is negative in
the medium- and low-risk groups, or following with biopsy if the ultrasound is negative and there is no
axillary involvement in the low-risk group.
TABLE 41 Diagnostic accuracy of biopsy and ultrasound by pre-test probability group
Pre-test probability of
GCA per diagnostic test
Reference diagnosis
GCA Not GCA
Test+/true+
Sensitivity (%)
(95% CI) Test–/true–
Specificity (%)
(95% CI)
High pre-test probability (n = 89)
Biopsy 52/83 63 (51 to 73) 6/6 100 (54 to 100)
US 47/83 57 (45 to 67) 5/6 83 (36 to 100)
Medium pre-test probability (n = 154)
Biopsy 40/120 33 (25 to 43) 34/34 100 (90 to 100)
US 68/120 57 (47 to 66) 31/34 91 (76 to 98)
Low pre-test probability (n = 138)
Biopsy 9/54 17 (8 to 29) 84/84 100 (96 to 100)
US 24/54 44 (31 to 59) 65/84 77 (67 to 86)
US, ultrasound.
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Appendix 15 contains an extensive list of combinations of different strategies that could be applied to
improve accuracy in diagnosing GCA, dependent on the initial pre-test probability of the diagnosis being
high, medium or low.
Exploratory findings
Birmingham Vasculitis Activity Score and Vasculitis Damage Index
The BVAS and the VDI have not been widely used either in patients with GCA nor in disease controls
because they were designed for use in patients who already had a diagnosis of vasculitis;66,69 therefore,
this is an exploratory part of the study. The BVAS and the VDI could be useful in the evaluation of patients
TABLE 42 Summary of potential diagnostic strategies for each pre-test risk group
Risk
group Description
Reference diagnosis,
n (%)
GCA Not GCA
High risk
Sensitivity
(N = 83)
Specificity
(N = 6)
Number of
TAB required
(N = 89)
H0 Assume GCA positive (no diagnostic test performed) 83 (100.0) 0 (0.0) 0 (0.0)
H1 GCA if either US or TAB positive 64 (77.1) 5 (83.3) 41 (46.1)
H2 GCA if either bilateral halo on US or TAB positive 59 (71.1) 5 (83.3) 53 (59.6)
H3 GCA if either US positive, US axillary involvement or TAB positive 67 (80.7) 5 (83.3) 36 (40.4)
H4 GCA if either bilateral halo on US, US axillary involvement or TAB
positive
63 (75.9) 5 (83.3) 47 (52.8)
Medium risk
Sensitivity
(N = 120)
Specificity
(N = 34)
Number of
TAB required
(N = 154)
M1 GCA if either US or TAB positive 75 (62.5) 31 (91.2) 83 (53.9)
M2 GCA if either bilateral halo on US or TAB positive 53 (44.2) 32 (94.1) 115 (74.7)
M3 GCA if either US positive, US axillary involvement or TAB positive 75 (62.5) 31 (91.2) 83 (53.9)
M4 GCA if either bilateral halo on US, US axillary involvement or TAB
positive
54 (45.0) 32 (94.1) 112 (72.7)
Low risk
Sensitivity
(N = 54)
Specificity
(N = 84)
Number of
TAB required
(N = 138)
L1 GCA if either US or TAB positive 27 (50.0) 65 (77.4) 95 (68.8)
L2 GCA if either bilateral halo on US or TAB positive 17 (31.5) 77 (91.7) 117 (84.8)
L3 GCA if either US positive, US axillary involvement or TAB positive 27 (50.0) 62 (73.8) 92 (66.7)
L4 GCA if either bilateral halo on US, US axillary involvement or TAB
positive
18 (33.3) 72 (85.7) 111 (80.4)
L5 GCA if both US positive and TAB positive 6 (11.1) 84 (100.0) 43 (31.2)
L6 GCA if any abnormality on US and TAB positive 8 (14.8) 84 (100.0) 51 (37.0)
US, ultrasound.
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in whom another form of vasculitis is suspected. Five patients in the study had vasculitis that was not GCA.
Two of these patients had BVAS values of at least 12, indicating significant multisystem features; one of
these patients had a VDI score of five at 6 months, indicating extensive damage. However, items on the
BVAS and VDI forms include features relevant to GCA, and the BVAS and the VDI could be seen as
further opportunities to cross-check that correct information has been recorded on the main CRF pages,
particularly in relation to presence of headache, complications as a result of GCA, visual loss or stroke. We
recorded the BVAS and the VDI score at 2 weeks and 6 months, but not baseline, to reduce the burden of
assessments required. As the VDI scores only items that are present for at least 3 months, there would be
minimal difference between the baseline and 2-week VDI scores.69,70
Birmingham Vasculitis Activity Score and Vasculitis Damage Index as
diagnostic tools
An analysis of the VDI score and the BVAS in relation to patient diagnosis was undertaken to assess
whether or not these may play a role in ruling GCA in or out. Table 43 shows the 2-week BVAS and VDI
score by the clinician-reported diagnoses at 2 weeks, as well as the eventual reference diagnosis. Neither
measure appears particularly associated with diagnosis. A BVAS of ≥ 4 was observed in 45 (12%) patients
with a non-GCA diagnosis at 2 weeks and 62 (16%) patients with GCA. Only seven of the non-GCA
cases and 26 of the GCA cases (9% overall) actually had at least one item of VDI damage recorded at
2 weeks. After 6 months, about one-third of patients were recorded as having damage in both GCA and
non-GCA groups.
There does not appear to be a difference between the proportions of participants with a 6-month VDI
score of ≥ 1 if we compare the 2-week diagnosis with the reference diagnosis (see Table 43). There is also
no difference in BVAS when comparing patients grouped according to the 2-week diagnosis and the
reference diagnosis.
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FIGURE 12 Sensitivity and specificity for the diagnostic strategy combinations. US, ultrasound.
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The reliability of assessing the Birmingham Vasculitis Activity Score and
Vasculitis Damage Index
Sixty-six study investigators were asked to complete 20 training cases for the BVAS and 20 for the VDI.
This consisted of paper case vignettes with half a page of description for each case. The assessors were
asked to complete the BVAS or the VDI for each of these cases. The pass marks were 85% agreement
with the gold standard for the BVAS and 75% agreement with the gold standard for the VDI (and no case
with a score of < 50% for either the BVAS or the VDI) in order to qualify each investigator for participation
in the study. Sixty-one investigators completed BVAS and VDI training. The average pass mark was 89.6%
for the BVAS and 86.4% for the VDI, but these included the values for investigators who failed at least
one of the assessments. Twenty-two investigators were asked to repeat at least one of the BVAS cases and
18 were asked to repeat at least one of the VDI cases. Altogether, 52 investigators eventually passed the
assessments. Three further investigators were exempted from the assessments (on the basis that they had
already demonstrated expertise in performing the BVAS and the VDI for other studies), giving a total of 55
investigators certified to perform the BVAS and the VDI.
Recording the BVAS at the 2-week visit would include reporting all items occurring since the onset of the
current condition regardless of duration and regardless of whether or not they had resolved.66,67 In other
words, if headache symptoms had been present for 2 weeks longer than at baseline, that is, because they
had already been reported on the CRF at baseline, they should still have been reported on the first BVAS,
which was completed at the 2-week visit, to reduce the burden of assessments required at the baseline visit.
In practice, this would mean that patients may have experienced features of their current presentation (such
as headache) for 2 weeks longer than they would have if evaluated at the baseline visit. In retrospect, this
may have caused some confusion among assessors, as evidenced by the fact that 113 patients with GCA
were reported as having no items on the BVAS at the 2-week assessment. It was not relevant to report the
VDI score at the baseline visit as well as the 2-week visit; we elected to report it during the 2-week visit,
because this would minimise the amount of the work required at the baseline visit.69,70
The VDI assessment performed at 6 months would aim to capture all damage occurring irrespective of
cause, which is a principle of the VDI. Therefore, any items relating to possible disease activity as a result of
GCA would not necessarily be reflected in the VDI. Equally, the VDI could report events that may have
TABLE 43 Relationship between the BVAS/VDI and diagnosis at 2-weeks/reference diagnosis
Score
Diagnosis
Two-week, n (%) Reference, n (%)
Not GCA (n= 124) GCA (n= 257) Not GCA (n= 124) GCA (n= 257)
BVAS: 2 weeks
0 33 (26.6) 113 (44.0) 43 (34.7) 103 (40.1)
1 29 (23.4) 34 (13.2) 26 (21.0) 37 (14.4)
2 to 3 17 (13.7) 48 (18.7) 15 (12.1) 50 (19.5)
4 to 6 29 (23.4) 37 (14.4) 26 (21.0) 40 (15.6)
≥ 7 16 (12.9) 25 (9.7) 14 (11.3) 27 (10.5)
VDI score: 2 weeks
0 117 (94.4) 229 (89.1) 115 (92.7) 231 (89.9)
≥ 1 7 (5.6) 26 (10.1) 8 (6.5) 25 (9.7)
VDI score: 6 months
0 65 (52.4) 144 (56.0) 72 (58.1) 137 (53.3)
≥ 1 39 (31.5) 84 (32.7) 35 (28.2) 88 (34.2)
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occurred at least 3 months prior to the 6-month assessment date, for example, development of the loss of
vision or stroke. However, when recording items in the VDI, the emphasis is on documenting the presence
of damage occurring after the onset of vasculitis, regardless of the cause of the damage (the item could
relate to disease or it could have been a complication of treatment, infection or exacerbation of or new
development of an unrelated comorbidity).
Centre effect
Twenty centres participated in the TABUL study; Table 44 shows the reference diagnosis and pre-test risk
and clinical pre-test certainty of GCA by centre. Overall, there was a good spread of patients with or
without GCA in centres recruiting 10 or more patients: between 50% and 100% of the patients recruited
from these centres had a reference diagnosis of GCA.
The pre-test risk of likelihood of having GCA based on our external model from the DCVAS data set shows
that, for centres recruiting at least 10 patients, there was a good spread of high-, medium- and low-risk
patients. The clinician’s pre-test certainty of diagnosis also showed a good spread across definite, probable
and possible cases for all centres recruiting at least 10 patients. We conclude that the selection criteria used
by different centres recruiting patients for the study were similar and allows for greater generalisability of
our results.
Health-related quality of life
The primary role of the EQ-5D data is to inform the economic analysis and modelling (see Chapter 7),
but they are also presented here as a summary of the state of health among patients within the cohort.
Table 45 shows EQ-5D over time, EQ-5D health state and thermometer health state increase by 2-week
assessment, but this effect is not sustained at 6 months. There is little difference in the EQ-5D by reference
diagnosis or steroid use at 6 months (Table 46).
Some of the patients who did not have GCA may have been treated with long-term steroids for other
reasons, for example, PMR. It is conceivable that other comorbidities may have influenced the EQ-5D more
strongly than GCA itself, but the tables do not suggest that there was a significant impact of having GCA
on health-related quality of life as measured by the EQ-5D at any of the time points assessed; nor was
there any significant change in health-quality related of life during the period of the study.
TABLE 44 Diagnosis and pre-test risk by centre
Centre N
Reference diagnosis,
n (%) Pre-test risk, n (%) Clinician pre-test certainty, n (%)
GCA Not GCA High Medium Low Definite Probable Possible
Chapel Allerton
Hospital, Leeds,
UK
16 12 (75) 4 (25) 4 (25) 6 (38) 6 (38) 10 (63) 4 (25) 2 (13)
City Hospital,
Birmingham, UK
4 4 (100) 0 (0) 1 (25) 2 (50) 1 (25) 0 (0) 4 (100) 0 (0)
Dudley Hospital,
Dudley, UK
4 4 (100) 0 (0) 1 (25) 2 (50) 1 (25) 0 (0) 3 (75) 1 (25)
Gateshead
Hospital,
Gateshead, UK
14 10 (71) 4 (29) 2 (14) 9 (64) 3 (21) 4 (29) 9 (64) 1 (7)
Great Yarmouth
Hospital, Great
Yarmouth, UK
2 2 (100) 0 (0) 1 (50) 1 (50) 0 (0) 0 (0) 2 (100) 0 (0)
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TABLE 44 Diagnosis and pre-test risk by centre (continued )
Centre N
Reference diagnosis,
n (%) Pre-test risk, n (%) Clinician pre-test certainty, n (%)
GCA Not GCA High Medium Low Definite Probable Possible
Hospital de
Santa Maria,
Lisbon, Portugal
2 1 (50) 1 (50) 1 (50) 1 (50) 0 (0) 0 (0) 1 (50) 1 (50)
Hospital of
Southern
Norway Trust,
Kristiansand,
Norway
25 21 (84) 4 (16) 5 (20) 14 (56) 6 (24) 6 (24) 12 (48) 7 (28)
Jena University
Hospital, Jena,
Germany
12 11 (92) 1 (8) 2 (17) 7 (58) 3 (25) 5 (42) 7 (58) 0 (0)
Musgrave Park,
Belfast, UK
6 4 (67) 2 (33) 2 (33) 3 (50) 1 (17) 0 (0) 4 (67) 2 (33)
Nuffield
Orthopaedic
Centre, Oxford,
UK
111 60 (54) 51 (46) 16 (14) 44 (40) 51 (46) 11 (10) 66 (59) 34 (31)
Princess
Alexandra
Hospital,
Harlow, UK
7 7 (100) 0 (0) 3 (43) 2 (29) 2 (29) 5 (71) 2 (29) 0 (0)
Queen
Alexandra
Hospital,
Portsmouth, UK
7 6 (86) 1 (14) 3 (43) 2 (29) 2 (29) 1 (14) 5 (71) 1 (14)
Queen’s
Hospital
Romford, Essex,
UK
8 7 (88) 1 (13) 5 (63) 1 (13) 2 (25) 3 (38) 4 (50) 0 (0)
Queen’s
Medical Centre,
Nottingham, UK
22 12 (55) 10 (45) 7 (32) 8 (36) 7 (32) 3 (14) 12 (55) 7 (32)
Royal Berkshire,
Reading, UK
4 4 (100) 0 (0) 2 (50) 2 (50) 0 (0) 0 (0) 4 (100) 0 (0)
Royal Derby
Hospital, Derby,
UK
3 2 (67) 1 (33) 1 (33) 0 (0) 2 (67) 1 (33) 1 (33) 1 (33)
Southend
University
Hospital,
Southend, UK
90 61 (68) 29 (32) 21 (23) 37 (41) 32 (36) 25 (28) 37 (41) 28 (31)
St Vincent
Hospital, Dublin,
Ireland
18 16 (89) 2 (11) 3 (17) 6 (33) 9 (50) 1 (6) 11 (61) 6 (33)
Stoke
Mandeville
Hospital, Stoke,
UK
20 10 (50) 10 (50) 7 (35) 5 (25) 8 (40) 5 (25) 13 (65) 2 (10)
Sunderland
Royal Hospital,
Sunderland, UK
6 3 (50) 3 (50) 2 (33) 2 (33) 2 (33) 0 (0) 3 (50) 3 (50)
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Safety and adverse events
We expected that the two interventions (biopsy and ultrasound) would produce a different profile of AEs.
We would expect the biopsy to result in discomfort, bruising, bleeding or infection around the biopsy site.
By contrast, we would expect very little in terms of harm from the ultrasound scan. We specifically sought
to document any potential harm caused by the interventions in our study.
In addition to collecting information on any adverse effects of the two main interventions, we had an
option for sites to collect information on any other adverse outcomes during the observation period.
All participants (100%) experienced at least one AE during the study. A total of 1229 AEs were reported
during follow-up (including repeated events). Table 47 shows expected AEs and Table 48 shows AEs
related to study tests. Fifty-seven patients experienced an AE related to the study test. Of these, 53 (6.3%)
of all expected adverse events were definitely related to biopsy, 10 were possibly related to biopsy and two
were definitely related to scanning. It was expected that the proportion of the AEs that would be related
to the study test would be 81%.
TABLE 46 Six-month EQ-5D by reference diagnosis and steroid use at 6 months
Measure (n= 381)
Reference diagnosis Steroid usage at 6 months
GCA (n= 224) Not GCA (n= 104) On steroids (n= 251) Not on steroids (n= 77)
6-month EQ-5D health state
Number (%) of responses 224 (100.0) 102 (98.1) 251(100.0) 75 (97.4)
Mean (SD) 0.72 (0.28) 0.65 (0.31) 0.71 (0.29) 0.67 (0.30)
Median (IQR) 0.78 (0.62–1.0) 0.69 (0.62–0.85) 0.74 (0.62–1.00) 0.73 (0.62–0.85)
TABLE 45 EuroQol-5 Dimensions assessment by all patients in the TABUL study by visit
Measure
Visit
Baseline (n= 365) 2 weeks (n= 369) 6 months (n= 328)
EQ-5D health state
Number (%) of responses 363 (99.5) 364 (98.6) 326 (99.4)
Mean (SD) 0.66 (0.27) 0.73 (0.26) 0.70 (0.29)
Median (IQR) 0.73 (0.62–0.80) 0.80 (0.65–1.00) 0.73 (0.62–1.00)
EQ-5D health state: change from baseline
Number (%) of responses – 350 (94.9) 312 (95.1)
Mean (SD) – 0.07 (0.25) 0.02 (0.31)
Median (IQR) – 0.00 (0.00–0.14) 0.00 (–0.11–0.20)
EQ-5D thermometer health state
Number (%) of responses 360 (98.6) 369 (100.0) 325 (99.1)
Mean (SD) 53.8 (29.7) 58.8 (30.5) 56.8 (30.8)
Median (IQR) 60.0 (30.0–80.0) 70.0 (40.0–84.0) 65.0 (30.0–80.0)
EQ-5D thermometer health state change from baseline
Number (%) of responses – 351 (95.1) 309 (94.2)
Mean (SD) – 4.9 (22.4) 1.4 (26.3)
Median (IQR) – 1.0 (–1.0 to 10.0) 0.0 (–10.0 to 11.0)
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TABLE 47 Expected AEs
Expected AEs n (%)
Number of participants who experienced > 1 expected AE 170 (44.6)
Number of all expected AEs (including repeated events) 836
Severity
Mild 660 (78.9)
Moderate 154 (18.4)
Severe 22 (2.6)
Related to scan?
Definitely related 2 (0.2)
Not related 833 (99.6)
Unable to assess 1 (0.1)
Related to biopsy?
Definitely related 53 (6.3)
Possibly related 6 (0.7)
Not related 777 (92.9)
Event type
Biopsy wound problems 15 (1.8)
Post-biopsy problems 38 (4.5)
US painful 2 (0.2)
Blurred vision 47 (5.6)
Breathlessness 20 (2.4)
Return of GCA 9 (1.1)
Mood/CNS/dizziness 112 (13.4)
Infection 85 (10.2)
Skin change/bruising 50 (6.0)
Flushing/sweating 64 (7.7)
Hypertension/ischaemic heart disease 34 (4.1)
Diabetes mellitus 32 (3.8)
Weight gain/bloating/indigestion 80 (9.6)
Weakness 38 (4.5)
Other drug toxicity 14 (1.7)
Other 196 (23.4)
CNS, central nervous system; US, ultrasound.
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The serious AEs reported during follow-up are shown in Table 49; 65 participants experienced 104 serious
AEs, none of which was related to either study test. Table 47 describes the details of the expected AEs
that occurred during the course of the study. This was not a mandatory part of the data collection and we
suspect that this is an underestimate of events occurring during the first 6 months of disease in patients
with GCA. We have based our analysis on 170 participants in whom at least one AE was reported. In total,
836 events were reported, only 3% of which were classed as severe. The majority of events were
unrelated to either scan or biopsy. Most events consisted of the complications that would be expected in
association with the diagnosis and treatment of GCA.
In Table 48 we have summarised the experience of AEs that are directly related to the study investigations.
Overall, 57 patients experienced 75 AEs related to the tests. A total of 63 out of the 75 of those events
were either definitely or probably related to biopsy. Two events were definitely related to the scan (which
consisted of pain at the time of the ultrasound examination). Several patients experienced biopsy-related
wound problems or post-biopsy problems such as pain or numbness, whereas none of the patients
described any of these features in relation to the ultrasound scan. Previous studies have suggested a much
lower rate of complications from biopsies. In one study only two complications were reported from
412 biopsies performed on 394 patients;74 in a smaller study of 45 cases, there were no biopsy-related
complications at all.75 Complications from biopsy can be serious, including facial nerve injury, as reported
in four cases when the biopsy was attempted in the pre-auricular area.76 An incidence of facial nerve injury
of 16% was reported in a study of 75 patients undergoing biopsy, of whom only 42% recovered.77
TABLE 48 Adverse events related to study tests
AEs related to study tests n (%)
Number of participants who experienced > 1 AE related to tests 57 (15.0)
Number of all related AEs (including repeated events) 75
Severity
Mild 66 (88.0)
Moderate 9 (12.0)
Related to study tests
Definitely related to biopsy 63 (84.0)
Probably related to biopsy 10 (13.3)
Definitely related to scan 2 (2.7)
Expected?
No 14 (18.7)
Yes 61 (81.3)
Event type
Biopsy wound problems 14 (18.7)
Post-biopsy problems 44 (58.7)
US painful 2 (2.7)
Mood/CNS/dizziness 4 (5.3)
Infection 1 (1.3)
Neuropathy 4 (5.3)
Other 6 (8.0)
CNS, central nervous system; US, ultrasound.
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TABLE 49 Serious AEs
SAEs n (%)
Number of participants who experienced > 1 SAE 65 (17.1)
Number of all SAEs (including repeated events) 104
Severity
Mild 4 (3.8)
Moderate 41 (39.4)
Severe 54 (51.9)
Missing 5 (4.8)
Related to scan?
Related 0 (0.0)
Related to biopsy?
Related 0 (0.0)
Expected? 47 (45.2)
Seriousness
Hospitalisation required 74 (71.2)
Death 16 (15.4)
Life- or limb-threatening 3 (2.9)
Persistent or significant disability/incapacity 5 (4.8)
Hospitalisation prolonged 2 (1.9)
Other important medical event 4 (3.8)
Event type
Blurred vision 1 (1.0)
Breathlessness 5 (4.8)
Return of GCA 2 (1.9)
Mood/CNS/dizziness 9 (8.7)
Infection 22 (21.2)
Skin change/bruising 2 (1.9)
Flushing/sweating 1 (1.0)
Hypertension/ischaemic heart disease 24 (23.1)
Diabetes mellitus 6 (5.8)
Weight gain/bloating/indigestion 1 (1.0)
Weakness 3 (2.9)
Admission 1 (1.0)
Cancer 5 (4.8)
Renal impairment/failure 2 (1.9)
Gastrointestinal bleed 1 (1.0)
Other 19 (18.3)
CNS, central nervous system; SAE, serious adverse event.
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We suspect that previous studies may have significantly underestimated the morbidity associated with TAB.
We do not think that the rate of complications that we have reported is outside the expected number seen
in clinical practice.
Table 49 describes the serious AEs in the cohort, none of which was related to either investigation; they
largely reflected the effects of older age, as well as of having GCA. There were 16 deaths in the study
cohort, reflecting an elderly population. Seventy-four patients required hospitalisation. We conclude that
the rate of AEs suggests that the study population was typical of many cohorts of patients with GCA
experiencing comorbidity and the complications of their disease and its treatment.
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Chapter 6 Analysis of inter-rater agreement and
clinical vignettes
Participation in the agreement and vignette exercises
Twenty sonographers from 16 sites and 26 pathologists from 19 sites were asked if they wished to
form the TABUL sonographers and TABUL pathologists groups that were responsible for the inter-rater
agreement exercises. Twelve sonographers from 10 centres and 14 pathologists from 13 centres joined the
groups and completed the exercise. Some centres had no eligible sonographers or pathologists to invite
because of their involvement as expert reviewers or designers of the exercise.
Twenty clinicians with experience in managing GCA and involved in, or associated with, the TABUL study
were invited to review vignettes for the clinical vignette exercise. Sixteen indicated that they were able to
do the exercise and 14 completed assessments of all 30 clinical vignettes.
Selection of patients
A total of 255 initially eligible patients were identified at the first stage of selection; the first 33 patients
from the randomly ordered list were selected for further screening. Twelve (36%) of these patients did not
meet the inclusion criteria and were replaced with the next 12 eligible patients. Following piloting of the
exercise and checking of the videos and images in the third stage, a further two patients were replaced
because the ultrasound images were considered to be of inadequate quality. Three further patients were
highlighted because of concerns about the ultrasound videos; two were retained because it was deemed
that their videos were difficult to interpret rather than of inadequate quality; and one case was modified
to include an alternative video for the same patient that better supported the original sonographer’s
interpretation. Finally, one of the rating cases was replaced post exercise with one of the three rated
reserve cases because the patient did not complete a follow-up assessment and was excluded from the
main analyses. Therefore, there were 30 unique cases, six of which were repeated, for evaluation by
12 sonographers and 14 pathologists.
Inter-rater agreement between sonographers and pathologists
Ratings based on images alone
Sonographers and pathologists rated each case as either consistent with GCA or not consistent with GCA;
they were also asked to report the confidence they had in their findings, using four categories to indicate
the level of certainty in their decision. The rating was done before and after seeing a brief clinical vignette
describing a few key characteristics of the patient.
The distribution of the results (consistent with GCA or not consistent with GCA) by the sonographers
for the 30 original cases assessed before being shown the clinical vignette is shown in Figure 13. The
12 sonographers unanimously agreed in 10 of the 30 cases: four as GCA positive and six as GCA negative.
In half the cases there was no unanimous agreement, but no more than two of the sonographers differed
from the majority view. In five cases there was greater disagreement, with three or four sonographers
differing from the majority.
All 14 pathologists agreed unanimously on 11 cases, six of which were consistent with GCA and five of
which were not consistent with GCA (Figure 14). There were 13 cases in which no more than two
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FIGURE 13 Frequency of evaluations consistent with or not consistent with GCA by 12 sonographers rating 30 cases.
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FIGURE 14 Frequency of evaluations consistent with or not consistent with GCA by 14 pathologists rating 30 cases.
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pathologists differed from the majority view. In six cases, there was greater disagreement, in one of which
opinion was evenly divided, with equal numbers of pathologists defining the patient as having or not
having GCA.
Eight of the 30 cases involved patients who had been assessed as biopsy positive by the original reporting
pathologist. All eight cases reported evidence of giant cells and these were the eight cases in the exercise
that all (six cases), or all except two (two cases), of the pathologists judged to be consistent with GCA.
A ninth patient was reported as biopsy negative by the original reporting pathologist but interpreted as
biopsy positive by the clinician based on the abnormalities described in the biopsy report (intimal
hyperplasia, fragmentation and reduplication consistent with previous GCA but no active inflammation).
Two of the pathologists judged the case to be GCA positive, but most concurred with the original biopsy
report and judged the case to be GCA negative.
For each GCA-positive or GCA-negative assessment, the sonographers and pathologists were asked to
indicate if they were certain or uncertain in their assessments. Analysis of differences in the certainty of
assessments indicated that sonographers judged fewer ratings as certain than did pathologists. For
GCA-positive ratings, 69.0% were judged as certain by sonographers, whereas 79.8% were judged as
certain by pathologists. For GCA-negative ratings the sonographers were certain for 54.5%, whereas the
pathologists were certain for 71.0%. However, a comparison between the 14 pathologists and the 12
sonographers in the proportion of cases judged as certain did not provide strong evidence for a difference
(Wilcoxon rank-sum test, p = 0.13). The distribution of these ratings is shown in Figures 15 and 16.
Ratings based on images and vignettes
The sonographers and pathologists were asked to give their assessment of each case before and after
seeing a brief vignette describing the patient. The vignettes provided information on the patient’s age, sex,
main symptoms and blood abnormalities. The additional clinical information had little impact on the
assessments made by the sonographers and pathologists; fewer than 5% of cases overall were amended
following the provision of the brief vignettes (Table 50).
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FIGURE 15 Frequency of certain and uncertain positive and negative assessments by 12 sonographers rating 30 cases.
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The extent of agreement between the sonographers and between the pathologists was evaluated by
estimating the intraclass correlation coefficient (ICC). There was little difference between the two groups
when restricting the decision to a binary GCA positive or GCA negative (Table 51). The intraclass
correlations were 0.61 (95% CI 0.48 to 0.75) for the sonographers and 0.62 (95% CI 0.49 to 0.76) for
the pathologists. A small reduction in agreement was observed if the agreement was assessed from the
post-vignette ratings: 0.58 (95% CI 0.44 to 0.72) for the sonographers and 0.59 (95% CI 0.45 to 0.73)
for the pathologists.
There was better agreement between the pathologists if the certainty of the assessment was taken into
account. The ICC for the pathologists was 0.72 (95% CI 0.60 to 0.83), whereas that for the sonographers
was 0.58 (95% CI 0.44 to 0.72). In other words, sonographers and pathologists achieved similar levels of
diagnostic accuracy, but sonographers were less confident in their diagnosis; perhaps this reflected their
limited experience of ultrasound in GCA in comparison with pathologists’ assessment of the histological
features. An analysis of the cases assessed after seeing the brief vignette produced slightly lower ICCs for
both sonographers and pathologists.
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FIGURE 16 Frequency of certain and uncertain positive and negative assessments by 14 pathologists rating 30 cases.
TABLE 50 Alteration of assessments after provision of a brief clinical vignette
Overall
Sonographers Pathologists
n % n %
GCA positive, no change 132 36.7 159 37.9
GCA positive to GCA negative 2 0.6 3 0.7
GCA negative to GCA positive 13 3.6 11 2.6
GCA negative, no change 213 59.2 247 58.8
Figures for 30 cases assessed by 12 sonographers (360 in total) and 14 pathologists (420 in total).
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The extent of agreement between the sonographers interpreting ultrasound videos and between
pathologists interpreting images of TABs was similar for the decision to categorise cases as positive or
negative. However, there was still a fair degree of disagreement. There was limited impact of the brief
vignettes, representing the type of information that a sonographer (while scanning a patient) or
pathologist (seeing a biopsy request form) might be aware of in routine practice, on the assessments made
and the extent of inter-rater agreement.
Intrarater agreement for sonographers and pathologists
Intrarater agreement was evaluated by including repeats of six of the cases during the exercise. Overall,
there were 10 instances of inconsistent assessments between the original and repeated cases made by the
12 sonographers and seven made by the 14 pathologists (Table 52). Overall, raw agreement was 86.1%
for the sonographers and 91.7% for the pathologists.
Analysis of the consistency of individual sonographers and pathologists is shown in Table 53. No individual
assessor was inconsistent for more than two of the cases. Over half (57%) of the pathologists and
one-third of the sonographers were completely consistent in their assessment of the six repeated cases.
However, no statistically significant difference was observed between the 12 sonographers and the
14 pathologists in the number of cases that were inconsistent (Wilcoxon rank-sum test, p = 0.21).
Kappa statistics were used to estimate ‘chance-corrected’ intrarater agreement for the sonographers and
pathologists. For the six of the cases that were repeated, the 14 pathologists achieved raw agreement of
91.7% for categorising cases as GCA or not GCA and an overall kappa statistic of 0.83 (Table 54).
TABLE 51 Intraclass correlation coefficients (with 95% CIs)
GCA positive or negative Sonographers Pathologists
Pre-vignette cases 0.612 (0.484 to 0.748) 0.621 (0.491 to 0.756)
Post-vignette cases 0.581 (0.450 to 0.724) 0.587 (0.454 to 0.730)
GCA positive/negative with certainty
Pre-vignette cases 0.575 (0.442 to 0.719) 0.719 (0.597 to 0.830)
Post-vignette cases 0.562 (0.424 to 0.711) 0.677 (0.548 to 0.799)
Estimated using two-way random-effects analysis of variance.
TABLE 52 Analysis of consistency of assessments by 12 sonographers and 14 pathologists for the six repeated cases
Repeated
case
Sonographers Pathologists
Both
negative Differed
Both
positive
Raw
agreement
(%)
Both
negative Differed
Both
positive
Raw
agreement
(%)
1 12 0 0 100 7 3 4 79
2 1 4 7 67 0 0 14 100
3 11 1 0 92 9 4 1 71
4 0 2 10 83 0 0 14 100
5 12 0 0 100 13 0 1 100
6 7 3 2 75 13 0 1 100
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The 12 sonographers achieved raw agreement of 86.1% and an overall kappa statistic of 0.69 for the
same cases. Once ratings are reported using four categories to allow for certainty in the assessments by
the sonographers and pathologists, the weighted kappa statistics for agreement are similar: 0.85 for the
pathologists and 0.81 for the sonographers.
Analysis of clinical vignettes with ultrasound in the absence
of biopsy
Fourteen clinicians reviewed the 30 clinical vignettes and provided responses for clinical decisions at two
stages: (1) the likelihood of a diagnosis of GCA and whether or not to perform a biopsy after seeing
information from a patient’s initial presentation; and (2) the likelihood of a diagnosis of GCA and whether
or not to continue with high-dose steroids after seeing a brief written summary of the patient’s ultrasound
results and clinical information after 2 weeks.
In 21 (70%) of the vignettes, the majority of the panel considered the likelihood of GCA to be probable or
definite, and for two vignettes the panel was split evenly (Table 55). In the remaining seven vignettes, which
were considered least likely to be GCA, the majority of the panel would perform a biopsy; the one exception
was for vignette case 8, for which only five of the 14 panel members would recommend a biopsy.
There was some evidence of an association between certainty of GCA and recommendation for biopsy.
Members of the panel were generally consistent in not recommending a biopsy for patients whom they
considered not to have GCA; biopsy was indicated for 10% of the time in these cases. Biopsy was
most frequently recommended (94% of the time) by panellists for vignettes judged as probable GCA.
The percentage of biopsy recommendations was lower for vignettes judged as definite GCA (78%
recommended for biopsy) and those judged as possible GCA (80% recommended for biopsy). These
findings suggest some reluctance to recommend biopsies in patients considered to have little chance of
TABLE 53 Intrarater agreement: number of inconsistent cases by rater
Number of inconsistent cases Sonographers, n (%) Pathologists, n (%)
0 4 (33) 8 (57)
1 6 (50) 5 (36)
2 2 (17) 1 (7)
3 0 (0) 0 (0)
≥ 4 0 (0) 0 (0)
TABLE 54 Kappa statistics for intrarater agreement for repeated cases
Diagnosis
Sonographers Pathologists
Raw
agreement
(%)
Expected
agreement
(%)
Kappa
statistic
Raw
agreement
(%)
Expected
agreement
(%)
Kappa
statistic
GCA positive or GCA negative 86.1 55.6 0.69 91.7 50.3 0.83
GCA positive or GCA negative with
level of certaintya
94.6 72.1 0.81 93.8 58.2 0.85
a Quadratic weights used for estimating kappa statistic.
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having GCA based on vignettes describing their symptoms and results of physical examinations and blood
tests. The findings also suggest some reluctance to recommend biopsies in patients who were regarded as
having very clear-cut evidence of GCA, based on their clinical presentation and the results of blood tests.
However, in patients who are diagnosed as having GCA without undergoing a biopsy, there may be a
concern that there is no irrefutable evidence of GCA if the diagnosis is subsequently questioned;
by contrast, the clinician’s interpretation is perceived as always open to reconsideration.
TABLE 55 Certainty of GCA and recommendation for a TAB at presentation for 30 clinical vignettes
Case
Certainty of GCA
Perform biopsy, n (%)Definite Probable Possible Not GCA
1 3 10 1 0 14 (100)
2 2 11 1 0 14 (100)
3 0 0 9 5 8 (57)
4 0 6 5 3 12 (86)
5 2 10 2 0 13 (93)
6 0 7 5 2 11 (79)
7 0 10 4 0 14 (100)
8 0 0 7 7 5 (36)
9 0 11 3 0 13 (93)
10 8 6 0 0 11 (79)
11 4 10 0 0 12 (86)
12 1 9 4 0 13 (93)
13 0 2 7 5 9 (64)
14 1 10 3 0 14 (100)
15 0 7 6 1 11 (79)
16 6 7 0 1 11 (79)
17 0 1 10 3 9 (64)
18 3 10 1 0 12 (86)
19 1 8 5 0 12 (86)
20 6 7 1 0 11 (79)
21 3 9 2 0 11 (79)
22 3 9 2 0 12 (86)
23 3 8 3 0 12 (86)
24 4 9 1 0 12 (86)
25 0 5 7 2 10 (71)
26 4 9 1 0 13 (93)
27 2 8 4 0 11 (79)
28 10 3 1 0 11 (79)
29 2 3 7 2 9 (64)
30 2 9 3 0 13 (93)
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Table 56 describes the panellists’ assessment of the diagnosis of GCA, once the ultrasound test result was
revealed and information about the symptoms, blood tests and physical examination had been provided.
Panel recommendations for continuing treatment for GCA with high-dose steroids were categorised as
agree, disagree or uncertain. The uncertain category was used when the median rating of the 14 panellists
TABLE 56 Certainty of GCA and appropriateness of continuing high-dose steroid treatment at the 2-week
assessment for 30 clinical vignettes
Case US result
Certainty of GCA
Appropriateness of continuing with high-dose
steroids for GCAa
Definite Probable Possible Not GCA 1–3 4–6 7–9 Median Appropriateness
1 + 12 2 0 0 1 0 13 9 Appropriate
2 – 1 7 4 2 4 3 7 6.5 Uncertain (D)
3 – 0 0 2 12 12 2 0 1.5 Inappropriate
4 – 0 5 3 6 7 5 2 4.5 Uncertain (D)
5 + 14 0 0 0 0 0 14 9 Appropriate
6 + 12 1 1 0 0 2 12 9 Appropriate
7 – 0 4 6 4 4 4 6 5 Uncertain (D)
8 – 0 0 1 13 14 0 0 1 Inappropriate
9 – 0 6 4 4 4 5 5 5.5 Uncertain (D)
10 + 13 1 0 0 0 0 14 9 Appropriate
11 – 1 6 5 2 3 4 7 6 Uncertain
12 – 0 6 5 3 3 5 6 6 Uncertain
13 – 0 0 6 8 9 4 1 2 Inappropriate
14 – 0 5 5 4 5 4 5 5 Uncertain (D)
15 – 0 7 2 5 5 2 7 6 Uncertain (D)
16 + 13 1 0 0 0 0 14 9 Appropriate
17 – 0 1 6 7 8 4 2 2.5 Inappropriate
18 – 1 6 3 4 4 4 6 6 Uncertain (D)
19 – 0 5 4 5 5 5 4 5.5 Uncertain (D)
20 – 4 9 1 0 1 2 11 8 Appropriate
21 + 14 0 0 0 0 0 14 9 Appropriate
22 + 14 0 0 0 0 0 14 9 Appropriate
23 + 14 0 0 0 0 0 14 9 Appropriate
24 – 2 6 4 2 3 4 7 6.5 Appropriate
25 – 0 3 4 7 8 3 3 3 Inappropriate
26 + 14 0 0 0 0 0 14 9 Appropriate
27 + 14 0 0 0 0 1 13 9 Appropriate
28 + 14 0 0 0 0 0 14 9 Appropriate
29 – 1 2 4 7 7 4 3 4 Uncertain (D)
30 – 0 8 4 2 3 3 8 7 Appropriate
D, disagreement; US, ultrasound.
a On a 9-point scale (1, extremely inappropriate; 5, uncertain; 9, extremely appropriate).
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lay in the mid-range or if there was wide variation (indicated as disagreement) in the recommendations of
the panellists regardless of the median. In 11 of the cases, the ultrasound test results were reported as
consistent with GCA, and panel members’ views were weighted strongly towards a definite diagnosis of
GCA for these vignettes. The panel members were also in agreement that high-dose steroids for GCA
should be continued for all 11 cases.
There were 19 ultrasound-negative vignettes and there was a reluctance to classify any of these vignettes
as definite GCA. In only 4 of the 19 vignettes did a majority of the panel categorise the patient as having
probable or definite GCA; in three of these four cases, the panel was in agreement that it was appropriate to
continue with high-dose steroids and in the fourth case the panel was uncertain, owing to disagreement.
Of the remaining 15 vignettes, the panel agreed that it was inappropriate to continue with high-dose
steroids in five of the case vignettes and was uncertain in the others. There was one vignette, number 20, for
which the biopsy was positive but the ultrasound was reported as negative. Despite the fact that the panel
members were not aware of the positive biopsy result, they were still in agreement that it was appropriate to
continue with high-dose steroids.
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Chapter 7 Cost-effectiveness analysis
Introduction
The economic evaluation of the two tests needs to consider any differences in the diagnostic accuracy
between them, as well as the costs and impact of the tests in terms of the development of GCA-related
complications, treatments and related side effects.
The starting point for the modelling is the statistical output showing the sensitivity and specificity of the
two individual tests and any diagnostic strategies which incorporate them (see Chapter 5). Sensitivity is the
proportion of patients with true GCA who are detected by the test or strategy; the remaining proportion is
made up of ‘false negatives’, that is, patients who test negative despite having GCA. Specificity is the
proportion of patients without GCA who are classified as negative by the test or strategy; the remaining
proportion is made up of ‘false positives’, that is, patients who test positive but who do not have GCA.
A problem with false-negative and false-positive results is that patients falling into these categories may
initially be managed in a different way, with potentially adverse consequences, compared with how they
would have been managed had their true disease status been known earlier. The economic analysis
estimates the relative cost-effectiveness of the alternative tests and strategies by quantifying and trading
off the following.
l The different costs of the tests or strategies.
l The different proportions of false negatives and false positives.
l The cost and health-related quality-of-life impact of a false negative, that is, when a patient remains
undetected with GCA for up to around 2 months, with the attendant risk of developing complications
such as vision loss.
l The cost and health-related quality-of-life impact of a false positive, that is, initiating or continuing
treatment with high-dose steroids in a patient without GCA for many months and the impact
that any unnecessary treatment has on the risk of AEs such as fractures, diabetes mellitus and
weight gain.
The primary objective of the economic analysis is to estimate the cost-effectiveness of ultrasound instead
of biopsy for the diagnosis of GCA. The secondary objective is to estimate the cost-effectiveness of
performing a biopsy following ultrasound as an alternative to TAB alone in the diagnosis of GCA. In
addition, alternative diagnostic strategies have been evaluated using estimates of sensitivity and specificity
from statistical modelling (as described in Chapter 5).
Biopsy and ultrasound are also evaluated when used in conjunction with clinical judgement, that is, the
clinician’s decision on the diagnosis at 2 weeks based on knowledge of the patient’s symptoms, signs and
available test results such as blood tests and the biopsy. This more closely reflects current clinical practice
of using biopsy results to aid the clinical diagnosis rather than to define the diagnosis.
Methods
In this section, the model structure is described, followed by details of the evidence sources used for the
various parameter values in the model. These include the performance of the diagnostic testing strategies;
risks of GCA-related complications and glucocorticoid-related AEs; and associated costs and health-related
quality-of-life effects. The costs of the tests and medications are also covered.
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The development of the economic model structure was informed by evidence from published research on
GCA in order to understand the main complications of the disease and steroid-related side effects. This
was supplemented with evidence from previous economic and decision-analytic studies of GCA78,79 and an
analysis of outcomes and cost-effectiveness of a fast-track service for GCA.80
Model structure
The model structure takes the form of a combination of three submodels: first, a decision tree for the
initial diagnostic testing; second, a risk submodel of the incidence of GCA-related complications and
steroid-related AEs over 2 or 3 years; and third, a submodel of the lifetime effects of these incident
complications and AEs. The model structure is shown in Figure 17.
Approach to obtaining values for parameters used in the economic model
We carried out a search for review articles in GCA and key evidence sources such as guidelines on
managing GCA, prescribing steroids and steroid-related complications. We also consulted the National
Institute for Health and Care Excellence (NICE) Clinical Knowledge Summary81 for GCA. It became clear
from an initial assessment of these sources that there was limited evidence on rates of complications in
GCA. Visual complications were most commonly reported but there was much heterogeneity of reported
outcomes and results were rarely for time periods relevant to our analysis. Furthermore, given the relatively
similar test performance of biopsy and ultrasound (especially when used in conjunction with clinical
judgement) and the low incidence of major comorbidity, it seemed likely that complication rates would not
be a major driver of cost-effectiveness.
We used an iterative approach to the cost-effectiveness modelling. Further review of this evidence was not
required once it became apparent that the results were unlikely to be sensitive to model parameters
relating to complications of GCA and steroids and that the cost difference between biopsy and ultrasound
was the major driver of the cost-effectiveness. Instead, our modelling focused on two aspects of test
performance that would be more important than had been previously realised: the need to focus on the
implications of using the test results in conjunction with clinical judgement and uncertainty around the
reference diagnosis for GCA.
The main sources of evidence for the model are summarised in Table 57.
The specific evidence sources are provided in the detailed sections that follow.
Test accuracy was derived from an analysis of data collected in the TABUL study. For other parameters,
such as the risk of complications from GCA (which were relatively infrequent in TABUL), evidence was
obtained from alternative sources. The precise sources of data are described in greater detail in the
following sections.
Performance of diagnostic strategies
The economic analysis considered three types of diagnostic strategy, as summarised in Table 58. One type
relies on the use of test results alone for the diagnosis of GCA. Such strategies may be as simple as testing
biopsy positive or biopsy negative, or they may involve combinations or components of tests. The second
type of strategy involves the combination of test results with clinical judgement (the clinician’s assessment
based on the patient’s characteristics and available test results) after the clinician has assessed the patient
at the 2-week visit. The third type, sequential diagnostic strategies, involves applying test results in
combination with characteristics of patients.
The sequential diagnostic strategies include those based around the three categories of pre-test risk
defined in Chapter 2 and reported in Chapter 5. The high-risk group comprised patients with tongue or
jaw claudication and a high ESR or CRP level at presentation or before starting steroids. A high ESR level
was defined as at least 60 mm/hour. A high CRP level was defined as at least 40 mg/l. The low-risk group
comprised patients with no evidence of claudication and no evidence of a high ESR or CRP level at
presentation or before starting steroids. The medium-risk group comprised the remaining patients.
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Central to the cost-effectiveness of the alternative test strategies are the impacts of missing some true
cases of GCA (the ‘false negatives’) and incorrectly categorising some patients without GCA as having the
disease (the ‘false positives’) and, therefore, receiving unnecessary treatment. These are measured by the
sensitivity and specificity of the test strategies. A strategy with high sensitivity will have few false-negative
cases and a strategy with high specificity will have few false-positive cases, but, invariably, the threshold
chosen will act positively on one at the expense of the other.
The performance (sensitivity and specificity) of the different test strategies was, in most cases, obtained
from the data analysed from the TABUL study and reported in Chapter 5. The data used to determine a
strategy indicated a positive or negative diagnosis of GCA each patient was obtained from the test results
for biopsy and ultrasound, the clinical data collected at the baseline and 2-week assessments, and the
clinician’s assessment of the GCA diagnosis at the 2-week assessment. The performance of the different
test strategies was evaluated against the reference diagnosis, as reported in Chapter 4. The only exception
was for test strategies involving a combination involving ultrasound and clinical judgement.
The sensitivity and specificity of the set of diagnostic strategies within the economic evaluation are shown
in Table 59. We included strategies specified in the protocol objectives and additional ones with the best
performance from those analysed within Chapter 5.
TABLE 57 Main sources of evidence for the model
Type of evidence Source of parameter values/evidence
Accuracy of diagnostic strategies (sensitivity and
specificity)
Statistical analyses of TABUL data
Risks of complications of GCA Review articles and guidelines
NICE Clinical Knowledge Summary81 for GCA and key cited
articles, other economic/modelling studies
Risks of AEs with steroids Review articles and guidelines on use of steroids and key cited
articles, citation searches
Costs and quality-of-life impact of GCA-related
complications
Various sources
Costs and quality-of-life impact of steroid-related
complications
Advice from a technology-assessment team that was reviewing
the evidence for a NICE report which has now been published82
Cost of biopsy and US NHS Reference Costs83
Steroid dosing schedule for GCA Clinical advice and analysis of TABUL data
Cost of steroids British National Formulary84
US, ultrasound.
TABLE 58 Types of diagnostic strategy
Type Example
Diagnostic tests alone Biopsy
Diagnostic tests used in conjunction with clinical
judgement
Biopsy and clinical judgement
Sequential diagnostic strategies Assume GCA if high risk, otherwise GCA if either US or biopsy
positive
US, ultrasound.
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Performance of ultrasound plus clinical judgement strategy
For this strategy, an additional source of diagnostic data was required because the design of the TABUL
study blinded clinicians to the ultrasound result. Therefore, we were unable to determine their opinion of
the diagnosis based on the ultrasound together with clinical judgement. In the study, all patients had both
ultrasound and biopsy tests but only the biopsy test result was given to the clinician managing the patient.
Decisions about continuing treatment and the clinician’s diagnosis were therefore based on the biopsy result
and a clinical assessment of the patient after 2 weeks. The ultrasound result was made available only if the
clinician intended to rapidly withdraw steroids at 2 weeks based on a negative biopsy and his or her clinical
assessment of the patient. The clinician could then change their treatment decision, that is, continue with
steroid treatment, and alter their diagnosis after seeing the ultrasound result. TABUL data are therefore
available on the treatment decisions made after 2 weeks only on the basis of the biopsy results; it is not
known what treatment decisions would have been made if the ultrasound test result, but not the biopsy
result, were provided to the clinician. Some assumptions are therefore required about what diagnoses and
decisions about treatment would have been made. For the purposes of the economic analysis the focus is on
the treatment decision to continue or withdraw treatment with high-dose steroids because it is this decision
that has implications for the risk of developing GCA complications or steroid-related AEs.
TABLE 59 Sensitivity and specificity of alternative diagnostic strategies
Strategy Sensitivity (%) Specificity (%) Having US (%)
Having
biopsy (%)
Technology-only strategies
Biopsy only (all patients) 39 100 0 100
US only (all patients) 54 81 100 0
Biopsy and US (both in all patients) 65 81 100 100
US followed by biopsy if US is negative 65 81 100 57
Technology followed by risk factors
US and biopsy with additional prognostic
baseline factors
67 81 100 57
Biopsy and older age and claudication with
81% specificity
68 81 0 100
Biopsy and older age and claudication with
90% specificity
59 90 0 100
Pre-test probabilities used to filter who needs a test
Composite pre-test strategy H0M1L1 72 77 77 46
Composite pre-test strategy H0M1L3 72 75 77 46
Composite pre-test strategy H0M5L7 68 77 77 0
Technology and clinical judgement (proportion continue with steroids)
Two-week decision: biopsy and clinical
judgement
91 81 0 100
Two-week decision: US and clinical
judgement
89 77 100 0
Two-week decision: biopsy and US and
clinical judgement
96 73 100 100
H0, in high-risk group, assume GCA positive (no diagnostic test performed); M1, in medium-risk group, GCA if either
ultrasound or biopsy positive; M5, GCA if ultrasound positive; L1, in low-risk group, GCA if either ultrasound or biopsy
positive; L3, GCA if either ultrasound positive, ultrasound axillary involvement or TAB positive; L7, GCA if ultrasound positive;
US, ultrasound.
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An algorithm was devised that would allow an implied treatment decision to be arrived at by considering
how the availability of the ultrasound rather than the biopsy would have influenced clinicians’ decision-
making. To do this, it is necessary to consider this separately according to what the biopsy and ultrasound
test results were; in other words, there are four possible combinations of biopsy and ultrasound test results
(both positive, both negative, only biopsy positive and only ultrasound positive).
A summary of the reasoning and inferred steroid treatment decision for each of the four combinations is
shown in Table 60.
For the case in which the biopsy is negative and the ultrasound is positive, two scenarios are described.
For scenario 2 (cases for which the ultrasound result was unblinded), for consistency with the TABUL study,
we allowed the ultrasound result to be over-ruled by clinical judgement, which was the case for five patients.
For the final combination, a positive biopsy and a negative ultrasound, it is not possible to infer what the
treatment decision would be; therefore, in the case of these 27 patients, an alternative approach based on
clinical vignettes was used to elicit the treatment decisions that would have been made.
TABLE 60 Inferred outcomes for the ultrasound plus judgement strategy according to biopsy result and
ultrasound result
Actual test results
for US and biopsy
Information available to the clinician and rationale for
inferring their decision if the US result available and
biopsy result blinded
Implied treatment decision for
the US plus judgement strategy
Biopsy positive It is assumed that treatment would be continued in all cases
with a positive US result. Similarly, a positive biopsy would
almost certainly result in a clinical diagnosis of GCA and
continuation of treatment. In TABUL this was the case for all
positive biopsies so it is assumed that the decision would be
the same
Same as actual treatment decision
with biopsy, that is, continue
steroid treatmentAND
US positive
Biopsy negative The clinical diagnosis and treatment decision relies on other
factors, for example signs, symptoms, blood tests, response
to treatment, in the presence of a negative test result. It is
assumed that the same decision would have been reached
regardless of which negative test result was provided to the
clinician
Same as actual treatment decision
with biopsy (either continue with
or withdraw steroids)AND
US negative
Biopsy negative Scenario 1: no unblinding of the actual US result happened in
the study. In this situation the clinician’s decision in the study
was to continue with steroid treatment because other factors
such as patient symptoms strongly suggested GCA. It is
assumed that a positive US result would have supported this
and so would not have altered this decision
Same as actual treatment decision
with biopsy, that is, continue
steroid treatmentAND
US positive
Scenario 2: the clinician planned to withdraw steroids in the
study because neither the biopsy nor signs and symptoms
suggested GCA, so the US result was unblinded. In this
situation the actual decision of the clinician after unblinding
the US result is known and has effectively taken the biopsy,
US and patient symptoms, etc. into account. For our implied
treatment decision (for which the clinician would not know
the biopsy result) it is assumed that knowledge of the
negative biopsy result in the study did not ultimately have any
influence on the decision made in the light of the US result
and patient symptoms, etc.
Same as actual treatment decision
from TABUL following unblinding
of US (either continue with or
withdraw steroids)
Biopsy positive In the study the decision was to continue treatment for all
these patients. However, it is not possible to know if the
same decision would have been made on the basis of other
factors (symptoms, etc.) alone. Therefore, it cannot be
assumed that the decision would be the same based on the
US result and clinical judgement
Cannot be inferred from study
data and outcomes. Need to
obtain decisions about treatment
from a separate clinical vignettes
exercise
AND
US negative
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All of these 27 patients were included in the clinical vignette exercise as part of the original random
sample (as reported in Chapter 6) or in an additional sample for the economic analysis. The panel members
rating the vignettes reported their assessment of the diagnosis (definite, probable, possible or not GCA)
and the appropriateness of continuing treatment with high-dose steroids (on a scale from 1 = extremely
inappropriate to 9 = extremely appropriate) using data collected at presentation and at 2 weeks plus the
result of the ultrasound. The economic analysis used the available results from the clinical vignettes, from
the first 12 clinicians who completed the exercise.
To dichotomise the continuation of high-dose steroids ratings into a yes/no outcome, a score of 5 or higher
was used to indicate a decision to continue treatment. Scores of 4 or lower would indicate a decision not to
continue. This threshold resulted in 63% of vignettes being categorised as ‘possible GCA’ by panel members
falling into the ‘continue treatment’ group. Alternative thresholds of 3, 4 or 6 would have resulted in 100%,
87% and 18% of ‘possible GCA’ vignettes being categorised as ‘continue treatment’, respectively.
A simulation was then run to model the diagnosis and treatment decisions if treatment decision had been
made by a single clinician for each patient, as was the case in the TABUL study. Decisions were randomly
sampled using the ratings from all 12 clinicians on the panel. The simulation was repeated for each vignette
100 times in order to give equal weight to the ratings from all clinicians. By comparing the sampled results
with the reference standard, the expected (average) numbers of true positives and false negatives were
obtained; there were no false positives or true negatives because all 27 were biopsy positive.
Application of the simulated results from the vignettes to the test strategy that combined ultrasound
with clinical judgement produced a sensitivity of 89.1% and a specificity of 76.6% (see Table 59).
These figures were slightly lower than the equivalent figures for the strategy involving biopsy and
clinical judgement.
Risks of complications of giant cell arteritis
Visual complications
Visual complications represent the greatest burden of complications of GCA, with about 25% of cases
resulting in sight loss if left untreated.85 The major presenting symptoms are amaurosis fugax (a transient
shade, dimming, fogging, blurring or monocular blindness), transient diplopia (double vision) or unilateral
or bilateral partial or complete vision loss.
For the economic model, we needed to identify the risk of onset of visual complications after patients had
presented to their GP, because an estimated 92% of visual complications arise prior to the initiation of
high-dose steroid treatment and therefore would not be affected by the diagnostic strategies considered in
TABUL. To do this, we created a submodel of visual complications, combining and modelling data from
various sources, as shown in Figure 18.
Blindness in both eyes is rare in GCA86 because steroid treatment is usually started when sight loss occurs in
one eye and should reduce the risk of sight loss occurring in the other eye. It is therefore assumed that there
will be no cases of bilateral sight loss and that steroids will have been started in all cases of unilateral sight
loss. The stages during the diagnostic and treatment pathway during which visual loss arises are illustrated
in Figure 17, based on 30% of patients experiencing visual complications,87 15% experiencing permanent
visual loss87 and 92% of visual complications arising before treatment as initiated.88 Of this 92%, one-fifth
of complications are assumed to be attributable to an initial false-negative diagnosis. Eight per cent are
estimated to arise in true positives after steroid treatment has started. The required estimates of incidence
rates of new visual loss among true positives and false negatives are shown by the solid arrows.
In order to assign costs of treatment and the quality-of-life impact of visual complications, we required an
assessment of severity, based on a previously reported analysis89 (Table 61).
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Although visual acuity is the primary criterion for determining vision loss, other types of vision loss (e.g.
peripheral vision loss or contrast sensitivity loss) are recognised as disabilities even if central visual acuity is
20/20. Partial sight loss in the centre of vision is different to partial sight loss in the periphery, but we have
no information on the nature of GCA-induced visual loss.
Stroke
For the incidence of GCA-related stroke, the models assume that 2.64% of cases of GCA result in a
stroke, as per Amiri et al.,90 and further assume that strokes arise after presentation to the patient’s GP.
It is also assumed that stroke occurring as a result of GCA has the same severity and likelihood of fatality
as stroke unrelated to GCA. Sixty per cent of strokes were assumed to be minor; case fatality in major
strokes was assumed to be 50%.
Mortality from giant cell arteritis
There have been numerous studies reporting an increased risk of mortality in the years following a
diagnosis of GCA. However, we decided that it was not necessary to include this in the model because
there is no evidence to suggest that a delay in the diagnosis of several weeks (as a result of an initial
false-negative test result) has an impact on this mortality risk. Hence, it is unlikely to have any impact on
the relative cost-effectiveness of different test strategies.
Use of steroids and risk of complications
Oral corticosteroids have potent systemic effects, including numerous side effects. Evidence on
complications arising from treatment with steroids is based on studies relating to oral corticosteroids;
almost all patients in TABUL were treated with oral high-dose glucocorticoid therapy. The dose schedule
for individuals with GCA is shown in Table 62. The second column describes the typical dose schedule for
a true positive, that is, a patient with GCA with ongoing treatment. The third column describes a shorter
duration of therapy for false-negative cases; this was adopted on the basis that steroid doses are likely to
be tapered more quickly in the absence of ongoing features of the disease. The data from the TABUL
study placed some doubt on this assumption; therefore, we performed a sensitivity analysis to include a
dose schedule for false positives that was the same as that for true positives.
The list of all possible side-effects of steroids is long, but they vary in severity and burden to the patient and
the NHS. Even treatment with low-dose steroids is associated with weight gain, hyperglycaemia, diabetes
mellitus, increased blood pressure and hypertension, decreased bone mineral density with increased risk of
fracture, cognitive dysfunction, increased risk of infection and cataracts.91 The economic analysis focused on
those AEs that were reported to have a high-cost impact or a detrimental effect on quality of life and that
were clearly attributable to the use of steroids (as opposed to possibly arising, at least in part, as a result of
TABLE 61 Analysis of the severity of visual loss by initial visual acuity in one eye
Visual acuity Oral therapy or intravenous therapy, n (%)
20/50–20/70 12 (13)
20/80–20/100 4 (4)
20/200–20/400 5 (6)
Counting fingers 19 (21)
Hand motion 15 (17)
Light perception 13 (15)
No light perception 21 (24)
Rates calculated from data in Hayreh et al.89
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having GCA). The AEs included in the model were fractures, diabetes mellitus and hyperglycaemia,
symptomatic steroid myopathy and steroid psychosis. Hypertension was not included because data from
the TABUL study showed little change in the use of antihypertensive medication. As rates of AEs in TABUL
were only for a 6-month period, we sought evidence from other studies for the rates to be used in the
economic model.
Fractures
The model includes vertebral body compression fractures, fractures of the hip/femoral neck, wrist/forearm
and proximal humerus (shoulder). The approach to modelling incidence of fractures in a GCA cohort is to
start with risks in the general population, then to apply uplift (hazard ratio) for the impact of steroid
treatment, and then to apply a relative risk for the effect of bone-protection therapy (Table 63).
The model used the fracture risks per annum shown in Table 63. These are specific to the 70–74 years age
group of the general population,92 the average age in TABUL being 71 years, and are prior to adjustment
for the effect of steroids.
We also obtained the hazard ratios for the increased risks because of the use of steroids with a dose
exceeding 7.5 mg daily from the same source.92 These are 5.2 for vertebral fracture, 2.35 for hip fracture
and 1.79 for osteoporotic fracture, which we used for fractures of the wrist/forearm and humerus.
Although uncertain, the evidence and clinical opinion suggest that the excess risk of fractures disappears
within 1 year of stopping steroid therapy.
TABLE 62 High-dose oral glucocorticoid regimen typically used for treating GCA, with tapering over time
Month
Dose (mg):
true positives
Dose (mg):
false positives Month
Dose (mg):
true positives
Dose (mg):
false positives
1 60 60 13 11.5 3
2 52.5 53 14 10.5 2
3 45 44 15 9.5 1
4 37.5 36 16 8.5 0
5 30 28 17 7.5 0
6 22.5 19 18 6.5 0
7 17.5 13 19 5.5 0
8 16.5 10 20 4.5 0
9 15.5 9 21 3.5 0
10 14.5 7 22 2.5 0
11 13.5 5 23 1.5 0
12 12.5 4 24 0 0
TABLE 63 Fracture risks per annum in the general population
Sex Vertebral fracture Hip fracture Wrist fracture Proximal humerus
Men 0.299 0.213 0.161 0.120
Women 0.533 0.379 0.699 0.246
Average 0.416 0.296 0.430 0.183
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Prevention of fractures
We assumed that all patients treated with high-dose steroids were classed as being at high risk of fractures
and so received bone protection therapy. There are various therapies available but, for simplicity, we
assumed that treatment was with a combination of a bisphosphonate, vitamin D and calcium, the
standard dose and costs84 for which are shown in Table 64. We assumed that the relative risks for fracture
following bone-protection therapy were 0.57 for vertebral fractures and 0.61 for fractures of the hip,
forearm or humerus.92
Diabetes mellitus and hyperglycaemia
In Niederkohr and Levin78 the combined overall incidence of hyperglycaemia and diabetes mellitus was
4.8%, the majority of which was likely to be hyperglycaemia below the threshold for diabetes mellitus.
Duru et al.93 reported the incidence of diabetes mellitus alone to be in the range 0–3%. For the model,
we used 1.5% as an estimate of the incidence of GCA-related diabetes mellitus. It was assumed that 80%
of these cases might be reversible (i.e temporary hyperglycaemia). It was assumed that episodes of
temporarily raised glucose would not be given a permanent label of diabetes mellitus (such a label would
result in a significant burden to the individual and resource use). For the remaining 20% of patients, in
whom it was assumed the incident diabetes mellitus was permanent, a proportion of these were likely to
have had non-diabetic hyperglycaemia before starting steroid treatment for suspected GCA. The impact of
starting steroids meant that the diagnosis of diabetes mellitus may have emerged earlier than it would
otherwise have done, that is, these patients would have eventually developed diabetes mellitus at some
point in the future regardless of their steroid therapy. Although it is therefore difficult to attribute a
proportion of the burden of such accelerated diagnoses to the use of steroids, we judged that it would be
reasonable to assume that the costs of managing diabetes mellitus would be incurred 5 years earlier than
they would otherwise have been without steroid treatment, that is, the impact of steroids accelerates the
occurrence of diabetes mellitus by 5 years.
Other adverse events
We assumed that the annual incidence of symptomatic steroid myopathy was 3.4% and the annual
incidence of steroid psychosis was 7.6% based on a GCA study by Niederkohr and Levin.78 For the many
other common and mild AEs, for example moon face (round, puffy-shaped swollen face), there is likely to
be a very small cost burden to the NHS. However, collectively there is a significant impact on quality of life;
therefore, an overall adjustment to quality of life was applied (see Chapter 7, Health utilities). For the
impact of diabetes mellitus on utility, based on Brown et al.,94 we assumed a multiplier of 0.88, which
leads to a decrement in quality of life because of diabetes mellitus of 0.09. This is assumed to persist
indefinitely because diabetes mellitus is a progressive condition and individuals with a longer duration of
diagnosed diabetes mellitus can be expected to have a greater prevalence of complications and associated
loss of quality of life.
TABLE 64 Bone protection therapy
Medication Dose Dose cost
Sodium alendronate (non-proprietary) alonea 10 mg daily 28-tablet pack = £1.64
Vitamin D (cholecalciferol) with calcium
carbonate
10 µg per day of cholecalciferol Accrete D3® net price
60-tablet pack (10 µg) = £2.95
Risedronate sodium, calcium carbonate
and cholecalciferol (Actonel® Combi,
Warner Chilcott)
Weekly cycle of 1 Actonel Once a Week®
(Risedronate sodium) tablet on the first
day followed by one calcium and
cholecalciferol sachet daily for 6 days
24-sachet plus four-tablet
pack = £19.12
a We assumed that GPs would prescribe alendronate on its own rather than in combination with colecalciferol. This is
because it would be much cheaper to prescribe alendronate and to separately prescribe vitamin D and calcium because
they are much cheaper. Bisphosphonates have been estimated to reduce the risk of fractures by 43%.92
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Unit costs of tests, medications and treatments
The evidence sources for the unit costs are described below. All costs are then adjusted for inflation to
bring them to 2014/15 levels.
Biopsy and ultrasound
Biopsy is estimated to cost £493 based on NHS Reference Costs for 2011/1283 (for lymph node biopsy/
salivary gland biopsy). This is assumed to include theatre cost, surgeon time, pathologist time, sample
processing, camera, microscope and other pathology equipment and administration cost. It has been
pointed out that some ‘biopsy costs’ shown in NHS Reference Costs83 may be understated, as they include
relatively minor procedures such as the removal of warts. However, we used a specific procedure code,
lymph node biopsy/salivary gland biopsy, which we expect to be robust in this case.
In the TABUL study, the typical time taken to perform ultrasound of both temporal and axillary arteries
was 30 minutes, although there was considerable variation (scans took between 20 and 60 minutes,
depending on the experience of the sonographer and the extent of the abnormalities to be defined).
The cost of a ‘direct access’ (as opposed to outpatient) ultrasound scan taking 20 minutes or more is £57
based on the NHS Reference Costs for 2013/14.95 This is assumed to include equipment cost, equipment
maintenance and calibration, sonographer time, radiology space/room cost, radiologist interpretation cost,
administration cost and a contribution for hospital overheads. Training costs for a hospital to set up a new
GCA sonography service are classed as ‘implementation costs’ so, in line with NICE convention, they are
excluded from the cost-effectiveness analysis. With uplifts for inflation, the costs for biopsy and ultrasound
are £514 and £58, respectively.
Giant cell arteritis-related complications
The costs of vision loss shown in Table 65 are applied to the visual acuity states in the model that are
worse than 6/60 m (20/200 feet), that is, those meeting the legal definition of blindness, in line with the
ranibizumab and pegaptanib sodium HTA assessment.96
The costs of registration of blindness, provision of low-vision aids and low-vision rehabilitation are one-off
rather than recurrent costs. Community care costs were estimated as the annual cost for a local authority
home care worker and residential care costs were based on the annual cost of private residential care
(taking into account that approximately 30% of residents pay themselves). Using the estimated
annual costs in Table 65 gives a cost of £5090 for the first year of blindness and £4903 for each
subsequent year.
The 5-year cost of a non-fatal stroke was estimated to be £29,400 in a NICE report.97
TABLE 65 Costs of vision loss below best corrected visual acuity of 6/60 in the better-seeing eye
Service Receiving services (%) Unit cost (£) Annual cost (£)
Blind registration 95 115 109
Low-vision aids 33 150 50
Low-vision rehabilitation 11 259 28
Community care 6 6,552 393
Residential care 30 13,577 4073
Depression 39 431 168
Hip replacement 5 5379 269
Adapted from Table 42 in Colquitt et al.96 This monograph may be freely reproduced for the purposes of private research
and study and may be included in professional journals provided that suitable acknowledgement is made and the
reproduction is not associated with any form of advertising.
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Steroid-related adverse events
The unit costs of AEs were obtained from published studies98–101 and are shown in Table 66.
Inflation
All unit costs were inflated to 2014/15 values using the Hospital and Community Health Services index.102
Health utilities
Utilities are valuations of health-related quality-of-life on a scale from 0 to 1, with 0 being equivalent to
dead and 1 being equivalent to perfect health. A loss of quality-of-life attributable to a complication such
as vision loss or an AE such as a fracture is called a utility decrement. The utility decrements used in the
model are shown in Table 67. The baseline utility for someone of 71 years of age is 0.716, based on an
age-related annual decrease in utility of 0.004.107
For visual loss, we obtained the required utility decrement by combining data on substates of visual loss. The
quality of life of various visual states was studied in Brown et al.,94 showing a wide range of utilities associated
with different levels of vision within the range of legal blindness (visual acuity < 20/200). We used the reported
time trade-off (TTO) values rather than standard gamble (Table 68), as these are consistent with the EQ-5D
quality-of-life instrument preferred by NICE. Multiplying these TTO values by the proportional occurrence of
visual loss by severity in Table 61 gives a weighted value of 0.524 (on a scale of 0 to 1). As the TTO values are
on a scale of 0 to 1, this was used as a multiplier to the age-specific utility in the model, giving an overall utility
value for vision loss of 0.375, which represents a decrement of 0.34 compared with the baseline utility of 0.716.
Utilities associated with vision loss tend to be higher after the first year, which we speculate is because of a
degree of adjustment made to the condition.
Model time horizon
Cost-effectiveness analyses need to capture all significant costs and utility effects that are relevant to the
intervention and condition of interest. As steroid treatment causes fractures and diabetes mellitus in a
small minority of patients, and because these have lifetime cost and/or quality-of-life impacts, it is
necessary for the model to take a long-term perspective. The model horizon is, therefore, 40 years, which
is effectively a lifetime perspective for a cohort with a baseline age of 71 years.
Mortality
As the model has a lifetime perspective, it is necessary to include both the mortality rate for the general
population and any excess mortality arising from GCA or steroid-related side effects. General population
mortality rates were obtained from standard Office for National Statistics tables.108 Stroke mortality is
modelled explicitly. For fractures, excess mortality was applied when vertebral or hip fractures occurred,
leading to an absolute estimated 1-year mortality of 4.4% and 6.0%, respectively (estimates for patients
aged 71 years, rates derived from van Staa et al.109).
TABLE 66 Unit costs of steroid-related AEs
Event type Cost (£) Source
Vertebral body compression fracture 1152 Gutiérrez et al.98
Hip fracture 4222 Gutiérrez et al.99
Forearm fracture 690 Gutiérrez et al.98
Proximal humerus fracture 690 Gutiérrez et al.98
Symptomatic steroid myopathy 2079 aBernatsky et al.100
Diabetes mellitus 2520 Manson et al.101
a CAD 4099 converted to GBP using 2008 conversion rate of 1.9717.
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TABLE 67 Utility decrement values for complications and AEs
Health state
Multiplier
(when applicable)
Utility
value
Utility decrement
versus baseline value Source
Baseline utility 0.716 See Health Utilities
Major stroke 0.260 –0.46 Post et al.103
Minor stroke 0.550 –0.17 Post et al.103
Vision loss 0.524 0.375 –0.34 See Health Utilities
Vertebral body compression fracture
Year 1 0.570 0.408 –0.31 ScHARR104
≥ Year 2 0.660 0.473 –0.24
Hip fracture
Year 1 0.690 0.494 –0.22 ScHARR104
≥ Year 2 0.850 0.609 –0.11
Proximal humerus fracture
Year 1 0.860 0.616 –0.10 ScHARR104
≥ Year 2 1.000 0.716 0.00
Forearm fracture
Year 1 0.880 0.630 –0.09 ScHARR104
≥ Year 2 0.980 0.702 –0.01
Diabetes mellitus 0.880 0.630 –0.09 Brown et al.105
Symptomatic steroid
myopathy
0.707 –0.01 Roberts et al.106
Steroid-induced psychosis 0.665 –0.05 Roberts et al.106
General decrement for
steroid users
–0.03 Niederkohr and Levin78
ScHARR, School of Health and Related Research.
The utility decrement for weight gain is included within the general utility decrement from general symptoms of GCA
(not AEs).
TABLE 68 Utility values of alternative visual states
Visual state
Mean utility TTO method94
except when specifieda Comments
20/50–20/70 0.88 Assumed equally spaced between
perfect health and 20/200
20/80–20/100 0.77
20/200–20/400 0.65
Light perception to counting fingersb 0.47
No light perception in one eye 0.37 Assumed in between LP and NLP
each eye in Brown et al.94
No light perception in each eye 0.26
a TTO (on a scale of 0 to 1, with 1 being perfect vision).
b The acuity state ‘Hand Motion’ falls within this category.
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Discount rates and perspective
Discount rates of 3.5% per annum are applied for both costs and health benefits as measured in
quality-adjusted life-years (QALYs) in line with NICE guidance.110 Discounting is undertaken to ensure
that both the overall costs and overall benefits are reported in comparable terms, in their present value.
A sensitivity analysis is undertaken with alternative rates of 0% for benefits (QALYs), as long-term benefits
are heavily discounted when a rate of 3.5% is applied. In line with NICE guidance, the model takes a
health and social care perspective. Wider societal impacts, such as time off work and private care home
costs, are excluded (except for specific sensitivity analyses).
Sensitivity analysis
The values described so far for the main analysis are referred to as the ‘base-case’ values. However, model
parameters have some uncertainty around their ‘true’ value, either because of sample sizes (as evidenced
by reported 95% CIs) or because there are multiple heterogeneous studies from which is it difficult to
obtain an unequivocal single ‘best estimate’. It is therefore standard practice to carry out sensitivity
analyses. Here the term ‘sensitivity’ refers to how much the economic outcomes change according to
changes in model parameters from their ‘base-case’ values.
Sensitivity analyses were undertaken for the following strategies:
l biopsy alone
l ultrasound alone
l biopsy in combination with clinical judgement (current routine care)
l ultrasound in combination with clinical judgement.
Uncertainty around the various parameters works both ways, so, for example, if the base-case estimate of
the cost of ultrasound is £57, we could test out what happens if the cost were 20% higher or 20% lower.
Given that initial analyses indicated that ultrasound is likely to be more cost-effective than biopsy, values
for the sensitivity analyses have been chosen, as shown in Table 69, in the direction which is likely to make
the cost-effectiveness of ultrasound and biopsy closer than in the base case.
Alternative reference diagnosis of giant cell arteritis
For GCA there is currently a lack of a universally accepted reference or gold standard definition for the
diagnosis of GCA. As a result, the performance (sensitivity and specificity) of each test or composite
screening strategy is inevitably influenced by the choice of reference standard. In TABUL, clinical
judgement played a major part in the reference standard, as well as the biopsy and ultrasound results.
However, there are alternative, more narrowly defined, reference standards that could be used for the
purpose of sensitivity analysis, such as the ACR criteria or combinations of the tests and ACR criteria/risk
factors. The concern is that if we vary the reference standard diagnosis, this will influence the relative
cost-effectiveness of the potential screening strategies.
We have therefore tested the impact of three alternative reference standards, which are defined such that
there are fewer ‘true’ GCA cases (Table 70). This is an exploratory analysis and the alternative reference
standards are merely to explore whether or not fewer true GCA cases might alter the base-case conclusions
and, having not been comprehensively evaluated, do not purport to have applicability to clinical practice.
The outcomes of the following subset of strategies were compared against the alternative reference
standard diagnoses:
l biopsy alone: as per protocol
l ultrasound alone: as per protocol
l a composite strategy (H0M5L7) in which high-risk cases are treated as GCA and others are treated as
GCA only if the ultrasound is positive
l biopsy and clinical judgement.
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TABLE 69 Sensitivity analyses to be undertaken
Number Parameter Values
Risks of GCA-related complications
1 Baseline risk of GCA-related complications: reduce the risks
to reflect introduction of a fast-track pathway across the UK
Apply a hazard ratio of 0.41 for GCA-related
events vs. conventional pathway (0.41 = 9%/
22% as per fast-track study)80
The fast-track pathway in Patil et al.80 involved raising
awareness of the fast-track pathway in general practice
(including publicity to patients) and providing training to GPs
to enable them to spot the symptoms of GCA, with
reminders every 3 months. Patients with features of GCA
and ischaemic symptoms were referred to A&E for
assessment, receiving advice from both ophthalmology and
rheumatology specialties
There was an overall reduction in inpatient costs and cost of
re-admissions, the savings being partially offset by the
training costs. There was little or no difference in costs of
medication, GP appointments, investigations or outpatient
appointments111
The UK Department of Health working group is now
evaluating ‘rollout’ of a fast-track pathway across the UK112
2 Ratio needed for the calculation of rates of new permanent
visual loss post presentation: ratio of true positives to false
negatives over past few decades (using biopsy and clinical
judgement). TABUL suggests that a ratio of 90 : 10 may be
the most up-to-date estimate
Historically this may have been lower, at
around 80/20, allowing for more recent
improved recognition of signs and symptoms
of GCA
3 Split of cases of visual loss that arise before treatment into
those arising before presentation vs. cases in false negatives
70/30 (i.e. 7 times more before presentation;
assumed to be 80/20 in base case)
Test performance/costs
4 Higher test sensitivity for biopsy and clinical judgement than
suggested by mean in TABUL
94% (the upper 95% CI) vs. 91% base case
5 Higher test specificity for biopsy and clinical judgement than
suggested by mean in TABUL
88% (the upper 95% CI) vs. 81% base case
6 Cost of US: £57 in base case per NHS Reference Costs95 £144 per TABUL reimbursement costing
Risks of steroid-related AEs
7 Persistence of raised fracture risk after cessation of steroids:
duration over which the risk gradually tapers off from the
level at steroid cessation to zero
3 years after cessation (assumed to be 1 year
in base case)
8 False negatives: shorter time to detection of GCA following
tapering off steroid treatment after initial test
1 month instead of > 2 months (base case)
9 Longer time to withdrawal of steroids in false positives than
in base case
Assume same steroid schedule as for true
positives
Cost and utility/quality of life
10 Overall cost and quality-of-life burden of AEs attributable to
steroids
100% higher than base case
11 Unit cost of vision loss (defined by visual acuity worse than
20/200)
Reduced by 20% (from £5090 to £4072 in
year 1)
12 Utility (quality-of-life) multiplier for visual loss (on 0–1 scale,
in which 1= perfect health, 0= equivalent to death)
Increased from 0.762 to 0.800
13 Alternative discount rate for QALYs 0% for QALYs
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Results
In this section, results are presented for the base case, then for the various sensitivity analyses, and the
budget impact, all based around the diagnostic reference standard applicable in the TABUL study. We then
investigate how varying the reference standard changes the results.
The two main measures of cost-effectiveness are the incremental cost-effectiveness ratio (ICER) and net
monetary benefit (NMB). Both of these are all-encompassing measures that trade off additional costs of
diagnosis, medication and treatment of complications against benefits in terms of improved life expectancy
TABLE 70 Definitions of the alternative reference standards
Number Alternative reference standard
Number of
GCA cases
Total GCA cases as % of
TABUL reference standard
1 As per reference standard diagnosis EXCEPT change
to ‘NOT GCA’ where:
l reference diagnosis =GCA positive AND
l low risk AND
l negative TAB AND
l negative US
234 91
2 As per reference standard diagnosis EXCEPT change
to ‘NOT GCA’ where:
l reference diagnosis =GCA positive AND
l negative TAB AND
l negative US AND
l either low risk or (medium risk AND no optic
neuropathy AND normal temporal artery)
215 84
3 As per reference standard diagnosis EXCEPT change
to ‘NOT GCA’ where:
l reference diagnosis =GCA positive AND
l negative TAB AND
l negative US AND
l no tongue/jaw claudication AND
l normal temporal artery AND
l no optic neuropathy AND
l ESR < 80
244 95
TABLE 69 Sensitivity analyses to be undertaken (continued )
Number Parameter Values
Willingness-to-pay threshold
14 Base case used £20,000/QALY £30,000 per QALY
No over-ruling of US result
15 As described earlier in relation to Table 60, in TABUL there
were five individuals for whom the US result was over-ridden
by clinical judgement
The resulting sensitivity and specificity become
93.9% and 72.6%, respectively (compared
with 93.1% and 72.6% for the base case)
A sensitivity analysis will examine the effect of allowing no
over-ruling of the US result when calculating the implied
treatment decision for ultrasound and judgement
US, ultrasound.
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and quality of life (e.g. through reduced incidence of blindness or reduced incidence of fractures).
Central to these measures is:
1. The QALY; for example, 2 years spent with a utility of 0.6 gives 1.2 QALYs.
2. The value placed on 1 QALY gained [often referred to as the willingness-to-pay (WTP) threshold],
which, in the UK, is stated by NICE to be typically in the range £20,000 to £30,000 per QALY. We will
use a threshold of £20,000 per QALY for our analysis because this is more usual for groups that are
not disadvantaged.
The preferred measure is the ICER. This shows how cost-effective one strategy is compared with another
by dividing the incremental costs by the incremental QALYs, but this can become complex to present when
there are many strategies. We shall therefore report ICERs to compare a small number of strategies, but
we shall use the NMB to compare the cost-effectiveness across all strategies. The NMB is the overall
monetary value of a screening/treatment strategy taking account of both costs and health benefits, with
the health benefits valued at £20,000 per QALY. The higher the NMB, the more cost-effective a strategy is;
this allows easy comparison across multiple strategies.
To calculate the NMB of a strategy, the steps are:
1. Calculate the total costs incurred (including the cost of the tests, medications and treatment of
complications and AEs).
2. Calculate the total QALYS over the model time horizon, in this case 40 years.
3. Multiply the total QALYs by the WTP threshold of £20,000 per QALY.
4. Deduct the costs calculated in (1) from the value in (3) to obtain the NMB.
Base-case results
In Table 71, results are shown for various alternative diagnostic strategies, all assuming base-case
model parameters.
Columns 2 and 3 show the performance of each screening strategy. Columns 4 and 5 show the proportion
of patients who would undergo each test. Columns 6–10 are the economic outcomes. Column 8 is the
NMB measure of cost-effectiveness. The NMB figures for each strategy appear to be of roughly the same
magnitude, and, although this might suggest that they are all almost the same, this would be an incorrect
interpretation. The higher the incremental net benefit in column 9 of a given strategy compared with
the biopsy-only strategy, the more cost-effective that strategy is. It should be remembered that these
monetary differences are per patient. The budgetary impact of selected strategies is explored later. Column
10 shows the ranking of each diagnostic strategy in terms of cost-effectiveness (based on the NMB);
the lower the ranking the more cost-effective the strategy. The last two columns show two clinical
outcome measures.
It may be easier to understand how the results compare visually on a cost-effectiveness plane, as shown in
Figure 19. The most cost-effective strategy is indicated by bold font, that is, ‘2-week decision: ultrasound
and judgement’. The green dotted line is known as a cost-effectiveness threshold, and it represents a line
along which any point would have the same cost-effectiveness (any point has a cost-effectiveness ratio of
£20,000 per QALY relative to this strategy). Any points below the line have a more favourable ratio of
additional costs to additional benefits and would be a more cost-effective option (if there were any). Any
points above the line are not cost-effective. In the case of the strategy ‘2-week decision: combined biopsy
and ultrasound and judgement’ connected by a blue dashed line, the gradient is clearly much steeper than
the green dotted line, indicating that the marginally higher QALY gains are not achieved in a cost-effective
way. Numerically, the additional 0.0018 (7.6482 – 7.6464) QALYs cost an extra £485 (£1406 – £921),
giving an ICER of £271,864, which far exceeds the acceptable threshold of £20,000 per QALY. For all
other strategies, both the costs and QALYs are inferior (higher cost and fewer QALYs) compared with the
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optimal ‘Two-week decision: ultrasound and judgement’ strategy, which is thereby said to dominate these
strategies (including ‘Biopsy and judgement’).
In light of these results, we undertook some further refinement of the ultrasound and clinical judgement
strategy as shown in Table 72.
The results lead to the following findings:
1. The most cost-effective strategies are those that include an element of clinical judgement.
2. Ultrasound and clinical judgement is the most cost-effective strategy, with the highest incremental
NMB. This is largely because of the difference in the cost of the tests (Table 73).
3. For the strategy in (2) above, the estimated cost saving is £475 patient and there is a very small QALY
gain of 0.0005 compared with biopsy and judgement. Rather than calculating an ICER, ultrasound is
said to dominate biopsy in this case as ultrasound results in both cost savings and QALY gains.
4. Ultrasound alone is more cost-effective than biopsy alone.
5. The three sequential diagnostic strategies that incorporate pre-test probabilities (those ranked 4, 5
and 6) offer a level of cost-effectiveness between those involving clinical judgement and those
(ranked 7 to 13) that include neither clinical judgement nor pre-test probabilities.
A further finding from the additional analyses in Table 72 is that the ultrasound and judgement strategy
may be improved slightly by undertaking a biopsy in cases in which the pre-test risk is high and the
ultrasound and judgement decision would be not to treat. It should be noted that only 2% of individuals
in TABUL were referred for biopsy under such a strategy, so there is some uncertainty around the benefit
of a biopsy in such circumstances. It would also require the timing of the decision to perform a biopsy to
be made after the outcome of the ultrasound plus judgement strategy is known. This is likely to mean that
the biopsy is delayed (so may be less accurate than in our model because of the change in histology since
patient presentation). Alternatively, an earlier biopsy would be possible if an ultrasound plus judgement
outcome was obtained before 2 weeks. However, this would mean that there is less information available
to the clinician on the patient’s symptoms and response to steroid treatment which, in turn, may lead to a
less accurate outcome as a result of a more rapid ultrasound and clinical judgement strategy.
Detailed analysis of results for ultrasound plus judgement versus biopsy
plus judgement
It is useful to break down the cost and QALY differences further, as shown in Table 73, to understand how
they arise. As previously stated, the cost difference is largely because of the difference in cost of the tests.
In terms of QALYs, compared with biopsy and judgement, ultrasound plus judgement leads to fewer false
negatives and so lower loss of health due to complications of GCA (difference = 0.0023). However,
approximately 75% of this QALY gain is offset by loss of health through prescribing steroids to a greater
number of false-positive cases (0.0017).
Sensitivity analyses
Table 74 shows the NMB (based on a £20,000/QALY acceptability threshold) under various alternative
model assumptions. The results relate to the biopsy plus clinical judgement strategy compared with the
ultrasound plus clinical judgement. The base-case difference was £485 in favour of ultrasound plus
clinical judgement.
The results from the sensitivity analyses indicate that the improved cost-effectiveness of ultrasound and
judgement (compared with biopsy and judgement) is not sensitive to alternative assumptions, with only
alternative cost or test sensitivity assumptions reducing the incremental NMB result below £400 (from
£485 base-case result). This is because the difference in the cost of the tests, in particular, is a very strong
driver of the cost-effectiveness. Even doubling the cost and quality-of-life burden from steroid-related AEs
did not change the outcome much.
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TABLE 73 Differences in costs and QALYs
Cost or QALY elementa Differenceb
Lower test cost of US –£456
Lower cost of treating complications of GCA in false negatives –£27
Higher cost of steroids and treating AEs in (mainly because of difference in false positives) £8
Total cost difference –£475
Lower QALY loss from GCA complications in false negatives 0.0023
Greater QALY loss from overtreatment of false positives –0.0017
Other difference –0.0001
Total QALY difference 0.0005
Monetary value of QALY difference at £20,000 per QALY £10
Incremental NMB (–475 to 10)c –£485
US, ultrasound.
a Lower or higher stated for ultrasound relative to biopsy.
b Ultrasound minus biopsy.
c The £485 reconciles to the difference between the incremental NMB figures of £1680 and £2173 in Table 71.
TABLE 74 Results from sensitivity analyses
Number Parameter Details
Biopsy and
clinical
judgement
(£)
US and
clinical
judgement
(£)
Difference
(US minus
biopsy) (£)
Base case (for reference) 151,523 152,008 485
Risks of GCA-related complications
1 Baseline risk of GCA-related
complications. Reduce the risks to
reflect introduction of a fast-track
pathway across the UK. The UK
Department of Health working
group is now evaluating ‘rollout’
of a fast-track pathway across
the UK112
Apply a hazard ratio of
0.41 for GCA-related
events vs. conventional
pathway (0.41 = 9%/22%
as per fast-track led by
Patil et al.80)
152,179 152,625 446
2 Ratio needed for the calculation of
rates of new permanent visual loss
post presentation: ratio of true
positives to false negatives over
past few decades (using biopsy and
clinical judgement). TABUL
suggests that a ratio of 90 : 10 may
be the most up-to-date estimate
(see Figure 17)
Historically this may have
been lower, around
80 : 20, allowing for more
recent improved
recognition of signs and
symptoms of GCA
151,545 152,001 456
3 Split of cases of visual loss that
arise before treatment into those
arising before presentation vs.
cases in false negatives
70 : 30 (i.e. 7 times more
before presentation;
assumed to be 80 : 20 in
base case)
151,487 151,980 493
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TABLE 74 Results from sensitivity analyses (continued )
Number Parameter Details
Biopsy and
clinical
judgement
(£)
US and
clinical
judgement
(£)
Difference
(US minus
biopsy) (£)
Test performance/costs
4 Higher test sensitivity for biopsy
and clinical judgement than
suggested by mean in TABUL
94% (the upper 95% CI)
vs. 91% base case
151,626 152,008 381
5 Higher test specificity for biopsy
and clinical judgement than
suggested by mean in TABUL
88% (the upper 95% CI)
vs. 81% base case
151,592 152,008 415
6 Cost of US: £57 in base case per
NHS Reference Costs95
£144 per TABUL
reimbursement costing
151,523 151,919 397
Risks of steroid-related AEs
7 Persistence of raised fracture risk
after cessation of steroids: duration
over which the risk gradually tapers
off from the level at steroid
cessation to zero. In base case,
assuming the risk tapers off to zero
after 1 year
Assume risk gradually tails
off from the level at
steroid cessation to zero:
3 years after cessation
(assumed to be 1 year in
base case)
150,595 151,067 472
8 False negatives: shorter time to
detection of GCA following
tapering off steroid treatment after
initial test
1 month instead of
> 2 months (base case)
151,626 152,087 461
9 Longer time to withdrawal of
steroids in false positives than in
the base case
Assume same steroid
schedule as for true
positives
151,471 151,944 473
Cost and utility/quality of life
10 Overall cost and quality-of-life
burden of AEs attributable to
steroids
100% higher than base
case
149,568 150,026 458
11 Unit cost of vision loss (defined by
visual acuity worse than 20/200)
Reduced by 20% (from
5090 to 4072 in year 1)
151,611 152,092 480
12 Utility (quality-of-life) multiplier for
visual loss (on scale 0 to 1, where
1= perfect health, 0= equivalent
to death)
Increased from 0.764 to
0.800
151,885 152,350 466
13 Alternative discount rate for QALYs 0% for QALYs 205,407 205,896 489
Willingness-to-pay threshold
14 Base case used £20,000/QALY £30,000 per QALY 228,011 228,463 452
No over-ruling of US result
15 As described in relation to Table 60,
there were five patients whose US
results were over-ridden by clinical
judgement
Sensitivity and specificity
become 94% and 73%,
respectively (compared
with 93% and 73% for
the base case)
151,523 151,995 472
A sensitivity analysis will examine
the effect of allowing no over-ruling
of the US result when calculating
the implied treatment decision for
ultrasound and judgement
US, ultrasound.
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Results based around an alternative reference standard
All of the results presented so far have been based on the reference diagnosis defined for the TABUL
study. In this section, we show the impact of alternative reference diagnoses that involve fewer true GCA
cases by removing some cases that rely solely on clinical judgement.
The results and their interpretation are best shown graphically (Figure 20). The x-axis shows four reference
standards: the one used in the TABUL study and then the three alternatives described earlier, with
increasing proportions of cases for which results might be considered more borderline. The y-axis
shows the incremental NMB of the four selected alternative diagnostic strategies compared with
biopsy alone.
The results show that, for all alternative reference standards tested, ultrasound plus clinical judgement
remains the most cost-effective strategy. It is only by adopting a reference standard with a significant
reduction in cases of GCA (16% fewer GCA cases than in the TABUL cohort) that a diagnostic strategy
based on pre-test risks and ultrasound might potentially become as cost-effective as ultrasound combined
with clinical judgement.
Budget impact
In the UK population, the annual incidence of GCA in those aged over 40 years is about 1 per 4500
people (or 22 per 100,000),113 giving an annual incidence of about 7000 cases.
The cost savings arising at the point of testing through use of ultrasound instead of biopsy (both alongside
clinical judgement) would be £456 (which represents the difference between £514 for a biopsy and £58
for ultrasound) per case or around £4,735,000 annually for the UK. Taking account of higher treatment
costs for biopsy (because of slightly lower sensitivity), the cost savings would be £475 per case or around
£4,933,615 annually for the UK.
If we use the strategy of ultrasound combined with clinical judgement but refer for biopsy cases that were
judged to be ‘not GCA’ if they had a high pre-test probability of GCA, the cost saving would be £477 per
case, or around £4,950,000 annually for the UK.
Discussion
Statement of principal findings
The results indicate that ultrasound alone is more cost-effective than biopsy alone, largely because of its
much lower cost and, to a lesser extent, its higher sensitivity.
In practice, patients are stratified for the risk of having GCA or not, based on demographic factors such
as age and sex, the clinical presentation and, in particular, the presence of more specific GCA-related
symptoms such as jaw claudication and/or visual loss combined with the evidence of an acute phase
response (elevated CRP level or ESR). Therefore, the biopsy test or ultrasound test are never used in
isolation and should be regarded as supplementary to the rest of the clinical evaluation in such patients;
this combination increases the sensitivity of the tests considerably. This is reflected in the main set
(base-case) results, which show that the most cost-effective strategies are based on a test in conjunction
with clinical judgement. Current clinical practice involves biopsy with clinical judgement. The results
indicate that ultrasound plus clinical judgement is more cost-effective than biopsy plus clinical judgement,
with a relative cost saving of £475 per patient and a larger QALY gain of 0.0005; thus, ultrasound is said
to dominate biopsy in this case (both in terms of cost savings and QALY gains). This is a very small
difference in QALYs, however, which is equivalent to < 1 day of full health on average across presenting
patients. Ultrasound plus judgement is also estimated to result in a marginally lower incidence of vision
loss (owing to its slightly higher sensitivity) than biopsy and judgement.
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One-way sensitivity analyses show that these findings are highly insensitive to changes in nearly all model
parameters. The only parameters having any sizeable effect, in terms of partly reducing the difference in
cost-effectiveness, are the cost of ultrasound and uncertainty around the sensitivity of ultrasound and biopsy.
In conjunction with clinical judgement, performing both a biopsy and an ultrasound test in all patients is
less cost-effective than ultrasound alone because the additional costs of testing are not justified by the
small reduction in treatment cost and increase in QALYs.
When we explored the impact of alternative diagnostic reference standards with up to 16% fewer GCA
cases, ultrasound plus clinical judgement remained the most cost-effective strategy.
Drivers of cost-effectiveness
By far the most dominant driver is the cost of TAB because it is estimated to be almost nine times the cost
of an ultrasound (£514 compared with £58). It is this that makes ultrasound plus clinical judgement more
cost-effective than biopsy plus clinical judgement. When comparing strategies involving clinical judgement
with equivalent strategies without clinical judgement (e.g. biopsy plus judgement compared with biopsy
alone), the different sensitivities to GCA are the main driver of the results.
Strengths and limitations
This is, to our knowledge, the first published economic evaluation of ultrasound compared with biopsy.
The evaluation not only includes costs incurred at the point of diagnostic testing, but also the costs and
QALY implications of different rates of false-positive and false-negative cases. We also carried out
additional analyses to allow for the fact that there is not a single universally accepted gold standard for
diagnosing GCA (see Chapter 8 for further discussion on the lack of a gold standard).
No evidence source was found for the cost of a biopsy of the temporal artery. It was therefore necessary
to use the cost of a procedure similar in terms of complexity and therefore resource use, a lymph node/
salivary gland biopsy. Ideally, a micro-costing study could have been undertaken to arrive at an estimate
specific to TAB. However, sensitivity analysis around the difference in cost between ultrasound and biopsy
showed that this only had a small impact on reducing the favourable cost-effectiveness of ultrasound.
The diagnostic outcomes for ultrasound plus clinical judgement were not a formal outcome of the TABUL
study so we had to use an algorithm (see Methods). Although this approach, and specifically the use of a
vignette exercise to obtain the outcome for 27 patients, introduces some uncertainty around the sensitivity
and specificity of ultrasound and clinical judgement, this is very unlikely to be large enough to have a
material effect on the economic findings. This can be seen in the sensitivity analysis that varied the
sensitivity and specificity of biopsy.
Owing to the complexity involved, our model was not sophisticated enough to include the impact of a
quicker turnaround of results with ultrasound and any benefits arising from being able to lower the steroid
dose sooner for cases with a negative diagnosis so there might be some further benefit to ultrasound-based
strategies not accounted for in the modelling.
Any general limitations of the TABUL study, as discussed in Chapter 8, that pertain to the observed
diagnostic yields (test sensitivity and specificity) apply to the economic analysis too. However, we carried
out uncertainty (sensitivity) analysis around these parameters and this did not affect the conclusions.
Implications
The results indicate that ultrasound plus clinical judgement is the most cost-effective strategy. Such use of
ultrasound rather than biopsy would result in significant reductions in costs as a result of the much lower
cost of the test (£514 vs. £58). Frequently, the upfront cost can be a barrier to uptake of cost-effective
technologies for which the economic benefits only materialise over the long term. This is not the case here,
however, with estimated savings to the UK of £4,735,000 annually based on annual incidence of 7000 cases.
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Unanswered questions and further research
We were unable to identify a study that would enable us to calculate dose-specific risks of fractures for
each fracture type. Studies generally reported hazard ratios by category of average steroid dose, for
example > 7.5 mg per day, rather than for specific and varying doses over time. This is a specific example
of the difficulty of synthesising the range of heterogeneous evidence available on risks of steroid therapy
in terms of study duration, starting dose, tapering schedule and set of AEs reported. Sensitivity analysis
indicates that our results are very insensitive to uncertainty around the burden of steroid-related AEs.
However, in a different context to this evaluation, for example, with a less dominant difference between
the costs of the tests, the difficulties in synthesising such evidence could be a far greater limitation.
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Chapter 8 Discussion and conclusions
We have undertaken a large multicentre evaluation of two diagnostic tests in patients with newlysuspected GCA. We performed both tests (ultrasound of temporal and axillary arteries and biopsy
of the temporal artery) in all cases. We kept the results of the scan blinded from the clinicians until after
the primary end point had been achieved (the clinicians’ diagnosis was recorded 2 weeks after initial
assessment). In order to conduct the study we needed to establish a new training programme for
ultrasound of temporal and axillary arteries and to measure the quality of all scans being performed.
We will discuss our main study findings, based on the original hypothesis examining the sensitivity and
specificity of both tests as well as an economic analysis of the tests alone or in different combinations.
We will describe and summarise the patient cohort and discuss the potential advantages and disadvantages
of the reference standard diagnosis used to compare the outcome of the two tests. We summarise the
ultrasound training programme and the scan results during the course of the study. We comment on the
biopsy findings in the cohort, and on the clinical diagnoses. We have subjected the clinical data to scrutiny
by an expert panel and have provided interobserver comparisons of the ultrasound and biopsy data.
We assess the changes in diagnosis or test result following expert review. We discuss the value of combined
strategies and the added role of clinical judgement or clinical risk stratification on either or both tests.
We look at the generalisability and implications of this study in routine practice.
Main findings
We conducted a prospective multicentre study to compare the relative value of ultrasound assessment of
both temporal and both axillary arteries with TAB in 381 patients with newly suspected GCA. In order to
ensure proficiency in performing ultrasound scans, we created an extensive training programme, which
was then compared with the established standard procedure of TAB, usually from the most symptomatic
side, in this patient population. No training was provided for performance of the biopsy within the study.
All patients in the study underwent both tests in sequence (ultrasound first followed by biopsy) and
our analysis included those who underwent both tests within 10 days of commencing high doses of
glucocorticoids. Usual care was given to the patients by their clinicians. The ultrasound result was not
revealed to the clinician caring for the patient, unless they specifically requested the result (because they
were planning rapidly to reduce and withdraw glucocorticoid therapy) after they made their clinical
diagnosis at 2 weeks’ follow-up, which was the main primary outcome in the study. A final follow-up
assessment was conducted at 6 months in case the diagnosis had changed.
The main objectives of the study were to compare the diagnostic performance (sensitivity and specificity) of
ultrasound as an alternative to biopsy for diagnosing GCA in patients who are referred with suspected
GCA and in whom a biopsy was going to be carried out and to perform a cost-effectiveness analysis to
compare different potential investigation strategies for diagnosing GCA, incorporating either or both
ultrasound and biopsy. The original hypothesis was that ultrasound would be a more sensitive test than
biopsy and would have a specificity of at least 83%.
Early studies suggested that biopsy had 95% sensitivity and 100% specificity for GCA;114 later studies
reported somewhat lower results of around 68–69% sensitivity but very high specificity.11,115 Patients who
had a positive biopsy but who did not have GCA were reported to have other forms of vasculitis.59
We wanted to compare the performance of ultrasound, which we predicted would provide 87% sensitivity
and 83% specificity or higher. Among 381 patients who had ultrasound and TAB for suspected GCA,
101 (27%) had a TAB consistent with GCA and 162 (43%) had an ultrasound result compatible with
GCA. The sensitivity of biopsy for diagnosis GCA was 39%, much lower than previously published; the
specificity was 100%. By contrast, the sensitivity of ultrasound was 54% with a specificity of 81%.
Therefore, we failed to find evidence to support our primary hypothesis because, although ultrasound was
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more sensitive than biopsy, it did not achieve specificity greater than 83%. Nevertheless, we demonstrated
that the current sensitivity of biopsy is much lower than previously published and that, in comparison, the
sensitivity of ultrasound is superior (14% higher). The specificity of ultrasound was 81%, which is lower
than expected from our original hypothesis. We cannot conclude that ultrasound can replace biopsy, based
on these findings. However, the data support a significant challenge to the role of biopsy as a ‘gold
standard’ test for diagnosing GCA. A combination strategy using both tests in sequence, with all patients
undergoing an ultrasound scan, but only scan-negative cases undergoing a biopsy, has 65% sensitivity and
81% specificity for the reference standard diagnosis of GCA. The addition of risk stratification based on
initial clinical features and measures of ESR or CRP levels can further increases the sensitivity to 77.1% and
specificity to 91.2%.
The cost-effectiveness analysis indicates that ultrasound alone is more cost-effective than biopsy alone
largely because of its much lower cost (£58 vs. £514) and higher sensitivity (54% vs. 39%). The use of
ultrasound combined with clinical judgement is not only more cost-effective than biopsy plus clinical
judgement but is estimated to result in both cost savings (largely owing to the lower cost of ultrasound)
and a very small QALY gain.
Patient details
A total of 730 patients were screened for the study: 430 participants were recruited from 20 sites in five
countries (England, Ireland, Norway, Germany and Portugal); and 300 patients either did not meet the
inclusion criteria or declined to participate. From the 430 patients included, there were 39 withdrawals
prior to the primary analysis being performed (at the 2-week assessment) and a further 49 withdrawals
after the primary analysis was performed. Of the remaining 391 patients, 10 were excluded from the
primary analysis; hence, the primary analysis was performed on 381 patients in total. The average age of
the cohort was 71.1 years and 72% of patients were female. The majority of patients (80%) were of white
British ethnicity, and the remainder were from either a white Irish or other white background or a
non-white background (3%). The majority of patients (88%) had significant new headache at presentation:
fatigue was reported in 65%, generalised scalp tenderness in 59% and 51% had pain over one or both
temporal arteries. PMR was present in 7%. Visual symptoms were frequently present at baseline (reduced or
lost vision reported in 133, amaurosis fugax in 14 and double vision in 31 patients). By 2 weeks, three,
five and zero patients experienced new loss of vision, amaurosis fugax and double vision, respectively;
by 6 months, new reports of these visual features occurred in seven, two and six patients, respectively.
Anterior ischaemic optic neuropathy was reported in 27 patients (7%) at baseline; posterior ischaemic optic
neuropathy was reported in seven patients (2%); by 2 weeks these findings were present in 4% and 0.5%
of patients, and by 6 months in 4% and 1% of patients, respectively. The results of inflammatory markers
(ESR and CRP level) were not always available (10% of patients had no baseline ESR result and 8% had no
baseline CRP level result). The median ESR at baseline was 43 (IQR 60–70) and the median CRP level was
46 (IQR 90–91). Many patients had hypertension at baseline (52%); 7% had angina and 14% had a
previous history of cancer. There was a small increase in the occurrence of diabetes mellitus during the
course of the study from 14% at baseline to 18% at 6 months. The main physical findings were of
tenderness (50%) or thickening (27%) of one or both of the temporal arteries, which were less likely
to be detected if the patients had received even a few days of steroid treatment.
Use of the reference diagnosis
There was no absolute gold standard that we could apply in this study to decide whether or not the patient
definitely had GCA. Use of the ACR classification criteria for GCA34 included using the result of the biopsy;
this would bias the interpretation of the clinician’s opinion in favour of stronger agreement with the biopsy
test when it was positive, and perhaps bias it against that diagnosis if it was negative. We attempted to
address this by including additional aspects of the patient’s condition that would be compatible with the
DISCUSSION AND CONCLUSIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
120
clinical diagnosis of GCA, such as the presence or development of visual loss attributed to GCA, the
presence of stroke or PMR. Other features such as jaw or tongue claudication or significant elevation of the
ESR or CRP level (above 60 and above 40, respectively) would have contributed to the clinician’s assessment
and the likelihood of diagnosing GCA. However, the interpretation of all the clinical features, laboratory
findings and results from the specific investigations would have to be considered individually on a case-by-case
basis. This would mean that the clinician could over-ride/ignore any individual results in favour of or against
the diagnosis of GCA. This is a clear limitation of the current study. However, including the ability to adjust
the reference standard diagnosis in light of the development of changes to the clinical state in the 6 months
following initial assessment (e.g. the development of features consistent with the diagnosis of GCA or,
equally, the development of features consistent with another diagnosis) strengthens the argument for using
this reference standard diagnosis as the gold standard, albeit a less than perfect one.
The use of presenting features to predict the likelihood of a diagnosis was suggested by Gabriel et al.116 In
a review of > 500 patients, the likelihood of a negative TAB was increased substantially in the absence of
claudication and the absence of significant elevation of the ESR. In the current study we used the reference
diagnosis rather than the biopsy as the standard for the model, but with similar findings. A limitation of
this study is the lack of a robust unequivocal standard for diagnosis against which each test could be
compared. In the absence of this, diagnostic criteria are being developed in the DCVAS study which might
provide a better surrogate gold standard than currently exists. The clinical evaluation of the patient at
baseline and after 2 weeks has the strongest influence on the diagnosis at 6 months. Part of the difficulty
is the concern of clinicians that if any of the clinical features, combined with measurement of the acute
phase response, are suggestive of GCA, despite negative further testing (biopsy or imaging), there is a
clearly demonstrated unwillingness to dismiss the diagnosis. Rather, the tests (biopsy or imaging) are being
used to provide further enhancement of the clinical opinion.
Ultrasound training
Ultrasound has not yet superseded TAB as a diagnostic test. This may reflect the poor consistency of the
scanning technique as a result of the lack of a standardised scanning protocol. We developed a
standardised protocol that was implemented in 439 healthy controls and subsequently in patients with
suspected GCA. We assessed each patient for evidence of typical ultrasound features of GCA: the
presence of a halo surrounding the vessel wall, stenosis or occlusion of the vessel. A detailed scanning
protocol was developed for all patients and controls. We reported the presence or absence of ultrasound
features of GCA in each segment of each temporal artery (common, parietal, frontal proximal and frontal
distal) and both axillary arteries. Sonographers were asked to acquire video and static images for each
patient to ensure accuracy of findings. The sonographer measured and documented halo diameter (based
on a normal range of up to 0.5 mm for the temporal artery and up to 1.0 mm in the axillary artery) and
length; pulse Doppler measurements prior to and within a stenosis (confirmed if the highest maximum
systolic velocity was over twice the lowest maximum systolic velocity); and arterial occlusion. Each study site
sonographer was required to be proficient in the protocol by scanning at least 10 healthy controls, passing
an online test showing normal and abnormal scans (pass mark > 75%) and scanning a patient with
ultrasound evidence of active GCA. The scanning protocol was started by 33 sites, with only 22 sites
completing the training in 6.7 months (range 0.2–16.4 months). A total of 439 controls were scanned
across 31 sites (one sonographer covered three sites). The online test was passed by 39 sonographers
(multiple sonographers at some sites) with an average of two attempts (range 1–4); 22 sonographers
successfully scanned an active GCA patient, as validated by the expert panel. The longest delay in
completing the training was a result of difficulty in recruiting a patient with active GCA, which was
necessary prior to commencement of the main study. Common issues encountered were a lack of time
away from clinical duties and locating a new suspected GCA case for the hot case assessment. We have
created a bank of 857 sets of consistently recorded images of temporal and axillary arteries from patients
with suspected GCA and from healthy controls. Expert review of the scans confirmed that the overall
rate of disagreement was 16%. Quality and accuracy are imperative for the clinical use of ultrasound data
DOI: 10.3310/hta20900 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 90
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Luqmani et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
121
in diagnosis. We have developed an effective protocol, including training, which ensures consistency and
proficiency in scanning. The methodology can be adapted and extended to allow for additional artery
assessment, including carotid, vertebral and subclavian, extending the value of a structured approach.
We recommend the current study scanning protocol as the standard approach for diagnosis of GCA
using ultrasound.
How could we improve on the ultrasound training programme
in practice?
We developed a novel training programme as part of the current study. The programme was based on
published evidence of performing ultrasound examination of GCA; most of the publications were from
experts within the study investigator group. The basic elements of the training programme consisted
of (1) a tutorial/lecture [which could be provided as a recording or annotated Microsoft PowerPoint®
(version 97–2003; Microsoft Corporation, Redmond, WA, USA) presentation], (2) hands-on training for
novice sonographers (which would not be required by more experienced sonographers), (3) evidence
of recorded images to show proficiency in performing scans on healthy individuals to demonstrate
non-diseased temporal and axillary arteries (primarily done remotely) and (4) evidence provided by
sonographers of recorded images to show their proficiency at performing scans in at least one individual
with active GCA, to demonstrate diseased temporal or axillary arteries (primarily done remotely). We
implemented the training requirements for the purpose of this study, which was deliberately based in
non-academic as well as academic centres, in order to test the practicality of establishing this new technique
of ultrasound in large numbers of local hospitals, where resources might be limited. We discovered
significant variation in the uptake of the training, primarily driven by local factors such as the availability of
sonographers and ultrasound machines; as a result, only half of the centres that originally attempted the
training programme actually preceded with the study. Given the nature of the condition (i.e. presentation
with acute-onset symptoms and the need to undertake scanning within a short time of starting steroid
therapy), there are minimum basic requirements in any individual centre to ensure that the technique is
performed to the correct standard and can be undertaken in a timely fashion. Furthermore, a minimum
number of cases scanned per annum would be advisable to ensure ongoing quality control; we found that
scanning reliability was higher for sonographers who had scanned at least five cases during the study
compared with those who had scanned fewer than this number. In practice, therefore, we may need to
explore other ways in which to deliver the training material and to develop a programme to maintain
proficiency in training. We speculate that some of the training elements could be provided as courses,
whereas other elements are bespoke to individual centres and would require clear demonstration of the
sonographers’ abilities to scan and to be able to clearly distinguish cases from non-cases. The nature of the
training programme itself could be adapted depending on the expertise of the sonographer, for example,
shortening it for more expert centres, while still maintaining minimum standards. Targeted training would
need to be more intense for novice sonographers (similar to the full training programme in this study),
and less intense for more expert centres (requiring the sonographers to provide evidence that they are
competent at performing the scans, by providing evidence that they have been regularly scanning cases,
as well as being able to submit the scans of an active case as proof that they can adequately recognise an
abnormal case. For centres with some experience, but that have not been performing scans regularly,
we could ask their sonographers to undertake the online quiz, to make sure that they can recognise
normal and abnormal scans, as well as to provide scans from an active case that they have recently seen.
Implementation of training programmes would be facilitated by their certification through Royal Colleges or
national bodies, such as the BSR. This would encourage accredited training and it would be feasible to apply
for this training activity to be recognised as continuing professional development.
Ultrasound findings
Ultrasound abnormalities consistent with GCA were found in 162 patients, predominantly in the temporal
arteries, but in 31% of patients, the axillary arteries were also involved and in a small number of patients
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(2.4%) they were exclusively involved. The predominant abnormalities on ultrasound that were considered
to be consistent with GCA were the presence of a halo in 162 patients, stenosis in 45 patients and
occlusion in 41 patients. The median halo size was 0.6 mm (range 0.4–0.9 mm) as measured in temporal
arteries. In patients with abnormal ultrasound scans, the median number of segments of artery involved
was 2.5 (range 1–6).
We measured differences in the size of the halo around the arteries depending on the duration of steroid
therapy prior to scanning; we correlated halo size with ischaemic symptoms of GCA. We analysed data
from 301 out of 415 patients with clinically defined definite or probable GCA at baseline using linear and
logistic regression models to determine the relationship between halo size and days of steroid treatment
and also with ischaemic symptoms of GCA (jaw and tongue claudication, amaurosis fugax and reduced,
lost or double vision). Fifty per cent of patients were scanned on or before receiving 2 days of high-dose
steroid treatment. Forty-three per cent (131) of patients had a halo in one or more temporal segments,
49% (146) of patients had bilateral temporal artery halos and 13% (38) of patients had axillary
involvement. The linear regression model showed a consistently smaller halo size in temporal arteries
during the 7 days of steroid treatment (p < 0.005). The likelihood of finding a halo diminished with time,
until day 4 of steroid treatment (p < 0.005). Jaw claudication occurred more frequently in patients with
a halo (p < 0.05). Temporal artery symptoms correlated with ipsilateral ultrasound findings (p < 0.05).
The findings suggest that, in newly diagnosed GCA, ultrasound halo size decreases rapidly with steroid
treatment and correlates with the presence of ischaemic symptoms, supporting its early use as a diagnostic
and potentially prognostic marker.
Biopsy findings
Only 353 out of 381 biopsies performed actually contained a sample of temporal artery; the remainder
either consisted of another tissue (such as vein or nerve) or no sample was obtained at all. The median
length of artery biopsied was 10 mm (range 7–15 mm). In 161 patients the TABs were defined as abnormal
and in 101 patients (27% overall) this was compatible with the diagnosis of GCA. In four patients the
biopsy was compatible with another form of vasculitis. In a further 35 patients, arteriosclerosis was the
dominant finding; 27 patients had a variety of other diagnoses (not GCA or vasculitis). Fragmentation in
the internal elastic lamina was reported in 156 biopsies, and reduplication in 82 patients. Thirty-nine per cent
of patients had intimal hyperplasia and 10% had arteriosclerosis in the intima. Of the 101 biopsies
consistent with GCA (27% overall and 39% of the patients diagnosed with GCA), giant cells were present in
72 biopsies (representing 19% of the overall cohort, but 71% of biopsies of patients with GCA). In 99%
of biopsy-positive cases, inflammatory infiltrates were present, which were transmural in 42% and
adventitial in 18% as the predominant sites of inflammation. Furthermore, seven patients had evidence
of recanalisation in at least one section of the biopsy.
Histological features in biopsy-positive patients with GCA were not confined to one form of inflammation.
The most common finding was transmural inflammation. The relatively low number of positive biopsies
may reflect the low index of suspicion of GCA in the cohort, technical difficulties in obtaining an adequate
sample, skip lesions or the effects of glucocorticoid therapy in changing the biopsy result. These findings
highlight the need for a better diagnostic strategy for patients with suspected temporal arteritis.
Change in diagnosis after expert review
Following expert review of the clinical cases, 21 patients had a change in diagnosis: in 13 of these, the
diagnosis changed from GCA to not GCA; and in eight patients the diagnosis changed from not GCA to
GCA. The diagnoses were predominantly made on the basis of symptoms and signs, blood abnormalities
and, to a lesser extent, the biopsy report. The most common diagnosis in patients who did not have GCA
was non-specific headache, myofascial pain, migraine, temporomandibular dysfunction and sinusitis.
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Five patients in total were diagnosed with another form of vasculitis including Takayasu’s arteritis, EGPA,
GPA and other undefined forms of vasculitis.
The confidence in the clinical diagnosis of GCA at the baseline was > 75% in favour of probable or
definite GCA; 86% of the patients, regardless of the confidence in diagnosis, were being treated with high
doses of steroids at baseline. Most patients did not have any change in their clinical diagnosis by the
observing clinicians from the 2-week assessment to the 6-month assessment. However, 19 patients had
their diagnosis changed from not GCA to GCA at the 2-week assessment after unblinding of the
ultrasound result. In 25 patients the diagnosis was changed at 6 months (6% of all patients); in 17 of
these patients the diagnosis was changed from GCA to not GCA and in three patients a diagnosis of GCA
was made. In the remaining five patients the diagnosis changed (but not from or to GCA).
Ultrasound compared with biopsy results
There was a significant association between the biopsy and ultrasound results (κ = 0.35), but more scans
were positive than biopsies, so that ultrasound was more likely to be used to diagnose GCA than biopsy
(162 positive ultrasound cases compared with 101 biopsy cases). Eighty-eight patients who had ultrasound
evidence consistent with GCA had a negative biopsy and 27 patients with biopsy evidence of GCA had a
negative ultrasound. There was a small number of patients (23) to whom steroids were given for longer
than 7 days prior to the biopsy being performed. If we excluded those patients from the analysis, the
agreement between ultrasound and biopsy increases slightly with a kappa of 0.37. The finding of a halo
appeared to be the most useful aspect of the ultrasound result to support a diagnosis of GCA. Combining
halo assessment with other aspects of ultrasound, namely stenosis or occlusion, did not increase the overall
interpretation of the ultrasound scan as being positive or negative. Ninety-three patients had bilateral halo
and a clinical diagnosis of GCA. Axillary involvement on ultrasound was present in 53 patients, nine of
whom did not have temporal artery involvement; three were biopsy positive and, in total, seven were given
a reference of diagnosis of GCA, suggesting that ultrasound of the axillary arteries can provide further
support for the diagnosis of GCA in the absence of either temporal artery ultrasound or biopsy evidence to
suggest GCA.
The effect of training and expert review of scan results
on diagnosis
Expert review of the ultrasound images was part of the protocol and was undertaken for ongoing quality
control purposes during the study. In 16% of scans the expert reviewers’ interpretation of the scans
differed from the sonographer’s interpretation; 14 patients were interpreted as GCA by the reviewers but
not GCA by the sonographer, and a further 47 were interpreted as not GCA by the reviewers but as GCA
by the sonographer. The overall impact of using the reviewers’ interpretation in place of the sonographer’s
interpretation was to increase the specificity of ultrasound from 81% to 87% but to reduce sensitivity
from 54% to 44%. One potential explanation for the lower sensitivity using the reviewers’ interpretations
is that the recorded ultrasound images and videos that the reviewers saw did not capture the
abnormalities seen by the sonographer during a patient’s scan. A second potential explanation is that a
sonographer’s interpretation may have been influenced by seeing the patient, for example, by observing a
tender or thickened artery during the scan, something the reviewers would not be aware of. For the
majority of discordant interpretations (those interpreted as not GCA by the reviewers) it is unclear if the
difference indicates problems with the sonographer’s interpretation or, as the reduction in sensitivity might
suggest, merely difficulties in capturing abnormalities in scan recordings. The discordant interpretations
that the reviewers interpreted as GCA were fewer in number, but may indicate issues with a sonographer’s
interpretation of the scans. For two sonographers in the study, retraining was required before they
resumed scanning patients.
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In 19 patients, the 2-week diagnosis based on the clinical findings and biopsy was not of GCA, but the
unblinding of the ultrasound result suggested that there were findings compatible with GCA. Unblinding
improved the sensitivity but reduced the specificity of the 2-week assessment compared with the
reference diagnosis (sensitivity of 0.96 and specificity of 0.77). We observed a training effect among the
sonographers. There was no significant change in the specificity of ultrasound for GCA by sonographers
when comparing their early (first 10) scans with their subsequent scans, but the sensitivity improved from
45% to 62%, strongly suggesting an improvement in the ability to detect the presence of halo. Such an
effect suggests that it is possible to achieve improved accuracy with ultrasound as sonographers gain
experience in scanning. It also raises the question of whether or not more extensive training and/or
supervision should be provided in addition to the training protocol developed for this study.
The effect of delay in testing and the effect of steroids
The accuracy of biopsy was likely to be greatest if performed within 3 days of starting steroids (sensitivity
of 48% at this stage, compared with 33% for biopsies performed from ≥ 7 days after the commencement
of steroid treatment). For ultrasound, the accuracy was highest for patients seen on no more than one
dose of steroids, but was still maintained up to 7 days. The effect of delay between the scan and the
biopsy being performed did not appear to influence the probable agreement between the tests.
Combination strategies and pre-test probability of having giant
cell arteritis
We derived a risk of having GCA based on data obtained from an independent cohort of patients (based
on the DCVAS study). We divided patients with GCA in the DCVAS cohort into three risk groups: those
with an ESR > 60 mm/hour or a CRP level > 40 mg/l combined with the presence of jaw or tongue
claudication were in the highest-risk group for having GCA; the lowest-risk patients had none of these
features; medium-risk patients had only either an elevated ESR or CRP level or symptoms of jaw or tongue
claudication. There was a significant relationship between the assignment of patients to one of these risk
groups and the certainty of diagnosis of GCA reported at baseline in the TABUL study cohort, the
reference diagnosis given and the biopsy findings. Although there was a trend for the ultrasound result,
it was not as consistent. In other words, the patients in the lowest-risk group still had a 31% likelihood
of a positive ultrasound compared with only 7% having a positive biopsy. Within the highest-risk group,
the sensitivity of biopsy was 63% and for ultrasound it was 57%, with specificities of 100% and 80%,
respectively. However, in the medium-risk group, biopsy had only 33% sensitivity, with a specificity of
100%, whereas ultrasound had 57% sensitivity and 91% specificity. Furthermore, in the low-risk group,
biopsy had the least sensitivity of 17%, with a specificity of 100%, whereas ultrasound had a sensitivity
of 44% and a specificity of 77%. One potential option is not to do either test (biopsy or ultrasound) if
patients are in the high-risk group, because there is 93% prevalence of likelihood of diagnosis GCA
according to the reference diagnosis in these patients. Looking at the potential combination of strategies,
the risk group (high, medium or low) would affect the sensitivity and specificity of diagnosing GCA by
performing either ultrasound and/or TAB (depending on the results of the ultrasound). In every instance,
combination strategies produced better receiver operating characteristic curves than biopsy alone,
supporting the role of ultrasound in supplementing or, in some patients, replacing biopsy as the diagnostic
test for GCA.
Assessment using vasculitis activity and damage scores and
quality of life
We used standardised generic scores of vasculitis activity and damage (the BVAS and the VDI score) in this
cohort of patients, primarily to screen for the possibility that some patients had a more widespread form of
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a different type of systemic vasculitis (and this was actually true in five patients). As an exploratory
outcome, we found that in 257 patients with GCA, disease activity scores were not significantly different
from patients who did not have GCA. This shows that the disease activity score is not discriminatory
between GCA and non-GCA (it was never designed for this purpose). However, the BVAS was more likely
to be lower at 6 months than at 2 weeks. We have to bear in mind that it is likely that the scores were
under-reporting disease activity at 2 weeks, because a significant number reported no abnormalities in the
GCA group. There did not appear to be any discriminatory effect of measuring the VDI score at 2 weeks or
at 6 months between patients and controls (the VDI was not designed to discriminate), but there was an
increase in the number of patients and controls with at least one item of damage reported after 6 months
compared with the 2-week assessment. Quality of life, as measured by the EQ-5D, did not differ
significantly between patients and controls and neither did it change significantly after 6 months.
Adverse events
In total, 1229 AEs were reported during the study; every patient suffered at least one event, the majority
of which were related to steroid therapy. When looking at events related to the study tests, 63 patients
had an AE definitely related to biopsy, 10 had events possibly related to biopsy and two had events
definitely related to the scan. There were 104 serious AEs among 55 participants, but none of them was
related to the study test. The serious events included 16 deaths and 74 hospitalisations; all of these
characteristics would be expected in a population of patients with suspected GCA and in whom high
doses of steroids have been used.42
Inter-rater agreement
We undertook inter-rater testing to evaluate agreement between pathologists and between sonographers
in their assessment of images biopsy and ultrasound images. We selected the ultrasound scan recordings
and histology slides from 33 patients in the study (a mixed group chosen at random, some of whom had a
reference diagnosis of GCA and some of whom did not). We performed an inter-rater exercise separately
for 14 pathologists and 12 sonographers. Agreement among 14 pathologists based on ICC was 0.62;
among the sonographers it was 0.61. This would suggest that the level of certainty for interpretation of
either test is variable, and it is perhaps more variable for pathologists than previously appreciated. The
agreements between observers for both tests were similar.
Strengths and weaknesses of the study
We recruited a large cohort of patients mostly from primary care practices in the UK to a large number of
centres, including academic and non-academic centres, to establish the generalisability of our findings. We
developed an ultrasound training module as part of the study to ensure proficiency of testing. We did not
offer any training in biopsy techniques or in biopsy processing and interpretation, as these are standard
and, as such, should not be required by participating sites. We were able to compare the effects of
ultrasound and biopsy independently on the diagnosis; however, the classification criteria for GCA include
the results of biopsy, introducing an inherent bias in the diagnosis of GCA which would be likely to be
given more or less weight depending on whether or not the biopsy was positive or negative. Despite this
bias we were still able to demonstrate that ultrasound was an effective strategy for diagnosis in a
significant proportion of patients. Nevertheless, neither of the tests is perfect, and we do not have a true
gold standard to compare the effectiveness of each test. Unblinding of the ultrasound result at 2 weeks
could have biased the results, but, in fact, a sensitivity analysis suggested that it had only a marginal effect
on the outcome of the study.
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Evolution in the presentation and suspicion of giant cell arteritis
Greater awareness of GCA may prompt primary care physicians to initiate treatment at a very early stage,
which might affect the likelihood of obtaining a positive test result. Studies of pathological specimens
obtained in other forms of vasculitis suggests that, whereas previously a biopsy showed clear evidence of
abnormality, if awareness of the disease and clinical suspicion of the diagnosis lead to earlier investigation
and treatment, we might actually be changing the natural history of the disease such that we do not see
the characteristic features of the disease as previously described on biopsy. For example, nasal tissue
biopsies have been reported to provide diagnostic appearances in 24–53% in patients with GPA.117,118 It is
possible that the level of suspicion for the diagnosis of GCA may have changed in line with the suspicion
of the diagnosis of the other form of vasculitis.119
Generalisability of current findings
One of the potential criticisms of the project is that we were introducing a specialist form of ultrasound
imaging to NHS hospitals and comparing this with established practice. The specialist techniques of
ultrasound imaging of temporal and axillary arteries might be perceived as being feasible to implement
only in specialised centres where more time and resources might be available to perform these scans and
that it might require more specialised equipment. However, we deliberately chose to recruit participants
from non-academic centres, as well as academic centres, in order to test whether or not our technique
was generalisable and could be applied, with suitable training in ultrasound performance and
interpretation.
Although there is a difference between sonographers in terms of experience, as demonstrated by our
evaluation of performance for centres recruiting fewer than 10 patients or more than 10 patients,
this in itself is not an issue of whether the centre is an expert academic centre or a non-academic centre.
This is to do with the volume of patients evaluated. Given the relative frequency of GCA in the general
population and the likelihood that patients who have suspected GCA are referred to hospital for
assessment, there is an opportunity for all centres to increase the number of patients evaluated to improve
the sensitivity and specificity of ultrasound as a diagnostic test for GCA.
What are the implications of the study findings?
Our data suggest that TAB is less effective as a diagnostic test for GCA than was previously appreciated.
Although it retains a high specificity, the sensitivity is only 39%. This could be because patients who are
being evaluated with this test have low pre-test probability of the diagnosis. However, patients were
selected for inclusion in the study on the basis that they have at least a possibility of GCA; in 53.5% of
patients there was probable diagnosis of GCA and 21% of patients were reported as having a definite
diagnosis of GCA at presentation as reported by the clinician. In comparison to other cohorts of patients
undergoing TAB, the biopsy yield was actually higher than the 15.1% reported previously.48 Difficulty in
interpreting the biopsy result is undoubtedly made worse by not obtaining any arterial tissue at all, which
occurred in 28 patients in the cohort. In a previous cohort of 567 consecutive biopsies, 2.5% had no
arterial tissue,49 suggesting limitations to the technique. The biopsy length obtained was an average of
1 cm in the current study, which is the minimum recommended by the BSR guidelines.5 However, other
studies have suggested that 0.7 cm is an adequate length;52 in fact, even smaller biopsies might be
adequate, with no evidence of a difference in positive biopsies for samples < 0.65 cm compared with
those longer than 0.7 cm.53 The biopsy length referred to in the current study is the measurement taken by
the pathologists once a specimen arrives in the laboratory. It is known that shrinkage occurs once the
specimen has been excised; we did not measure the length of the specimen obtained by surgeons at the
time of sampling.
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Pathologists are usually expected to provide an opinion on the diagnosis based on the interpretation of the
biopsies. Our data suggest that the variation in agreement between observers can be considerable,
especially for less clear-cut cases. If the specimen did not contain characteristic features of GCA, the
interpretation of changes consistent with GCA, such as reduplication of the internal elastic lamina or
intimal thickening or proliferation, could be that of early features of GCA, or of healing GCA, but, equally,
these findings can occur in patients who have arteriosclerosis or age-related changes in their temporal
arteries specimen and do not have any features of GCA at all.47 We should give consideration to
encouraging pathologists to report on the uncertainty of interpreting the findings rather than forcing them
to make a clear-cut distinction between GCA and not GCA on the basis of the histology alone if there is
insufficient information to make such a distinction with confidence.
We did not provide any training specifically to either the surgeons undertaking the biopsy or to the
pathologists preparing and interpreting the sample results. We did not provide any reference standards to
compare abnormal results or require any evidence of proficiency by the pathologists in the interpreting
biopsies. The effect of training or use of reference standards may have improved our biopsy results.
We have developed an ultrasound training protocol that was effective in allowing 20 different sites with
variable experience of use of vascular ultrasound (in some cases none at all) to undertake and interpret
images of the temporal and axillary arteries to a standard acceptable by an expert panel in over 90% of
patients undergoing a scan. Using this methodology, we have demonstrated that we can improve on
sensitivity of biopsy by using ultrasound. However, there is a lower specificity and neither technique alone
provides a high rate of confidence in the diagnosis of GCA, without the interpretation of the clinical
features. We have shown that ultrasound is cost-effective compared with biopsy.
However, in a significant number of patients, both tests will be negative and yet the clinician will still
diagnose GCA because the patient has clinical features that strongly suggest the diagnosis (such as jaw or
tongue claudication or the development of ischaemic events compatible with the clinical syndrome of
GCA). Until we have a more robust measure as a diagnostic test of GCA, these two tests (biopsy and
ultrasound) could be used in combination to improve early diagnosis and treatment of GCA. It is feasible
that other imaging techniques could have a higher yield than ultrasound (e.g. MRI). In 64 patients who
underwent MRI (and a proportion who also underwent TAB), the sensitivity and specificity of MRI was
reported as 80.6% and 97.0%, respectively, compared with histology, which had 77.8% sensitivity and
100% specificity.120 A comparison study between ultrasound and magnetic resonance showed almost
identical positive and negative predictive values.121 Unfortunately, magnetic resonance changes resolve
within a few days of starting glucocorticoid therapy and access to magnetic resonance is likely to be a
limiting factor, whereas access to ultrasound is much more rapid.13 The effects of steroids on image
appearances for both magnetic resonance and ultrasound have been compared in 59 patients undergoing
both tests, as well as in a proportion undergoing TAB. Whereas the sensitivity of ultrasound and magnetic
resonance were 92% and 90%, respectively, up to 1 day following steroid therapy, this is reduced to 50%
and 80% with > 4 days of steroid therapy.122
It is conceivable that clinicians may feel some discomfort over having to rely on a clinical diagnosis of GCA
supported by an imaging test such as ultrasound, but not confirmed by histological examination of the
artery on biopsy. The concern would be that they are potentially overtreating a patient, who does not have
a true diagnosis of GCA. However, the current study demonstrates that videos and images can be stored
and reviewed later. Expert reviews of stored imaging tests were as reliable as expert reviews of stored
biopsy specimens. There is increasing use of ultrasound as a diagnostic test in GCA in some centres for
which confidence in the technical proficiency is high123 as more scans are performed. The methods in this
study will enable naive centres to gain proficiency and improve sensitivity and specificity of the tests. We
have shown that it is practical and achievable to become proficient at vascular ultrasound, but that it does
require specific training. Trained sonographers could initially perform scans in suspected cases that also
undergo biopsies, until adequate sensitivity and specificity for ultrasound are achieved (in the current study
there was an improvement in specificity after 10 scans). A recent retrospective review of 43 patients
diagnosed with GCA based on ultrasound findings allows further characterisation of patients into those
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who have isolated cranial vessel involvement and those who have extracranial features.124 Patients with
extracranial disease on axillary or subclavian artery ultrasound have a lower risk of permanent blindness,
but a slightly higher risk of relapse and greater steroid requirement.19,21,36,124
Problems with interpreting tests for giant cell arteritis
The inter-rater analysis for both tests (ultrasound and biopsy) revealed that the agreement between assessors
is more variable than perhaps appreciated. The variability is significantly influenced by the degree of
abnormality, as is to be expected with any test result. Borderline findings are likely to be subject to more
dispute by different assessors than results showing either clear-cut abnormal appearances or clear-cut highly
abnormal appearances. As demonstrated in the graphs of the inter-rater agreement (Figures 13–16), this
problem appears to be present for both interpretations of ultrasound images as well as the evaluation of
histological samples.
Biopsy has been regarded as a gold standard in diagnostic testing for many conditions including vasculitis,
but when there is more uncertainty about the test results, our expectations of the pathologist or
sonographer should perhaps be lowered. When we originally designed the study we were expecting a
positive or negative outcome from each of the tests, so that we could compare the differences. What we
have discovered is that in up to one-third of cases there is insufficient information available in the sample
to determine confidently whether the diagnosis should be ruled in or ruled out. For some conditions, such
as thyroid cancer, pathologists recognised that indeterminate histology was a significant problem in around
10% of cases discussed in a recent analysis of 14 studies comprising > 60,000 samples.125 In these
patients, a repeat sample was obtained and in 57% of patients the repeat biopsy was sufficient to make a
definitive diagnosis. However, interestingly, in 42% of patients, a second opinion from an independent
pathology review of the original sample resulted in a definitive diagnosis. Histological analysis of other
conditions such as ulcerative colitis can be challenging in the presence of atypical histological features,
which can lead to variations in the interpretation of diagnosis or severity of the condition.126
Issues with the choice of reference diagnosis for giant cell arteritis
Evaluations of diagnostic tests rely on a ‘gold standard’ reference diagnosis in order to determine the
accuracy of the test(s) being evaluated. A reference diagnosis should ideally be independent of the test(s)
being evaluated and the timing of its measurement should coincide with the timing of the test(s). No
reference diagnosis exists for GCA that meets these standards. ACR classification criteria exist but these are
not diagnostic criteria and they use the results of biopsy. The design of the study therefore sought an
approach to determining the reference diagnosis that balanced these different limitations; neither a clinical
diagnosis nor the ACR classification criteria alone were considered suitable.
We used an algorithm that took the clinician’s diagnosis at 2 weeks as the starting point and this decision
inevitably took account of the clinician’s knowledge of the result of the biopsy. This allowed clinicians to
use their judgement based on their knowledge of the patient and many biopsy-negative patients were
judged to have GCA. As expected, all biopsy-positive patients were judged to have GCA. The clinician’s
diagnosis was confirmed as the reference diagnosis depending on consistency with the ACR classification
criteria for GCA and the presence or absence of specific GCA-related symptoms or complications during
follow-up. In around half of patients, a reference diagnosis was not confirmed this way. We used expert
review of these patients to determine the reference diagnosis and for 23 (6%) patients the expert review
confirmed a reference diagnosis that differed from the clinician’s diagnosis.
Our finding that interobserver agreement in interpreting biopsy images is moderate undermines the
assumption that a positive biopsy should be regarded as confirming a GCA diagnosis. The reference
diagnosis is not independent of the biopsy result because it is incorporated in the clinician’s judgement
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and is part of the ACR classification criteria used to confirm the reference diagnosis. One implication is that
the 100% specificity (and also the sensitivity) of biopsy may be overestimated and that false-positive biopsy
results have not been identified. A second implication is that the performance of biopsy compared with
ultrasound may also be overestimated in favour of biopsy.
The lack of independence of the reference diagnosis is also an issue for interpreting testing strategies that
combine test results with clinical judgement. Clinical judgement, that is, the clinician’s diagnosis at
2 weeks, is part of the test strategy, but is also the starting point for determining the reference diagnosis.
Clinical judgement may also draw on patients’ symptoms at presentation that also feature in the ACR
classification criteria and that, in turn, may confirm the reference diagnosis. This lack of independence may
therefore overestimate the performance of strategies incorporating clinical judgement. The use of expert
review and GCA-related symptoms and complications during longer-term follow-up (albeit only 6 months)
for confirming reference diagnoses provides some protection against this lack of independence. However,
the use of emerging symptoms or complications and expert review raises the issue of timing and the
possibility that the reference diagnosis is capturing newly incident GCA that was not present at the times
at which biopsy and ultrasound were done. Both this timing effect and the potential for expert review to
incorrectly classify a patient’s true diagnosis may mean that the performance of tests and testing strategies
is underestimated.
The economic modelling included additional analyses based around alternative reference standards
constructed for the purpose of testing whether or not the findings could be sensitive to the reference
standard criteria. Under the alternative reference standards evaluated, ultrasound in combination with
clinical judgement remained a more cost-effective strategy than biopsy plus clinical judgement.
Could the results of the study be used to improve the existing
service for diagnosis of suspected giant cell arteritis?
The low sensitivity of biopsy for diagnosis of GCA was one of the most surprising findings from the study.
There are likely to have been several factors leading to this outcome. We could speculate on how the
sensitivity of biopsy could be improved. The selection of patients could be based on a higher pre-test
probability of having GCA, with careful clinical evaluation of each individual case. Patients would need to
be seen promptly, either before or very shortly after commencing high-dose glucocorticoid therapy, which
would require a fast-track service for these patients. The biopsy procedure should be performed by senior
surgeons with expertise in the procedure. The samples should be processed and evaluated by experienced
pathologists with the potential for central review of the histology. The interpretation of the biopsy should
include the possibility that the result is non-diagnostic or non-specific, in order to provide more detailed
results to enable the clinician to weigh up the likelihood of diagnosis in the presence of intermediate or
indeterminate results. This could be achieved without recourse to ultrasound, in order to enhance the
current service provision for patients with suspected GCA.
Fast-track service in giant cell arteritis
The potential window of opportunity to diagnose GCA is small once the patient has been commenced on
high doses of glucocorticoid therapy. To optimise either test (ultrasound or biopsy) the important first step
is to develop a rapid-access service for patients with suspected GCA. The current study provides evidence
for the rapid decline in diagnostic performance with time and the economic analysis supports the
introduction of ultrasound as a cost-effective means of achieving the diagnosis more effectively at much
lower cost than the existing standard of care. Furthermore, fast-track services for GCA, which incorporate
the use of ultrasound, have been shown to reduce the incidence of sight loss in this population, further
justifying their role in the management of suspected GCA.111,127
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Summary of findings
Giant cell arteritis or temporal arteritis remains a diagnostic and therapeutic challenge. Unfortunately, the
treatment options available are relatively limited and patients usually require a very high dose of steroids
for prolonged periods of time, which results in significant toxicity in > 80% of patients. If, however, the
diagnosis is missed and the patient is not treated with a high dose of glucocorticoid therapy, there is a
significant risk of permanent visual loss or other ischaemic complications.
The current study was performed in an attempt to explore the value of ultrasound as a diagnostic tool in
assisting the management of patients with suspected GCA. Ultrasound is a readily accessible investigation
in most hospitals, whereas obtaining a TAB remains problematic in the NHS. Furthermore, the diagnostic
value of TAB has been questioned owing to some studies reporting low sensitivity.
Ultrasound examination of temporal arteries is a relatively specialist procedure; we wanted to explore the
generalisability of diagnostic testing in GCA within a NHS setting. We therefore had to design a training
programme that was effective enough and applicable enough to be generalised to clinicians and
sonographers working in a variety of centres throughout the UK. We deliberately chose a mixture of
district general hospitals and teaching hospitals to explore this generalisability. We trained sonographers in
the technique of ultrasound examination of temporal and axillary arteries by developing a training
programme based on established expertise.
The effect of the training programme was tested thoroughly by an expert review panel established
specifically to view all images obtained from the main study for quality control. This ensured that the
images acquired and interpreted by site sonographers were of a sufficiently high standard to be
comparable to those that would have been obtained by experts.
For the main study, we needed to test the value of ultrasound as a diagnostic tool without interfering with
the normal diagnostic process. We therefore designed the study so that patients underwent the normal
diagnostic process if they were suspected of having GCA. This meant that they underwent a clinical
assessment followed by a TAB in every case. We undertook a blinded ultrasound test before biopsy was
performed, but the results of the ultrasound tests were not given to the clinician managing the patient.
However, the results of the biopsy test were given to the clinician as would occur in normal practice. The
results of the biopsy test, together with the clinical condition of the patient when re-evaluated 2 weeks
after initial assessment, were used by the clinician to make a diagnosis. If the clinician had made a
diagnosis that was not GCA and was planning to bring the patient off high doses of glucocorticoid
therapy or was not planning to start high doses of steroids, we built in a safety mechanism whereby the
clinicians were asked to contact the TABUL office to be given the results of the ultrasound scans just in
case there was a disparity between the scan result and the clinical decision. It was then up to the clinician
managing the patients to decide whether or not to alter their diagnosis and management plan, but this
decision was not used as the basis for the primary outcome, although it was reported.
We asked for a 6-month follow-up visit to determine whether or not any new features consistent with the
diagnosis of GCA had emerged or, indeed, whether or not any features consistent with other diagnoses
had emerged and whether or not the clinician had an opportunity to change the diagnosis in 6 months.
We felt that this study design was realistic and represented usual practice, but with the addition of the
ultrasound scan.
Our results showed that the sensitivity of biopsy was only 39%, which was lower than in previously
published studies. The sensitivity of ultrasound was 54%. The specificity of biopsy was always going to be
high and in this study was 100% compared with 81% for ultrasound. As both of the tests had been
performed in all patients, we were able to hypothesise on a potential sequence of tests that could have
been performed to try to improve sensitivity and specificity and also to look at the cost implications of
these strategies. We therefore analysed the data according to a potential strategy of performing both tests
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in different combinations. However, the tests were never performed in isolation from the clinical evaluation
of patients; we therefore introduced two methods to define the likelihood of the patient having or not
having GCA, based on clinical features and blood test results, before looking at the results of either test.
One method was simply to ask the clinicians to state their opinion of the likelihood of GCA (definite,
probable or possible); the other method was to use an external data set obtained from DCVAS to try to
define patients as being at high, medium or low risk of having GCA. We used the presence of jaw or
tongue claudication and elevated inflammatory response (ESR > 60 mm/hour or CRP level > 40 mg/l) as
parameters that would define a patient as being at a high likelihood of having GCA. Patients defined
as having a low likelihood of GCA did not have any of these parameters. Patients were defined as being
tat intermediate risk of having GCA if they had either claudication (of jaw or tongue) or an elevated
acute-phase response (ESR or CRP level) but not both of these. Using this strategy would make clinical
sense. The clinicians would normally assess the patient and decide whether or not it was worthwhile to
investigate a patient further for the possibility of GCA, and therefore defining who should or should not
have a test such as TAB or ultrasound.
Using this strategy-based approach we demonstrated that without a clinical evaluation, a combined
approach of scanning all patients and performing a biopsy only on those for whom the scan was negative
would achieve a sensitivity of 65% and specificity of 81%. If we took a risk strategy approach, by only
investigating those patients with the high likelihood of GCA based on clinical presentation, the sensitivity
and specificity increases to 77% and 91%, respectively. However, for patients at moderate or low risk of
having GCA based on the clinical presentation, the sensitivity and specificity were lower and this would
inevitably result in a cohort of patients for whom there was still a clinical suspicion of diagnosis of GCA,
but for whom both ultrasound and biopsy were negative. We have demonstrated that in the TABUL study
there is a significant cohort of such patients (about one-quarter of all patients defined as having GCA).
In terms of cost-effectiveness, biopsy is more expensive than ultrasound (an almost ninefold difference)
and this higher cost was the key factor in the greater cost-effectiveness of strategies using ultrasound.
The similarity in the diagnostic performances of the two tests (when combined with clinical judgement),
the estimated impact of GCA-related complications from false-negative results, and the estimated impact
of steroid toxicity from false-positive results was insufficient to alter the results.
In a parallel study, we used data from the TABUL project to measure the reliability of the interpretation of
ultrasound or biopsy findings. In order to do this we produced a series of 30 patients from the TABUL
cohort (containing a mixture of patients with positive and negative ultrasound and biopsy results). We
prepared the ultrasound scans and the histological slides of those patients and showed a brief clinical
vignette together with either the scans or histology slides to a group of sonographers and pathologists,
respectively, to determine inter-rater reliability of these two tests. We found that there were similar levels
of agreement, with kappa values of 0.61 for sonographers and 0.62 for pathologists. The areas of
disagreement among the pathologists occurred when the histological results were less clear cut,
particularly when no giant cells were found. These findings suggest that the pathologist’s interpretation of
biopsy material should be qualified according to the level of severity of the findings. If there are very
obvious features of GCA (such as transmural inflammation or giant cells), this should be stated by
pathologists, but if there are much less obvious features that might be consistent with GCA, but that
equally could be consistent with normal ageing, then it is important that the pathologists are able to
express this diversity of possible diagnosis rather than having to state that the biopsy is consistent with
GCA but not declare that the biopsy is also consistent with normal ageing findings. The clinicians
managing patients may feel less comfortable with the fact that the pathologists are not giving a clear-cut
interpretation of the biopsy, but this should improve the management of patients if we avoid making
conclusions based on insufficient evidence. Although no clear pattern emerged from an evaluation of cases
disputed by sonographers, similar remarks would apply in interpreting ultrasound findings. Until we have a
more effective diagnostic tool, the clinical evaluation of the patient remains paramount in the decision-
making process.
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We have challenged the place of TAB as the gold standard for the diagnosis of GCA. We have demonstrated
that in 381 patients with newly suspected GCA, the application of clinical risk stratification (based on the
presence of ischaemic symptoms of tongue or jaw claudication and/or an elevated acute phase response),
combined with either ultrasound of temporal and axillary arteries or biopsy, will result in a high sensitivity
and specificity in the diagnosis of GCA. In order to achieve this, we have created a training programme to
ensure the proficiency of sonographers in performing the scans. We compared the results obtained from
these scans with the traditional factors used in making a diagnosis of GCA, namely the application of clinical
judgement (strongly influenced by ACR classification criteria for GCA). Despite the inherent bias of using a
reference diagnosis that incorporates the results of the biopsy, ultrasound examination was more sensitive
but less specific than biopsy as a diagnostic test. We tested the reliability of both tests, by asking a number of
pathologists and sonographers to respectively review biopsy and scan findings from an anonymous sample
of patients drawn from the cohort. We showed that the reliability of both techniques was similar (ICC of
0.61–0.62), revealing that both tests have some fallibility. Further analyses of the diagnostic strategies to
combine clinical risk stratification with one or both tests in appropriate cases can be used effectively to
significantly improve the diagnostic accuracy of patients with newly suspected GCA. The economic
evaluation of the test strategies used in this cohort of patients has shown that an ultrasound-based approach
is more cost-effective than a biopsy-based strategy if used in conjunction with clinical risk assessment.
Conclusions
Implications for health care
The inclusion of ultrasound scanning of temporal and axillary arteries can be a clinically effective and
cost-effective addition to the current strategy of tests to aid in the diagnosis of GCA among individuals
referred from the community to hospital. We have shown that it is practical to introduce an ultrasound
training module to ensure minimum standards of proficiency in scanning temporal and axillary arteries for
evidence of GCA. Ultrasound is more sensitive but less specific than biopsy. It would be possible to introduce
a clinical pathway that involves scanning all patients with suspected GCA without performing biopsies. Such
a strategy is clinically effective as well as cost-effective (an incremental NMB of £485 per case compared
with standard current practice of biopsy and clinical judgement) and avoids an invasive biopsy procedure.
However, the strategy will be successful only if patients have rapid access to the diagnostic pathway while
the scan abnormalities are still present (and not affected by the effects of glucocorticoid therapy).
It will be important to define the acceptability of any new diagnostic strategies in the management of GCA
both for patients and for clinicians. If we follow the most cost-effective strategy, we would rely on
ultrasound and clinical judgement alone as a means of diagnosis. Some clinicians and patients may be
uncomfortable with this strategy and may prefer that biopsies are performed in all cases that are
ultrasound negative or in all cases with medium or high risk of GCA on clinical features but in which there
has been a negative ultrasound scan. The reason for the additional use of biopsy, despite a negative scan,
would be to provide further evidence to rule in the disease as well as to support withdrawing therapy in
the event that both tests are negative. Although these combined strategies would be more expensive, they
remain more cost-effective than current practice (performing a biopsy in all suspected cases) and may be
more acceptable to patients and clinicians.
Recommendations for research
The current study has challenged the previously secure place of biopsy as the gold standard in the
diagnosis of GCA. Although ultrasound may not be the perfect replacement for biopsy, it has significant
advantages over biopsy, as well as some limitations, as discussed in this report. The following areas would
merit further exploration:
l What should be the gold standard for diagnosis of GCA? Can our assessment of the pathological
findings be improved, removing the previously used dichotomous decision on normal or abnormal
findings, to generate a grade of likelihood of diagnosis, especially for those patients whose biopsies do
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not contain giant cells? Do we need to develop a training programme for pathologists to maintain
standardisation in the reporting of findings in GCA? Do we need to re-examine surgical training in
performing biopsies for patients with suspected GCA? Do we need to re-evaluate the histological
characteristics that define the presence or absence of GCA? How can we better account for the
influences that alter the histological findings in the temporal artery, such as the presence of
arteriosclerosis, the effect of glucocorticoid therapy and the effects of ageing? Should a hierarchical
approach to diagnosis be developed, with clinical features, laboratory features, ultrasound and biopsy
evaluated to develop an algorithmic approach to standardise the investigation and evaluation of
patients with suspected GCA?
l Are biomarkers available to improve the diagnostic certainty in GCA? Many groups have attempted to
introduce alternative tests to increase the diagnostic yield in GCA. Assessments of the ESR, circulating
levels of CRP, vascular endothelial growth factor or pentraxin 3 have been tested and were found to
lack sensitivity and specificity for the diagnosis of GCA; however, could they add value in the diagnosis
of GCA if combined with ultrasound? Are there any new biomarkers to be tested in suspected GCA?
l Can ultrasound examination of temporal arteries be used to guide responses to therapy? If ultrasound
becomes more widely used than biopsy, this provides a new opportunity to assess ultrasound as a
biomarker to measure the response of the scan findings to the effects of therapies. This could mean
allowing more rapid reduction of glucocorticoid therapy for those cases showing a fast resolution, with
rapid reintroduction for cases in which the scan abnormality is returning, either in the context of a
clinical relapse or in patients who are asymptomatic. How often must a scan be repeated to evaluate
this risk? In addition, adjunctive therapies (steroid-sparing agents) could be tested for their role in
resolving and maintaining a normal ultrasound appearance of the arteries. The rate of ultrasound
response to treatment might be a guide to future risk of relapse.
l How can we improve the standardisation of ultrasound assessment of suspected GCA? We have
developed and introduced a novel training protocol for the ultrasound of temporal and axillary arteries.
We applied the training protocol to all centres included in the study, most of which had never
performed vascular ultrasound before. With the benefit of this training protocol, we observed that
86% of recorded images from the patients recruited into the study were technically satisfactory.
It is possible that the training methods that we devised could have been improved by being tailored
to the expertise of the sonographer. As technology advances, it is possible that the amount of training
required to adequately prepare a sonographer to examine these arteries may decrease. In addition, as
ultrasound becomes more widely used, some sites may become more familiar with the techniques, and
their training requirements will be reduced. As more patients are scanned, more experience can be
gained to maintain standards. Testing new training methods should be considered, as well as the
development of methods to maintain expertise.
l How should we explore the acceptability of introducing new combined diagnostic strategies into
clinical practice? How will clinicians respond to the idea that they should no longer be requesting a
biopsy in the majority of cases to rule in or rule out GCA? Will they have confidence in the clinical
features plus scan evidence of having GCA? Will they or their patients be willing to accept a diagnosis
without a histopathological test to verify the diagnosis? By contrast, how acceptable will a negative
scan be in ruling out the diagnosis? We shall need to consider the impact of these changes to a
well-established diagnostic pathway, especially in centres that do not have any experience of using
ultrasound in the assessment of GCA.
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Appendix 1 Ultrasound case report
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Appendix 2 Completion of the ultrasound case
report form
The standard operating procedure for completion of the ultrasound case report form can be accessed viathe following link: http://ora.ox.ac.uk/objects/uuid:7990dde3-0714-4414-b590-3e0aa1b7d761
(accessed 27 May 2016).
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Appendix 3 Screening case report form
DOI: 10.3310/hta20900 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 90
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Luqmani et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
157

Appendix 4 Patient information sheet
PATIENT INFORMATION SHEET 
The role of ultrasound compared to biopsy of temporal arteries in 
the diagnosis and management of giant cell arteritis (TABUL) 
We would like you to consider this research study and then decide whether or not you wish 
to take part.  Before you decide whether to participate or not it is important for you to 
understand why the research is being done and what it will involve.  Please take time to read 
the following information carefully and to decide whether or not you wish to take part.  
1. What is the purpose of this study? 
Our study will examine the role of ultrasound in helping to diagnose Giant Cell Arteritis 
(GCA). It causes narrowing and blockage of some of these blood vessels; it can cause 
severe headache and in some cases may affect eyesight. It is important that a prompt 
diagnosis of GCA can be made in order to start treatment with steroid tablets or injections. 
Currently there is no test that is 100% accurate for diagnosing GCA.  
To help to confirm a diagnosis of GCA, the patient will usually have a biopsy of a temporal 
artery (a minor surgical procedure performed under local anaesthetic to remove a 1 to 3 
centimetre sample of one of the arteries to the scalp). The examination of the biopsy sample 
usually confirms that the patient has GCA and steroid treatment can be continued.  
However, some patients with GCA will have a normal biopsy result. For these patients with a 
normal biopsy result it is difficult to confirm if they do or don’t have GCA and whether or not 
steroid treatment should be continued.  
The main study 
It is important to find better ways of diagnosing GCA to ensure that more patients are treated 
appropriately.  Another test that may help in diagnosing GCA is examination of ultrasound 
scans of the arteries in the side of the head and under the arms. Ultrasound does not involve 
surgery; it is a simple test which can be performed in a radiology department.  Gel is applied 
to both sides of the head and under each arm.  A sound probe is placed over the artery at 
each of these areas to produce the scan for expert examination
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The sub-studies 
We are asking you to take part in the main study described above, but in addition, there are 
a number of separate sub-studies that you can also choose to participate in, to look at 
immune abnormalities in GCA; make an educational website for doctors to use and to store 
ultrasound images, samples and other data in a Biobank for future studies. 
2. Why have I been invited? 
You have been chosen because you have been suffering a new onset of headache which is 
suspected as being giant cell arteritis and the doctors looking after you have decided that 
you need a biopsy of your temporal artery to clarify the diagnosis. 
3. Do I have to take part? 
It is up to you to decide whether or not to take part.  You are free to withdraw at any time and 
without giving a reason.  If you decide to take part we will ask you to sign a consent form 
indicating your willingness to participate in the study.  Any current or future healthcare that 
you receive will not be affected by deciding whether or not to take part in the study.  Taking 
part in the study is voluntary. 
4. What will happen if I take part? 
If you take part in the study, you will need to attend for an ultrasound scan of your scalp and 
armpit arteries before the planned biopsy. The scan will take about 30 minutes to complete. 
At the first study visit, you will be assessed by the study nurse or doctor and asked to 
complete questionnaires about your health; you will be reviewed two weeks (study visit 2) 
and six months (final study visit) later where the study nurse or doctor will repeat the 
assessment and ask you to complete the same health questionnaires.  Your ultrasound scan 
result will not be disclosed to you or to the doctors and nurses looking after you.  If you 
agree to take part in any sub-studies, you will also need to give blood samples on each of 
the 3 study visits.    
 
Participating in the TABUL study will not affect the care you receive from the National Health  
Service (NHS). 
5. What do I have to do? 
The main study 
By the time you read this, you will have been referred to hospital for a possible diagnosis of 
GCA.  The doctors looking after you will have told you about the study and asked your  
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permission to contact the study nurse or study doctor.  We have given you this information 
sheet about the study.  The study nurse or doctor will get in touch with you; they will either 
see you on the day of your scheduled hospital visit, or telephone you so that they can give 
you more information about the study.  The research nurse or doctor will arrange to see you 
after you have had an opportunity to read the information and ask any questions.  At this 
time you can ask further questions about the study, if you decide to take part in the study, at 
this point you will be asked to sign a consent form (study visit 1).  A friend or relative can 
sign the consent form on your behalf if needed.   If you agree to participate in the study, you 
will be assessed by the study nurse or doctor and asked to complete a questionnaire.  An 
appointment will be made for you to have the ultrasound scan before your biopsy.  We will 
make sure that your biopsy has been arranged. You would usually be attending hospital 
regularly after the biopsy to check on your health and adjust your treatment.  You will be 
asked to attend for 2 further follow up visits after 2 weeks (study visit 2) and after 6 months 
(final study visit). On each study visit, the study nurse or doctor will assess you. We will ask 
you questions about your condition and how it affects your daily life, using standard 
questionnaires. We expect the first study visit to last about 60-90 minutes, and for each of 
the 2 subsequent study visits to last between 45-60 minutes. The doctor or nurse in the clinic 
will complete specialised clinical questionnaires, to assess your diagnosis, but we will also 
ask you to complete health questionnaire on your ability to carry out normal activities of daily  
living and your quality of life.  We anticipate that it will take about 5-10 minutes for you to 
complete the questionnaires. 
You will have an ultrasound scan of your scalp arteries (temporal arteries) and armpit 
arteries (axillary arteries) in addition to your routine biopsy of one temporal artery.  The 
ultrasound scan is entirely painless.  It will involve applying gel to the both sides of your 
head, and both armpits.  The person performing the scan will place a sound probe over 
these 4 sites in order to identify the arteries.  The probe will be used to record the images, 
and test each artery for signs of swelling, blockage and narrowing.  The probe will be moved 
over the arteries and different settings will be applied using the dials on the machine to get 
the best picture.  We hope to test the value of performing an ultrasound scan of these 4 
arteries as an alternative to a biopsy of one temporal artery.  We expect the scan to take 
about 30 minutes to complete.  For training purposes, and if you are willing to do so, more 
than one scan may be performed. 
We will store the biopsy samples and images of the ultrasound scans in one centre (Oxford), 
so that we can use the material to make sure that all the different hospitals taking part in the 
study are performing and interpreting the biopsy and scan results according to a high 
standard of accuracy  
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Sub studies 
We would like to perform some further tests on your biopsy and blood samples we collect 
from you so that we can gain a better understanding of the disease.  In addition to the main 
study, we are planning to undertake a number of sub studies, making use of the biopsy 
sample that will normally be taken, as well as the video images of the scans and extra blood 
samples which we will ask you to provide on each of the 3 study visits. These sub studies 
are optional.  You can take part in the main study and choose not to take part in the sub 
studies.  The sub studies will look at the immune abnormalities in the biopsy sample and 
blood samples to try to determine what type of cells and inflammatory chemicals are 
responsible for the condition.  This will involve processing the biopsy sample and blood 
samples to extract the cells, measure the inflammatory chemicals in the blood and look at 
the biopsy in detail, using special attaining techniques.  If you agree to the sub-studies, we 
will take the additional blood samples (maximum total of 85 ml): 
1. Study Visit 1 - 6 tubes of blood (approx. 35 ml total, equivalent to about 7 
teaspoonfuls). 
2. Study Visit 2 (2 weeks) - 5 tubes of blood (approx. 25 ml total, equivalent to about 5 
teaspoonfuls). 
3. Study Visit 3 (6 months) - 5 tubes of blood (approx. 25 ml total, equivalent to about 
5 teaspoonfuls). 
Please note that these will be in addition to your routine blood samples at each visit. 
We would like to make use of the video images of the scans and of the images of the biopsy 
samples in order to develop and test the usefulness of a training website to teach other 
doctors about the best way to diagnose temporal arteritis.  No personal details will be used 
on the website. 
We would like your permission to store your samples of blood and your biopsy in a Biobank 
for future related studies 
We will remove your personal details from all research samples so that they are all 
anonymous and your personal details will remain confidential.  However, it will be possible to 
link the clinical and laboratory details through a unique laboratory code to enable us 
compare your clinical state with the laboratory findings. Your blood samples will be stored in 
a laboratory freezer until used.  
We would like to store some of your DNA extracted from the blood samples to form part of 
our Biobank that we can use in future genetic studies. This is purely for research purposes  
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and you will not be told the results of the tests on your samples. The anonymous genetic 
information may be shared with other research groups conducting similar investigations.  
6. Expenses and payments 
If you incur travel expenses in order to attend especially for the ultrasound scan this extra 
appointment will be reimbursed on request.   
7. What are the possible benefits of taking part? 
Your condition of suspected giant cell arteritis will be treated by the doctors in hospital in the 
normal way, using widely recognised means.  You will not directly benefit from taking part in 
this study but the information we get from this study will help improve future treatment of 
people with suspected giant cell arteritis.   
8. What are the possible risks of taking part? 
Ultrasound is a safe technique. The temporal artery biopsy procedure would be part of 
routine care so you would be undergoing this procedure whether you decide to take part in 
the study or not.   Complications following a temporal artery biopsy are rare, but include 
bleeding, swelling over an artery due to formation of a blood clot (haematoma), damage to 
branches of the facial nerve, failure to identify the artery, development of infection at the 
biopsy site,  wound breakdown and very rarely scalp necrosis.  
9. Will my taking part be kept confidential? 
All patient information is stored on password protected computer databases and in locked 
filing cabinets and will only be accessible to the TABUL research team and regulatory 
authorities for auditing and monitoring purposes.  You will be allocated a unique study 
number and staff not directly involved with you will know you only by this number.  When the 
results of the study are reported, individuals who have taken part will not be identified in any 
way.  Again we must emphasise that none of your samples will identify you in any way as we 
will use your unique study number when storing them.  Responsible members of the 
University of Oxford or the local Hospital NHS Trust may be given access to data for 
monitoring or audit of the study to ensure we are complying with regulations. 
10. What if I change my mind about taking part? 
If you decide to withdraw from the study, your standard of care will not be affected.  You will 
still be asked to attend the routine follow-up clinics required by your doctor and hospital as 
part of your standard care. These follow up clinics will not be part of the study.  
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If you withdraw from the study, all samples and clinical information that we have obtained up  
to the point of you coming out of the study will continue to be used for the purpose of the 
study.   
11. What if there is a problem? 
If you wish to complain about any aspect of the way in which you have been approached or 
treated during the course of this study, you should contact Dr Raashid Luqmani on XXXX or 
you may contact the University of Oxford Clinical Trials and Research Governance (CTRG) 
office on XXXX or the head of CTRG, email XXXX. 
The University has arrangements in place to provide for harm arising from participation in the 
study for which the University is the Research Sponsor. NHS indemnity operates in respect 
of any clinical treatment with which you are provided. 
12. Will my GP be informed of my involvement in the study? 
Yes. We will send your GP a brief letter informing them of your participation in the study. 
13. What will happen to any samples I give? 
The video images of your scans, tissue and blood samples collected for the TABUL study 
will be sent to the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal 
Science, in Oxford, for analysis.  Samples of blood will be stored for future studies, including 
DNA studies to learn more about the nature of giant cell arteritis.  None of these will identify 
you in any way as we will use your unique study number when storing them.  However, if 
your local hospital requires the biopsy sample to be returned for clinical care, we will be able 
to trace the sample from the unique study number, supplied by your hospital, so that the 
sample can be returned.  We will use the video images of the scans and the biopsy samples 
to train the investigators in the study to make sure that we maintain a high standard of 
quality control. In order to do this, at least 2 experts trained in ultrasound from the study 
panel will independently review all the video images of the scans; 1 or 2 expert pathologists 
from the study panel will independently review all the biopsy slides.  If there is a 
disagreement with the findings of the local investigator, this will be discussed.   
If you agree to take part in the sub-studies, we will store your biopsy sample and blood 
samples in a Biobank at oxford.  All specimens will be carefully catalogued and maintained 
in a facility which is fully compliant with the requirements of the Human Tissue Act.  This will 
allow us to safely and securely keep your samples in a freezer, for use in future studies,  
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which will be reviewed and approved by a Research Ethics Committee, before we make use 
of these specimens.  
14. How will the information I provide be used? 
We plan to publish the results in a health journal so others can read about and learn from the 
results of the study. 
15. Who is organising and funding the research? 
This nationwide trial is being funded through the Health Technology Assessment (HTA) 
Programme, which is part of the Department of Health.   You can access information about 
them on the HTA website (www.hta.nhs.uk).    
The Nuffield Department of Orthopaedic, Rheumatology & Musculoskeletal Sciences 
(www.ndorms.ox.ac.uk) a department of the University of Oxford, in Oxford will undertake 
the day to day running of the trial, under the supervision of Dr Raashid Luqmani.   The 
University of Oxford will act as a sponsor for the study and will be responsible for the 
governance of the trial.  The Sheffield Clinical Trials Unit will be responsible for collecting 
and monitoring the information generated. 
16. Who has reviewed this study? 
The Berkshire Research Ethics Committee have reviewed the study and given it a 
favourable opinion. In addition your local NHS hospital Trust have and your local 
rheumatologist or ophthalmologist have approved the study. 
17. Further Information 
If you require more information about this study please call one of the telephone numbers 
provided to speak to a clinical member of the research team or, alternatively look at the 
clinical trials website:  
http://clinicaltrials.gov/ct2/show/NCT00974883. 
 
Thank you for reading this. 
If you have any questions or would like any more information please contact the 
TABUL Office by phone: 
XXXX (XXXX) or XXXX (XXXX) 
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Or email XXXX
Please keep this information sheet for your records. 
 
If you agree to enter the study, please sign the attached consent form and we will 
return a copy to you 
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Appendix 5 Patient consent form
Patient Consent Form 
 
Chief Investigator: Dr Raashid Luqmani 
Local Investigator: (“Please add per site”) 
Address and telephone number of local investigator: (“Please add per site”) 
 
SITE NUMBER:    
PARTICIPANT STUDY NUMBER:  
E P -   -    
 
Please initial in the boxes if you agree. 
 
PART A 
 
 
1. I confirm that I have read and understood the information sheet dated 
……………………………………………. (Version ……….), and have had the 
opportunity to ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, and without my medical care or my legal 
rights being affected. 
 
 
3. I agree that the video images from my ultrasound scan can be used for quality 
control for the study 
 
4. I agree to the use of my temporal artery biopsy sample for quality control for 
the study 
 
5. I agree for my personal information to be stored confidentially by the TABUL 
research team so that they can contact me in the future to invite me to 
participate in any future related research studies. I understand that my 
participation in any future related study will be entirely voluntary and I can 
decide not to participate 
 
DOI: 10.3310/hta20900 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 90
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Luqmani et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
167
6. I understand that responsible members of the TABUL research team may look 
at sections of my medical notes where it is relevant to my taking part in 
research.  I give permission for these individuals to have access to my records 
 
7. I agree to my GP being informed of my participation in this study  
8. I understand that my data may be accessed by responsible members of the 
University of Oxford and the University of Sheffield for the purpose of 
monitoring or audit 
 
 
9. I agree that my non identifiable data can be stored on a password encrypted data 
base for the purpose of this study and undefined future related studies 
 
10. I understand that the samples collected will be considered a gift to the 
University of Oxford 
 
11. I agree that if I change my mind and withdraw consent from this study at a later 
date, any clinical information, samples or images obtained that have been 
donated by me until the time that I withdraw from the study will continue to be 
used for the study. 
 
PART B  
PLEASE INITIAL YES OR NO TO EACH OF THE FOLLOWING 
STATEMENTS 
 
1. I agree that the video images from my ultrasound scans and photographic 
images of my temporal artery biopsy can be stored together with my 
anonymised clinical details and used in  this study and future GCA related 
ethically approved studies to help improve the training in use of ultrasound and 
biopsy in the diagnosis of GCA 
YES 
NO 
2.  agree to give an additional 85ml of my blood during the study YES 
 
NO 
 
3. I agree to the use and storage of my blood samples in a bio bank, including 
DNA and temporal artery biopsy,  for further ethically approved studies to 
examine the role of inflammatory cells and mediators in the condition  
 
YES 
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 NO 
 
 
 
I agree to take part in all or part of this study as clearly outlined in the questions that I 
have initialled and answered Yes or No to. 
 
 
Signed…………………………………………………………….D.O.B…………
………. 
 
Full 
name………………………………………………………...Date…………………
… 
 
 
Name of 
Researcher……………………………………………Date…………………… 
 
Signed………………………………………………………………………………
………. 
 
 
(Copies: Top copy for Study Office, 1 for patient, 1 for hospital notes)
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Appendix 6 Recruiting and consenting
participants
The standard operating procedure for recruiting and consenting participants can be accessed via thefollowing link: http://ora.ox.ac.uk/objects/uuid:2603e653-8498-4b1a-854a-be889f1d9c38 (accessed
27 May 2016).
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Appendix 7 Clinical case report form
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Appendix 8 Completion of the clinical case
report form
The standard operating procedure for completion of the clinical case report form can be accessed viathe following link: http://ora.ox.ac.uk/objects/uuid:0eb6d248-0fe9-47a4-b151-81bfc6dfc982 (accessed
27 May 2016).
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Appendix 9 Adverse event case report form
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Appendix 10 Completion of the safety report
form
The standard operating procedure for completion of the safety report form (describing any AEs orserious AEs) can be accessed via the following link: http://ora.ox.ac.uk/objects/uuid:b717083c-d287-
4489-b06a-041d0000eaca (accessed 27 May 2016).
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Appendix 11 Collection, processing and storage
of biopsy samples
The standard operating procedure for collection, processing and storage of biopsy samples can beaccessed via the following link: http://ora.ox.ac.uk/objects/uuid:b5132a1c-a1d4-4c99-8c45-
7b9f43d98512 (accessed 27 May 2016).
DOI: 10.3310/hta20900 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 90
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Luqmani et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
207

Appendix 12 Biopsy case report form
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Appendix 13 Completion of the biopsy report
case report form
The standard operating procedure for completion of the biopsy report case report form can be accessedvia the following link: http://ora.ox.ac.uk/objects/uuid:eeebc59f-9ee3-4e40-a7dd-1b3d6179f972
(accessed 27 May 2016).
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Appendix 14 Statistical analysis plan
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Screening for eligibility 
 
Recruit and week 0 
assessment (n=435-
445) 
Ultrasound (results 
hidden) and temporal 
artery biopsy (n=402) 
Week 2 assessment 
(n=402) 
Week 26 assessment 
and 'gold-standard' 
diagnosis (n=380) 
Ultrasound and 
temporal artery biopsy 
image central storage  
Inter-rater assessment 
of ultrasound and 
temporal artery biopsy 
Expert panel rating of 
GCA clinical vignettes 
Patient cohort 
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(Adapted by permission from BMJ Publishing 
Group Limited. Modiﬁcaon and validaon of the Birmingham Vasculis Acvity Score (version 3),
Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al., 68, 2009.)
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(Republished with permission of John Wiley and Sons Inc,
from Development and inial validaon of the Vasculis Damage Index for the standardized 
clinical assessment of damage in the systemic vasculides, Exley AR, Bacon PA, Luqmani RA,
Kitas GD, Gordon C, Savage CO, Adu D, 40(2), 1997; permission conveyed through
Copyright Clearance Centre Inc.)
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Appendix 15 Diagnostic accuracy for
combination of strategies for the pre-test risk groups
The definitions of strategies H0 to H4, M1 to M4 and L1 to L6 are given in Table 42. We considereddifferent diagnostic strategies depending on the pre-test probability of having GCA. Patients were
defined as having a high, medium or low pre-test probability of having a diagnosis of GCA. We examined
the sequential strategies of performing an initial ultrasound in the high-risk group and then performing a
biopsy if the scan is negative (i.e. the scan is not consistent with a diagnosis of GCA).
Patients were defined as having GCA if they met any of five possible criteria:
1. No tests were performed but the likelihood that the patient has GCA is high (defined as H0).
2. The sonographer’s opinion is that the ultrasound scan is consistent with a diagnosis of GCA (H1).
3. Halo is present bilaterally (in either temporal or axillary arteries) (H2).
4. Either the sonographer’s opinion is that the ultrasound is consistent with a diagnosis of GCA or there
are abnormalities in the axillary arteries (regardless of the sonographer’s overall opinion) (H3).
5. Halo is present bilaterally or any axillary involvement is present (H4).
In the medium-risk groups we considered the above strategies (except for the ‘no test’ strategy), in which
ultrasound is performed first, followed by biopsy (M1 to M4 would be equivalent to H1 to H4).
In the low-risk groups, we considered the same four strategies as well as two further strategies:
1. Using a negative ultrasound result as a ‘rule-out’ test for GCA. If ultrasound is positive, then perform a
biopsy and take the diagnosis from the biopsy result (L5).
2. Using the absence of any abnormal finding on the ultrasound as a ‘rule-out’ test for GCA. If there are
any abnormalities, perform a biopsy and take the diagnosis from the biopsy result (L6).
Strategies M1 and M3 resulted in the same classification of participants so we deliberately omitted
repeating the data because the result was identical.
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TABLE 75 Sequential strategies of performing an initial ultrasound in the high-risk group and then performing a
biopsy if the scan is negative
Strategy GCA Not GCA
Number of
TABs required
(N= 381), n (%)
High
pre-test risk
Medium
pre-test risk
Low
pre-test risk
Sensitivity
(N= 257), n (%)
Specificity
(N= 124), n (%)
H0 M1 L1 185 (72.0) 96 (77.4) 178 (46.7)
L2 175 (68.1) 108 (87.1) 200 (52.5)
L3 185 (72.0) 93 (75.0) 175 (45.9)
L4 176 (68.5) 103 (83.1) 194 (50.9)
L5 164 (63.8) 115 (92.7) 126 (33.1)
L6 166 (64.6) 115 (92.7) 134 (35.2)
M2 L1 163 (63.4) 97 (78.2) 210 (55.1)
L2 153 (59.5) 109 (87.9) 232 (60.9)
L3 163 (63.4) 94 (75.8) 207 (54.3)
L4 154 (59.9) 104 (83.9) 226 (59.3)
L5 142 (55.3) 116 (93.5) 158 (41.5)
L6 144 (56.0) 116 (93.5) 166 (43.6)
M4 L1 164 (63.8) 97 (78.2) 207 (54.3)
L2 154 (59.9) 109 (87.9) 229 (60.1)
L3 164 (63.8) 94 (75.8) 204 (53.5)
L4 155 (60.3) 104 (83.9) 223 (58.5)
L5 143 (55.6) 116 (93.5) 155 (40.7)
L6 145 (56.4) 116 (93.5) 163 (42.8)
H1 M1 L1 166 (64.6) 101 (81.5) 219 (57.5)
L2 156 (60.7) 113 (91.1) 241 (63.3)
L3 166 (64.6) 98 (79.0) 216 (56.7)
L4 157 (61.1) 108 (87.1) 235 (61.7)
L5 145 (56.4) 120 (96.8) 167 (43.8)
L6 147 (57.2) 120 (96.8) 175 (45.9)
M2 L1 144 (56.0) 102 (82.3) 251 (65.9)
L2 134 (52.1) 114 (91.9) 273 (71.7)
L3 144 (56.0) 99 (79.8) 248 (65.1)
L4 135 (52.5) 109 (87.9) 267 (70.1)
L5 123 (47.9) 121 (97.6) 199 (52.2)
L6 125 (48.6) 121 (97.6) 207 (54.3)
M4 L1 145 (56.4) 102 (82.3) 248 (65.1)
L2 135 (52.5) 114 (91.9) 270 (70.9)
L3 145 (56.4) 99 (79.8) 245 (64.3)
L4 136 (52.9) 109 (87.9) 264 (69.3)
L5 124 (48.2) 121 (97.6) 196 (51.4)
L6 126 (49.0) 121 (97.6) 204 (53.5)
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TABLE 75 Sequential strategies of performing an initial ultrasound in the high-risk group and then performing a
biopsy if the scan is negative (continued )
Strategy GCA Not GCA
Number of
TABs required
(N= 381), n (%)
High
pre-test risk
Medium
pre-test risk
Low
pre-test risk
Sensitivity
(N= 257), n (%)
Specificity
(N= 124), n (%)
H2 M1 L1 161 (62.6) 101 (81.5) 231 (60.6)
L2 151 (58.8) 113 (91.1) 253 (66.4)
L3 161 (62.6) 98 (79.0) 228 (59.8)
L4 152 (59.1) 108 (87.1) 247 (64.8)
L5 140 (54.5) 120 (96.8) 179 (47.0)
L6 142 (55.3) 120 (96.8) 187 (49.1)
H2 M2 L1 139 (54.1) 102 (82.3) 263 (69.0)
L2 129 (50.2) 114 (91.9) 285 (74.8)
L3 139 (54.1) 99 (79.8) 260 (68.2)
L4 130 (50.6) 109 (87.9) 279 (73.2)
L5 118 (45.9) 121 (97.6) 211 (55.4)
L6 120 (46.7) 121 (97.6) 219 (57.5)
M4 L1 140 (54.5) 102 (82.3) 260 (68.2)
L2 130 (50.6) 114 (91.9) 282 (74.0)
L3 140 (54.5) 99 (79.8) 257 (67.5)
L4 131 (51.0) 109 (87.9) 276 (72.4)
L5 119 (46.3) 121 (97.6) 208 (54.6)
L6 121 (47.1) 121 (97.6) 216 (56.7)
H3 M1 L1 169 (65.8) 101 (81.5) 214 (56.2)
L2 159 (61.9) 113 (91.1) 236 (61.9)
L3 169 (65.8) 98 (79.0) 211 (55.4)
L4 160 (62.3) 108 (87.1) 230 (60.4)
L5 148 (57.6) 120 (96.8) 162 (42.5)
L6 150 (58.4) 120 (96.8) 170 (44.6)
M2 L1 147 (57.2) 102 (82.3) 246 (64.6)
L2 137 (53.3) 114 (91.9) 268 (70.3)
L3 147 (57.2) 99 (79.8) 243 (63.8)
L4 138 (53.7) 109 (87.9) 262 (68.8)
L5 126 (49.0) 121 (97.6) 194 (50.9)
L6 128 (49.8) 121 (97.6) 202 (53.0)
M4 L1 148 (57.6) 102 (82.3) 243 (63.8)
L2 138 (53.7) 114 (91.9) 265 (69.6)
L3 148 (57.6) 99 (79.8) 240 (63.0)
L4 139 (54.1) 109 (87.9) 259 (68.0)
continued
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TABLE 75 Sequential strategies of performing an initial ultrasound in the high-risk group and then performing a
biopsy if the scan is negative (continued )
Strategy GCA Not GCA
Number of
TABs required
(N= 381), n (%)
High
pre-test risk
Medium
pre-test risk
Low
pre-test risk
Sensitivity
(N= 257), n (%)
Specificity
(N= 124), n (%)
L5 127 (49.4) 121 (97.6) 191 (50.1)
L6 129 (50.2) 121 (97.6) 199 (52.2)
H4 M1 L1 165 (64.2) 101 (81.5) 225 (59.1)
L2 155 (60.3) 113 (91.1) 247 (64.8)
L3 165 (64.2) 98 (79.0) 222 (58.3)
L4 156 (60.7) 108 (87.1) 241 (63.3)
L5 144 (56.0) 120 (96.8) 173 (45.4)
L6 146 (56.8) 120 (96.8) 181 (47.5)
M2 L1 143 (55.6) 102 (82.3) 257 (67.5)
L2 133 (51.8) 114 (91.9) 279 (73.2)
L3 143 (55.6) 99 (79.8) 254 (66.7)
L4 134 (52.1) 109 (87.9) 273 (71.7)
L5 122 (47.5) 121 (97.6) 205 (53.8)
L6 124 (48.2) 121 (97.6) 213 (55.9)
M4 L1 144 (56.0) 102 (82.3) 254 (66.7)
L2 134 (52.1) 114 (91.9) 276 (72.4)
L3 144 (56.0) 99 (79.8) 251 (65.9)
L4 135 (52.5) 109 (87.9) 270 (70.9)
L5 123 (47.9) 121 (97.6) 202 (53.0)
L6 125 (48.6) 121 (97.6) 210 (55.1)
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